Promethease Report

Magnitude: 2

possibly type A blood according to the ABO blood group types. From a molecular point of view, there are 2 A types: AA, and AO, based on whether the individual is carrying two type A alleles or one type A allele plus one type O allele.

27.7%

rs8176720 (A;A)

References:0

42.6%

rs505922 (C;T)

References:7

1.2x risk of pancreatic cancer

45.5%

References:5

None

References:0

None

References:2

None

References:1

57.4%

Magnitude: 0
References:1

57.4%

rs8176746 (C;C)

Magnitude: 0
References:3

57.4%

rs8176749 (G;G)

Magnitude: 0
References:0

None

i4000504 (C;C)

Magnitude: 0
References:0

None

i4000505 (G;G)

Magnitude: 0
References:0

None

rs1053878 (C;C)

Magnitude: 0
References:1

None

rs41302905 (C;C)

Magnitude: 0
References:0

None

rs55964869 (C;C)

Magnitude: 0
References:1

None

rs7853989 (G;G)

Magnitude: 0
ambig
References:0

None

rs8176740 (T;T)

Magnitude: 0
ambig
References:0

None

rs8176747 (G;G)

Magnitude: 0
ambig
References:1

1 genoset 17 snps

Addiction

(hide) Addiction

31.0%

Magnitude: 2
References:31

1.3x increased risk of lung cancer

17.5%

References:1

21.8%

References:1

24.8%

References:1

27.0%

References:1

29.7%

References:1

29.7%

References:3

30.7%

References:24

slightly higher risk for nicotine dependence, lower risk for cocaine dependence

31.7%

References:4

31.7%

References:1

36.6%

References:4

38.6%

References:6

39.6%

References:4

51.5%

References:7

None

References:19

normal

None

References:0

None

References:0

None

References:5

None

References:1

None

References:4

None

References:1

None

References:1

None

References:3

None

References:13

1.4x higher schizophrenia risk

None

References:1

58.4%

Magnitude: 0.1
ambig
References:7

52.5%

Magnitude: 0
References:34

A2/A2 [[bupropion]] effective

55.4%

rs1076560 (C;C)

Magnitude: 0
References:9

normal

64.4%

rs4648317 (C;C)

Magnitude: 0
References:4

normal

66.3%

rs1534891 (C;C)

Magnitude: 0
References:3

69.3%

rs12364283 (A;A)

Magnitude: 0
References:4

89.1%

rs1799978 (A;A)

Magnitude: 0
References:4

92.1%

rs694066 (G;G)

Magnitude: 0
References:1

None

rs1799913 (C;C)

Magnitude: 0
References:3

34 snps

Addison's disease

(hide) Addison's disease

64.6%

rs12150220 (A;A)

ambig
References:4

slightly increased risk for several autoimmune diseases

98.0%

Magnitude: 0
References:25

normal

2 snps

AIDS

(hide) AIDS

27.7%

rs9264942 (C;C)

Magnitude: 2.2
References:7

90% reduction in HIV viral load The rs9264942(C;C) genotype is reported to be associated with a 90% reduction in viral load in HIV-infected individuals. See also rs9264942 and HIV.

45.5%

rs1801157 (A;G)

Magnitude: 1.4
References:6

1.4x higher risk for breast cancer

29.7%

References:1

36.6%

References:13

complex; generally greater risk for cancer progression

37.6%

References:1

40.6%

References:1

45.5%

References:1

54.0%

References:1

54.5%

References:1

70.3%

References:1

95.0%

References:1

64.0%

Magnitude: 0
References:1

66.3%

rs1360517 (G;G)

Magnitude: 0
References:1

68.0%

rs2395029 (T;T)

Magnitude: 0
References:10

common The rs2395029(T;T) genotype is the common genotype for this SNP, against which the rs2395029(T;G) and rs2395029(G;G) genotypes that are associated with reduced HIV viral load in HIV carriers are compared. See also rs9264942 and HIV.

None

i3003626 (I;I)

Magnitude: 0
References:0

not resistant to HIV

None

rs1799864 (G;G)

Magnitude: 0
References:5

None

rs5968255 (T;T)

Magnitude: 0
References:1

17 snps

Alcoholism

(hide) Alcoholism

4.0%

rs279858 (G;G)

Magnitude: 2.1
References:1

apparently more prone to alcoholism interacts with the medicine Finasteride

0.0%

References:1

11.9%

References:1

21.0%

References:3

normal; increased agreeableness (?)

25.7%

References:1

26.7%

References:7

normal

32.7%

rs1042173 (G;G)

References:2

normal

34.7%

References:1

50.5%

References:1

68.3%

References:1

92.0%

References:1

94.9%

References:1

None

References:1

None

References:3

None

References:19

normal

None

References:3

None

References:2

None

References:13

1.4x higher schizophrenia risk

12.9%

ambig
References:2

None

ambig
References:2

None

ambig
References:1

None

Magnitude: 0.1
References:2

common one paper reports increased risk of alcoholism for African-Americans with this genotype.

58.4%

rs324650 (T;T)

Magnitude: 0.1
ambig
References:7

15.8%

rs27048 (T;T)

Magnitude: 0
References:1

normal

30.7%

rs1799971 (A;A)

Magnitude: 0
References:10

normal

38.6%

rs27072 (C;T)

Magnitude: 0
References:6

normal

52.5%

Magnitude: 0
References:34

A2/A2 [[bupropion]] effective

55.4%

rs1076560 (C;C)

Magnitude: 0
References:9

normal

None

rs1229984 (G;G)

Magnitude: 0
References:12

normal; more frequent alcohol consumption

None

rs2232165 (C;C)

Magnitude: 0
References:2

normal

None

rs2948694 (A;A)

Magnitude: 0
References:2

normal

None

rs846664 (T;T)

Magnitude: 0
References:2

32 snps

Allergies

3 snps

Allograft rejection

(hide) Allograft rejection

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

80.0%

rs4986791 (C;C)

Magnitude: 0
References:5

normal

82.0%

Magnitude: 0
References:9

normal

3 snps

Alopecia Areata

(hide) Alopecia Areata

2.0%

rs694739 (C;C)

References:2

7.9%

rs1143634 (T;T)

References:9

complex; see details

7.9%

References:1

14.9%

References:1

21.8%

References:1

24.8%

References:3

27.7%

References:1

47.5%

References:2

48.5%

References:5

52.5%

References:1

89.1%

Magnitude: 0
References:2

normal

11 snps

Alpha-1 antitrypsin deficiency

2 snps

Alzheimer's disease

(hide) Alzheimer's disease

27.7%

Magnitude: 2.4
References:27

impaired motor skills learning? On a driving-based motor learning task subjects with this genotype showed greater error during short-term learning and poorer retention over 4 days, relative to subjects without the polymorphism. The presence of this BDNF polymorphism is associated with differences in brain motor system function, altered short-term plasticity, and greater error in short-term motor learning. Wired discusses the research as does spittoon. Alzheimer's disease risk for non ApoE4 carriers is affected by the heterozygous form of rs6265

gs187

Magnitude: 1.5

An APOE3 allele was observed

45.0%

rs3851179 (A;G)

Magnitude: 1.5
References:5

0.85x decreased risk for Alzheimer's disease

6.9%

References:1

14.9%

References:1

14.9%

References:6

15.8%

References:1

17.8%

References:3

17.8%

References:2

18.8%

References:1

19.8%

References:1

19.8%

References:1

1.58x increased risk of Alzheimer's

20.8%

References:1

21.0%

References:1

22.8%

References:1

23.8%

References:1

23.8%

References:1

25.7%

References:1

normal

27.1%

rs1803274 (A;G)

References:4

possible increased Alzheimer's risk

27.7%

References:1

27.7%

References:1

common

30.0%

References:1

31.7%

References:2

31.7%

References:3

31.7%

References:1

32.7%

References:1

1.5x increased Alzheimer risk in non-ApoE4 carriers

32.7%

References:1

33.7%

References:1

34.7%

References:1

36.6%

References:1

36.6%

References:1

36.6%

References:1

1.18x increased risk for LOAD

36.6%

rs6313 (C;C)

References:11

higher risk for RA

36.6%

References:1

37.4%

References:3

increased risk for Alzheimer's

37.6%

References:3

38.6%

References:2

39.0%

References:1

39.6%

References:1

39.6%

References:1

39.6%

References:1

39.6%

References:4

39.6%

References:1

42.6%

References:8

42.6%

References:1

1.24x increased risk for Alzheimer's

42.6%

References:6

44.6%

References:1

45.0%

References:1

45.5%

References:1

45.5%

References:7

46.0%

References:2

46.5%

References:2

46.5%

References:1

48.5%

References:6

normal

49.0%

References:1

49.5%

References:3

0.70x reduced risk for Alzheimer's risk

50.0%

References:1

50.5%

References:1

50.5%

References:1

50.5%

References:4

50.5%

References:3

50.5%

References:19

50.5%

References:1

50.5%

References:1

50.5%

References:5

lower risk of dementia and Alzheimer's disease

51.5%

References:2

51.5%

References:1

52.0%

References:1

52.0%

References:1

52.5%

References:1

no positive effect of AChE inhibitors for Alzheimer's patients

53.5%

References:4

55.4%

References:1

55.4%

References:3

55.4%

References:1

55.4%

References:2

in ALZ patients, increased risk of delusions

56.4%

References:1

57.4%

References:1

57.4%

References:2

None

57.6%

References:1

60.4%

References:1

60.4%

References:1

66.3%

References:1

69.3%

References:2

70.0%

References:1

70.3%

References:1

74.3%

References:1

76.2%

References:1

76.2%

References:1

76.2%

References:1

77.2%

References:1

78.2%

References:1

79.8%

References:1

80.2%

References:1

81.2%

References:1

81.2%

References:1

83.2%

References:4

83.2%

References:1

84.2%

References:1

85.1%

References:1

common

87.1%

References:1

90.1%

References:2

normal

92.1%

References:1

92.1%

References:13

more likely to gain weight if taking olanzapine

95.0%

References:1

95.0%

References:1

95.0%

References:1

96.0%

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:10

None

References:1

None

References:2

None

References:3

None

References:1

None

References:1

normal

None

References:1

None

References:1

None

References:2

None

References:1

None

References:2

normal

None

References:1

None

References:1

None

References:1

None

References:2

None

References:2

None

References:1

normal

None

References:1

None

References:10

None

References:1

None

References:1

3.0%

ambig
References:1

23.8%

ambig
References:1

0.83x risk for Alzheimers

75.2%

rs1800795 (G;G)

ambig
References:19

more IL6; certain risks, see details rs1800795 is a SNP in the promoter of the interleukin-6 IL6 gene, affecting the levels made of this important cytokine. In the literature, it is almost universally referred to as the IL6 '-174' polymorphism. It tends to be quite polymorphic in Caucasians, but Asian and African populations are almost monomorphic (for the (G) allele). The rs1800795(G) allele, generally associated with higher levels of IL6, has been associated with increased risk in the following studies: * The rs1800795(G) allele was significantly associated with type-2 diabetes (odds ratio 1.51, CI: 1.11-2.07, p=0.0096) in a study of 700 elderly Caucasians. * Following a kidney transplant, patients with rs1800795(G;G) genotypes have a higher risk of new-onset diabetes and higher C-react...

None

ambig
References:1

None

ambig
References:2

None

ambig
References:2

normal

None

rs2071746 (A;A)

ambig
References:5

normal

None

ambig
References:1

None

ambig
References:2

None

ambig
References:2

None

ambig
References:2

average

6.9%

rs1699103 (G;G)

Magnitude: 0
References:1

0.85x risk for Alzheimers

8.9%

rs1784931 (A;A)

Magnitude: 0
References:1

normal

11.9%

rs10892759 (G;G)

Magnitude: 0
References:1

normal

11.9%

rs1792113 (G;G)

Magnitude: 0
References:1

0.90x risk for Alzheimers

16.8%

rs726601 (C;C)

Magnitude: 0
References:1

normal

27.0%

rs5984894 (G;G)

Magnitude: 0
References:4

normal

40.6%

rs10519262 (G;G)

Magnitude: 0
References:2

average

45.5%

rs688 (C;T)

Magnitude: 0
References:3

normal risk for Alzheimer's; higher total and LDL cholesterol in females

46.0%

rs242557 (A;G)

Magnitude: 0
References:4

normal

47.5%

rs9886784 (C;C)

Magnitude: 0
References:2

average

51.5%

rs11136000 (C;C)

Magnitude: 0
References:6

normal

55.0%

rs7019241 (C;C)

Magnitude: 0
References:2

average

55.4%

rs10868366 (G;G)

Magnitude: 0
References:2

average

66.3%

rs6583817 (C;C)

Magnitude: 0
References:2

66.3%

rs669 (A;A)

Magnitude: 0
References:3

normal

66.3%

rs7910977 (C;C)

Magnitude: 0
References:3

72.4%

rs13213247 (A;A)

Magnitude: 0
References:1

78.2%

rs2075650 (A;A)

Magnitude: 0
References:15

normal

81.2%

rs2066853 (G;G)

Magnitude: 0
References:4

82.0%

Magnitude: 0
References:9

normal

87.0%

rs4420638 (A;A)

Magnitude: 0
References:26

Normal/Average risk for Alzheimer's

89.1%

rs3818361 (C;C)

Magnitude: 0
References:5

normal

90.1%

rs2279420 (T;T)

Magnitude: 0
References:1

normal

93.1%

rs11754661 (G;G)

Magnitude: 0
References:4

95.0%

rs3781835 (G;G)

Magnitude: 0
References:1

None

Magnitude: 0
References:10

normal although rare for caucasians, normal for the asian population studied

None

Magnitude: 0
References:19

common

None

rs908832 (G;G)

Magnitude: 0
References:3

normal

1 genoset 170 snps

Aneurysm

(hide) Aneurysm

27.7%

Magnitude: 2.1
References:7

increased risk for heart disease

8.9%

References:2

21.8%

References:2

28.7%

References:10

1.52x increased myocardial infarction risk, 1.67x increased aneurysm risk

35.6%

References:1

36.6%

References:4

38.6%

References:4

59.4%

References:3

~1.18x increased risk of aneurysm

43.6%

rs10958409 (G;G)

Magnitude: 0
References:4

normal

9 snps

Angioedema

2 snps

Ankylosing spondylitis

(hide) Ankylosing spondylitis

47.5%

rs10865331 (A;G)

Magnitude: 1.2
References:3

1.2x higher risk for ankylosing spondylitis

25.7%

References:2

34.7%

References:3

35.4%

References:1

38.6%

References:3

0.83x lower risk for spondylitis

39.6%

References:3

43.6%

References:2

44.6%

References:6

1.4x higher risk for spondylitis

45.5%

References:3

45.5%

References:10

1.5x risk for certain autoimmune diseases; 2x risk for Graves disease

46.5%

References:1

49.5%

References:12

1.5x risk

56.4%

References:2

61.4%

References:1

66.3%

References:1

70.3%

References:1

None

References:5

1.4x higher risk for spondylitis

21.8%

rs1495965 (A;A)

Magnitude: 0
References:6

1.2x higher risk for spondylitis

22.8%

rs11209032 (G;G)

Magnitude: 0
References:7

normal risk

71.3%

rs1343151 (C;C)

Magnitude: 0
References:6

normal risk

87.1%

rs10050860 (C;C)

Magnitude: 0
References:5

normal risk

87.1%

rs2287987 (T;T)

Magnitude: 0
References:4

normal risk

89.0%

rs17482078 (C;C)

Magnitude: 0
References:4

0.76x lower risk for spondylitis

99.0%

Magnitude: 0
References:27

common

None

rs11465804 (T;T)

Magnitude: 0
References:6

normal risk

None

rs7302230 (A;A)

Magnitude: 0
References:1

26 snps

Arthritis

(hide) Arthritis

42.6%

References:1

54.5%

References:1

66.3%

References:9

1.7x risk for RA; 1.6X for T1D; also MS?

None

rs10818488 (G;G)

References:5

normal

None

References:2

91.1%

Magnitude: 0
References:2

99.0%

Magnitude: 0
References:14

Not a C282Y hemochromatosis carrier.

None

rs2066845 (G;G)

Magnitude: 0
ambig
References:8

appears to be common on the 23andMe platform

8 snps

Asian flush

1 snp

Asthma

(hide) Asthma

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

1.0%

rs3804100 (C;C)

References:1

somwhat increased risk for type-1 diabetes and allergic asthma

2.0%

References:1

13.9%

References:1

14.9%

References:1

14.9%

References:3

15.8%

References:3

16.8%

References:3

18.8%

References:6

23.8%

References:2

25.0%

References:2

30.7%

References:14

normal

31.7%

References:1

31.7%

References:1

31.7%

References:14

34.7%

References:2

36.6%

References:1

37.6%

References:1

40.6%

References:4

41.0%

References:3

41.6%

References:3

42.6%

References:1

44.6%

References:1

45.5%

References:1

normal

45.5%

rs4795400 (C;T)

References:3

normal

45.5%

rs7216389 (C;T)

References:8

1.5x increased risk for asthma

46.5%

References:1

46.5%

References:6

normal

46.5%

rs8069176 (A;G)

References:3

normal

48.5%

References:14

49.5%

References:4

51.5%

References:3

52.5%

References:3

52.5%

References:2

54.0%

References:10

1.8x increased prostate cancer risk

54.5%

References:5

58.4%

References:1

59.4%

References:1

61.6%

References:1

63.4%

References:1

increased risk

64.3%

References:1

64.4%

References:1

65.7%

References:3

66.7%

References:1

68.3%

References:1

71.3%

References:0

71.3%

References:1

73.3%

References:2

81.2%

References:3

82.0%

References:1

None

References:2

None

References:1

increased risk for adult asthma

None

References:1

None

References:1

average

None

References:0

None

References:11

None

References:1

None

References:3

None

References:1

None

References:1

None

References:1

None

References:1

if a smoker, somewhat more likely to develop COPD

None

References:1

None

References:2

None

References:1

1.5x increased risk for mild asthma

None

References:3

None

References:1

None

References:12

complex; see details for increased risks

None

References:3

None

References:1

None

References:1

None

References:1

None

References:2

None

References:9

None

References:1

None

References:2

None

References:1

7.9%

ambig
References:2

13.9%

ambig
References:3

None

ambig
References:2

None

ambig
References:0

None

ambig
References:2

common

None

ambig
References:1

None

ambig
References:1

None

ambig
References:2

None

ambig
References:1

None

ambig
References:1

43.6%

Magnitude: 0
References:1

common

44.6%

rs4794067 (T;T)

Magnitude: 0
References:2

common

61.0%

rs2251746 (T;T)

Magnitude: 0
References:2

normal but highest IgE levels

67.3%

rs11650354 (C;C)

Magnitude: 0
References:2

8x risk for allergic asthma

75.2%

rs689466 (A;A)

Magnitude: 0
References:8

normal

76.2%

Magnitude: 0
References:4

1.12x risk on diuretic; if hypertensive, better outcome when treated with calcium channel blocker than with diuretic

76.2%

rs5067 (A;A)

Magnitude: 0
References:1

normal

77.2%

rs16947078 (A;A)

Magnitude: 0
References:1

common

80.0%

rs4986791 (C;C)

Magnitude: 0
References:5

normal

82.0%

rs1805018 (T;T)

Magnitude: 0
References:1

82.0%

Magnitude: 0
References:9

normal

82.8%

rs2306168 (C;C)

Magnitude: 0
References:1

93.1%

rs4815617 (C;C)

Magnitude: 0
References:2

95.0%

rs569108 (T;T)

Magnitude: 0
References:3

normal

None

rs119774 (G;G)

Magnitude: 0
References:1

None

rs2427837 (G;G)

Magnitude: 0
References:1

normal but highest IgE levels

None

rs574174 (C;C)

Magnitude: 0
References:2

common for Caucasians on the 23andme platform

None

rs612709 (G;G)

Magnitude: 0
References:2

common for Caucasians on the 23andme platform

105 snps

Atherosclerosis

(hide) Atherosclerosis

20.8%

References:3

34.3%

References:1

43.6%

References:1

90.1%

References:2

normal

None

rs10893081 (T;T)

References:1

normal

5 snps

Atopic dermatitis

(hide) Atopic dermatitis

46.5%

References:1

52.5%

References:2

57.4%

References:6

None

References:1

4 snps

Abdominal aortic aneurysm

(hide) Abdominal aortic aneurysm

27.7%

Magnitude: 2.1
References:7

increased risk for heart disease

None

Magnitude: 2.1
References:20

1.6x risk for MI

25.7%

References:3

35.6%

References:3

43.0%

References:3

60.4%

References:2

None

References:7

~1.3x increased risk for heart disease

None

References:2

55.4%

ambig
References:3

None

ambig
References:8

None

Magnitude: 0
ambig
References:9

appears to be common on the 23andMe platform

11 snps

Age related macular degeneration

(hide) Age related macular degeneration

12.9%

rs10490924 (T;T)

Magnitude: 3.5
References:23

8.2x risk for age related macular degeneration

51.5%

rs5888 (C;T)

Magnitude: 2.5
References:1

3x higher risk for age-related macular degeneration

52.5%

rs2511989 (A;G)

Magnitude: 2.1
References:8

0.63x decreased age-related macular degeneration risk

49.5%

rs3764261 (G;T)

Magnitude: 2
References:13

associated with higher HDL cholesterol

None

rs3025039 (C;T)

Magnitude: 2
References:7

2.6x increased risk for ARMD

9.9%

References:1

12.9%

References:1

12.9%

References:1

13.9%

References:2

13.9%

References:1

14.0%

References:1

36.6%

References:2

41.6%

References:1

42.0%

References:1

42.4%

References:2

42.6%

References:4

43.0%

References:1

43.6%

References:1

43.6%

References:5

1.5x increased risk of wet ARMD

44.6%

References:3

46.0%

References:1

48.5%

References:2

69.3%

References:1

86.1%

References:1

None

References:1

None

References:14

2.5x risk for AMD; higher mortality among nonagenarians

None

References:1

None

References:10

None

References:4

1.5x risk for ARMD

None

rs380390 (C;G)

References:6

None

None

ambig
References:2

50.0%

Magnitude: 0
References:1

50.0%

rs800292 (C;C)

Magnitude: 0
References:6

normal

61.4%

rs3775291 (G;G)

Magnitude: 0
References:9

normal

62.2%

rs641153 (C;C)

Magnitude: 0
References:6

63.0%

rs429608 (G;G)

Magnitude: 0
References:2

67.3%

rs547154 (C;C)

Magnitude: 0
References:4

82.0%

rs3753396 (A;A)

Magnitude: 0
References:2

93.1%

rs9621532 (A;A)

Magnitude: 0
References:2

None

rs1047286 (C;C)

Magnitude: 0
References:5

None

rs28357980 (A;A)

Magnitude: 0
References:0

normal common for Caucasians on the 23andme platform

None

rs529825 (C;C)

Magnitude: 0
References:1

None

rs9380272 (G;G)

Magnitude: 0
References:1

None

rs2230199 (C;C)

Magnitude: 0
ambig
References:12

3.2x risk of ARMD

None

rs4151667 (T;T)

Magnitude: 0
ambig
References:5

None

rs9332739 (G;G)

Magnitude: 0
ambig
References:4

normal

46 snps

Amyotrophic Lateral Sclerosis

(hide) Amyotrophic Lateral Sclerosis

1.0%

rs3849942 (A;A)

Magnitude: 1.4
References:3

1.4x increased risk for ALS

1.0%

rs2814707 (A;A)

Magnitude: 1.2
References:3

>1.2x increased risk for ALS

2.0%

References:2

17.8%

References:1

21.8%

References:2

22.8%

References:1

25.7%

References:0

30.7%

References:1

32.7%

References:1

33.7%

References:3

35.6%

References:1

36.0%

References:3

36.5%

References:2

38.0%

References:1

40.6%

References:1

40.6%

References:2

1.2x increased risk for ALS

41.6%

References:1

43.6%

References:1

45.5%

References:1

47.5%

References:2

47.5%

References:2

48.5%

References:1

50.5%

References:1

50.5%

References:1

54.5%

References:1

1.3x risk for ALS

55.0%

References:1

63.4%

References:1

68.3%

References:2

71.3%

References:1

73.3%

References:1

74.3%

References:3

74.3%

References:3

75.2%

References:3

87.1%

References:1

89.1%

References:1

None

References:1

None

References:3

None

References:2

None

References:1

None

References:2

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:4

1.2x increased risk for ALS

61.0%

ambig
References:1

33.7%

Magnitude: 0
References:1

37.6%

rs10260404 (T;T)

Magnitude: 0
References:6

average

42.6%

rs3825776 (A;A)

Magnitude: 0
References:1

average

62.0%

rs11241713 (C;C)

Magnitude: 0
References:1

71.3%

rs2836061 (C;C)

Magnitude: 0
References:1

79.2%

rs7702057 (G;G)

Magnitude: 0
References:1

85.1%

rs2306677 (C;C)

Magnitude: 0
References:2

92.1%

rs10438933 (A;A)

Magnitude: 0
References:1

99.0%

rs855913 (G;G)

Magnitude: 0
References:1

59 snps

Anorexia nervosa

2 snps

Anxiety disorder

(hide) Anxiety disorder

62.4%

rs4570625 (G;G)

Magnitude: 1.9
References:7

higher scores on anxiety-related personality traits; greater placebo response One study of 25 people shows this genotype was a significant predictor of clinical placebo response, being associated with greater improvement in anxiety symptoms. This SNP has been linked to several psychiatric and/or behavioral phenomena, including: *higher scores on anxiety-related personality traits *obsessive compulsive disorder *panic disorder with a possible gender-dependent effect

36.0%

References:8

55.4%

References:1

64.4%

References:1

more anxious females, less anxious males

67.3%

References:1

77.2%

References:1

93.1%

References:1

None

References:1

None

References:1

18.8%

ambig
References:1

None

ambig
References:4

complex; possible association with anxiety related behaviours

None

Magnitude: 0
References:11

12 snps

Atrial fibrillation

(hide) Atrial fibrillation

4.0%

rs13376333 (T;T)

Magnitude: 2
References:4

~2x higher risk of atrial fibrillation

4.0%

References:5

7.9%

References:6

13.9%

References:15

normal risk

41.4%

References:2

41.6%

References:1

44.6%

References:3

46.5%

References:3

66.3%

References:2

75.2%

References:2

82.2%

References:1

None

References:1

62.4%

ambig
References:2

65.0%

Magnitude: 0
References:5

normal

75.2%

rs2200733 (C;C)

Magnitude: 0
References:10

normal

76.2%

Magnitude: 0
References:4

1.12x risk on diuretic; if hypertensive, better outcome when treated with calcium channel blocker than with diuretic

None

rs17375901 (C;C)

Magnitude: 0
References:1

None

rs5800 (G;G)

Magnitude: 0
References:1

normal

18 snps

Attention deficit hyperactivity disorder

(hide) Attention deficit hyperactivity disorder

27.7%

Magnitude: 2.4
References:27

62.4%

rs4570625 (G;G)

Magnitude: 1.9
References:7

5.0%

References:1

5.9%

References:1

7.0%

References:1

7.9%

References:1

8.9%

References:2

11.9%

References:3

14.9%

References:5

<0.62x risk for restless legs

14.9%

References:3

15.8%

References:2

15.8%

References:1

16.8%

References:1

19.8%

References:1

20.6%

References:1

20.8%

References:6

common

21.8%

References:1

22.8%

References:1

22.8%

References:1

23.8%

References:2

26.7%

References:2

26.7%

References:2

27.0%

References:2

27.7%

References:1

27.7%

References:1

29.7%

References:1

32.7%

References:2

33.7%

References:1

34.7%

References:1

34.7%

References:1

35.6%

References:1

35.7%

References:2

36.0%

References:2

36.6%

References:1

36.6%

References:1

37.6%

References:1

38.6%

References:1

40.0%

References:1

40.6%

References:1

40.6%

References:1

41.6%

References:1

41.8%

References:2

42.6%

References:1

42.6%

References:1

43.6%

References:1

43.6%

References:1

44.6%

References:1

44.6%

References:2

haplotype at risk for restless legs

45.5%

References:1

45.5%

References:1

46.5%

References:1

47.5%

References:1

47.5%

References:1

47.5%

References:1

48.5%

References:1

50.5%

References:1

50.5%

References:1

51.5%

References:2

52.0%

References:1

53.5%

References:2

55.4%

References:2

57.4%

References:1

57.4%

References:2

57.4%

References:1

58.4%

References:4

normal

58.4%

References:1

61.4%

References:1

62.0%

References:1

67.0%

References:2

67.3%

References:1

67.3%

References:1

68.3%

References:2

69.3%

References:1

71.3%

References:1

normal risk of ADHD

74.3%

References:2

75.2%

References:1

76.2%

References:1

78.2%

References:1

80.2%

References:1

81.2%

References:1

83.2%

References:1

87.1%

References:2

95.0%

References:2

96.0%

References:2

97.0%

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:3

None

References:1

None

References:2

None

References:1

None

References:2

None

References:2

None

References:1

None

References:1

None

References:1

None

References:2

None

References:1

None

References:0

None

References:2

None

References:2

None

References:1

None

References:1

None

References:2

None

References:1

None

References:2

None

References:1

None

References:5

None

References:1

None

References:2

None

References:2

None

References:2

None

References:2

None

References:2

None

References:1

None

References:1

None

References:2

None

References:2

31.7%

ambig
References:1

37.6%

ambig
References:1

54.5%

ambig
References:1

72.3%

ambig
References:2

83.2%

ambig
References:1

85.1%

ambig
References:1

88.1%

ambig
References:1

93.1%

ambig
References:1

None

ambig
References:2

None

ambig
References:2

None

ambig
References:2

None

ambig
References:1

None

ambig
References:1

None

ambig
References:2

27.7%

Magnitude: 0
References:3

common

31.7%

rs12593813 (G;G)

Magnitude: 0
References:4

common

38.6%

rs27072 (C;T)

Magnitude: 0
References:6

normal

45.5%

rs12469063 (A;A)

Magnitude: 0
References:3

>1.7x risk for restless legs

45.5%

rs2300478 (T;T)

Magnitude: 0
References:6

common

66.3%

rs6791644 (A;A)

Magnitude: 0
References:1

73.7%

rs1202199 (C;C)

Magnitude: 0
References:1

92.1%

rs11134178 (T;T)

Magnitude: 0
References:3

None

rs11568324 (C;C)

Magnitude: 0
References:1

None

Magnitude: 0
References:11

None

rs11178997 (T;T)

Magnitude: 0
ambig
References:6

common for Caucasians on the 23andme platform

149 snps

Autism

(hide) Autism

4.0%

rs2745557 (A;A)

References:2

autism risk?

15.8%

References:1

16.8%

References:4

26.7%

References:3

None

26.7%

rs759178 (T;T)

References:1

None

30.7%

References:0

31.7%

References:10

likely to require more methadone during heroin withdrawal

32.7%

References:3

37.6%

References:12

38.6%

References:6

39.6%

References:0

39.6%

References:4

40.6%

References:1

43.6%

References:1

45.5%

References:4

46.5%

References:1

46.5%

References:1

46.5%

References:1

47.5%

References:1

48.5%

References:1

49.5%

References:1

49.5%

References:1

60.4%

References:3

65.0%

References:1

74.3%

References:3

81.2%

References:1

94.1%

References:1

95.0%

References:2

normal

95.0%

References:1

None

References:1

None

References:5

None

References:1

None

None

rs2538991 (T;T)

References:1

None

None

References:3

None

References:1

None

References:12

complex; see details for increased risks

None

rs1143674 (A;G)

References:1

1.3x increased autism risk

None

References:3

None

References:6

1.6x increased autism risk

None

References:1

None

References:1

29.7%

Magnitude: 0
References:9

normal

32.7%

rs167771 (A;A)

Magnitude: 0
References:3

69.3%

Magnitude: 0
References:45

None

rs12740310 (C;C)

Magnitude: 0
References:3

None

rs1804197 (C;C)

Magnitude: 0
References:2

34.7%

rs7794745 (A;A)

Magnitude: 0
ambig
References:5

normal risk

47 snps

Bardet-Biedl syndrome

3 snps

Basal Cell Carcinoma

3 snps

Behçet's disease

(hide) Behçet's disease

15.8%

References:1

15.8%

References:2

51.5%

References:1

60.6%

ambig
References:1

21.8%

Magnitude: 0
References:6

1.2x higher risk for spondylitis

98.0%

Magnitude: 0
References:25

normal

None

Magnitude: 0
References:10

normal although rare for caucasians, normal for the asian population studied

7 snps

Bladder cancer

(hide) Bladder cancer

22.8%

rs2294008 (T;T)

Magnitude: 2.1
References:12

increased risk of gastric and bladder cancer

45.0%

Magnitude: 2.1
References:34

1.2x risk of prostate cancer 1.2x risk of prostate cancer

34.7%

rs828907 (T;T)

References:3

slightly increased risk of bladder cancer

42.6%

rs9642880 (T;T)

References:8

1.5x increased bladder cancer risk

64.4%

References:4

73.0%

References:3

normal

74.3%

rs710521 (A;A)

References:6

1.4x increased bladder cancer risk

None

rs6869366 (T;T)

References:6

normal

None

rs760805 (A;A)

ambig
References:3

2x increased risk for bladder cancer

37.8%

rs5275 (T;T)

Magnitude: 0
References:13

normal

79.2%

rs868 (A;A)

Magnitude: 0
References:1

81.2%

rs1136410 (T;T)

Magnitude: 0
References:3

normal

None

rs1052133 (C;C)

Magnitude: 0
ambig
References:10

normal

13 snps

Blood

(hide) Blood

10.9%

References:1

27.7%

References:0

30.7%

References:1

42.6%

References:7

1.2x risk of pancreatic cancer

45.5%

References:5

46.5%

References:1

None

Magnitude: 1
References:5

Duffy-positive This genotype is associated with European populations and south-western Native American populations.

None

rs590787 (C;C)

Magnitude: 1
References:0

Rh- (Rhesus negative)

None

References:0

None

References:2

None

References:1

57.4%

Magnitude: 0
References:1

57.4%

rs8176746 (C;C)

Magnitude: 0
References:3

57.4%

rs8176749 (G;G)

Magnitude: 0
References:0

97.0%

rs8176058 (C;C)

Magnitude: 0
References:1

common

None

rs2285644 (C;C)

Magnitude: 0
References:1

None

rs28362692 (C;C)

Magnitude: 0
References:1

None

rs28399653 (G;G)

Magnitude: 0
References:1

None

rs28937582 (A;A)

Magnitude: 0
References:1

None

rs28940571 (C;C)

Magnitude: 0
References:1

None

rs28940572 (G;G)

Magnitude: 0
References:1

None

rs55964869 (C;C)

Magnitude: 0
References:1

None

rs7853989 (G;G)

Magnitude: 0
ambig
References:0

None

rs8176740 (T;T)

Magnitude: 0
ambig
References:0

None

rs8176747 (G;G)

Magnitude: 0
ambig
References:1

25 snps

Blood pressure

(hide) Blood pressure

gs185

Magnitude: 1.5

15 point drop in blood pressure when taking the beta blocker metoprolol due to rs1801252(A;A) and rs1801253(C;C):

10.1%

References:1

10.9%

References:2

15.8%

References:1

altered pediatric blood pressure

16.8%

References:1

25.7%

References:2

25.7%

References:2

25.7%

References:0

31.0%

References:2

35.6%

References:1

36.4%

References:2

38.0%

References:2

38.6%

References:4

38.6%

References:1

lower blood pressure

40.6%

References:2

43.6%

References:2

52.0%

References:2

55.4%

References:1

66.3%

References:2

67.3%

References:0

70.3%

References:1

76.2%

References:3

78.2%

References:7

83.2%

References:2

83.2%

References:1

90.1%

References:2

93.1%

References:1

normal

None

References:1

None

References:1

None

References:1

None

References:2

None

References:2

None

References:2

None

References:2

None

References:2

None

References:3

slightly higher blood pressure if Caucasian

None

ambig
References:2

37.6%

Magnitude: 0
References:1

37.6%

rs2681492 (A;A)

Magnitude: 0
References:1

71.3%

rs10508517 (G;G)

Magnitude: 0
References:2

71.3%

rs6198 (A;A)

Magnitude: 0
References:4

78.2%

Magnitude: 0
References:16

normal

91.1%

rs1055419 (G;G)

Magnitude: 0
References:1

93.1%

rs5068 (T;T)

Magnitude: 0
References:1

1 genoset 43 snps

Baldness

(hide) Baldness

None

rs925391 (T;T)

Magnitude: 3
References:1

unlikely to go bald

None

rs2223841 (G;G)

Magnitude: 2
References:1

less likely to go bald less likely to experience baldness before age 40

8.2%

rs1385699 (C;C)

Magnitude: 1.5
References:1

slightly less likely to go bald decreased risk of baldness

85.1%

rs6036025 (G;G)

Magnitude: 1.2
References:0

more likely to go bald more likely to go bald

8.2%

References:1

9.9%

References:3

None

53.5%

References:4

53.5%

References:4

54.5%

References:1

None

ambig
References:1

None

Magnitude: 0.5
References:2

able to go bald baldness is possible

11 snps

Bicuspid aortic valve

1 snp

Bipolar disorder

(hide) Bipolar disorder

55.4%

rs1344706 (T;T)

Magnitude: 1.2
References:13

1.2x increased risk for schizophrenia

0.0%

References:1

3.0%

References:1

7.9%

References:1

9.0%

References:3

9.9%

References:2

9.9%

References:1

12.9%

References:1

13.9%

References:10

17.8%

References:2

19.8%

References:1

23.0%

References:3

24.8%

References:1

normal

24.8%

References:3

25.7%

References:1

26.7%

References:1

26.7%

References:3

27.7%

References:2

1.3x risk

29.7%

References:1

31.0%

References:1

1.5x risk

31.7%

rs1344484 (T;T)

References:1

1.5x risk

31.7%

References:1

31.7%

References:1

1.5x risk

31.7%

References:1

32.7%

References:1

33.0%

References:1

38.6%

References:4

2x risk

41.6%

References:1

41.6%

References:1

1.5x increased risk for bipolar disorder

41.6%

References:1

42.0%

References:1

42.4%

References:1

44.6%

References:1

47.0%

References:0

47.5%

References:1

50.5%

References:1

50.5%

References:2

51.5%

References:1

51.5%

References:1

58.4%

References:1

1.3x risk

59.4%

rs140504 (G;G)

References:2

normal risk

62.0%

References:1

62.4%

References:5

63.0%

References:2

65.3%

References:1

1.5x risk

67.3%

References:1

70.0%

References:2

71.3%

References:1

71.3%

References:1

71.3%

References:1

72.3%

References:1

79.2%

References:2

79.2%

References:1

81.2%

References:1

84.2%

References:1

86.1%

References:1

88.9%

References:1

None

References:8

None

References:1

None

References:1

None

References:1

None

References:8

common

None

References:1

None

References:1

None

References:1

None

References:2

None

References:1

None

References:1

None

References:1

None

References:2

None

References:2

56.4%

ambig
References:2

2.1x risk

93.1%

ambig
References:2

None

ambig
References:1

None

ambig
References:1

None

ambig
References:1

None

ambig
References:1

None

ambig
References:2

normal

54.5%

rs131702 (G;G)

Magnitude: 0.2
References:1

This genotype is normal for caucasians, but is reported to have 1.5x increased risk for bipolar disorder in one small study of japanese patients.

29.7%

rs7757037 (G;G)

Magnitude: 0
References:1

normal

50.5%

rs6458307 (C;C)

Magnitude: 0
References:2

1.4x risk

51.0%

rs1006737 (G;G)

Magnitude: 0
References:14

66.3%

rs1534891 (C;C)

Magnitude: 0
References:3

67.3%

rs4713902 (T;T)

Magnitude: 0
References:2

0.47x decreased risk for bipolar disorder

68.3%

rs945032 (G;G)

Magnitude: 0
References:1

72.3%

rs4948418 (C;C)

Magnitude: 0
References:1

73.3%

rs10134944 (C;C)

Magnitude: 0
References:1

normal

74.3%

rs11123857 (A;A)

Magnitude: 0
References:1

79.2%

rs7570682 (G;G)

Magnitude: 0
References:1

normal

84.2%

rs683395 (T;T)

Magnitude: 0
References:2

normal

90.1%

rs6990255 (C;C)

Magnitude: 0
References:1

98.0%

rs2609653 (T;T)

Magnitude: 0
References:1

normal

None

Magnitude: 0
References:11

None

rs17110563 (C;C)

Magnitude: 0
References:3

None

rs11178997 (T;T)

Magnitude: 0
ambig
References:6

common for Caucasians on the 23andme platform

95 snps

Breast cancer

(hide) Breast cancer

22.8%

rs762551 (C;C)

Magnitude: 2.5
References:7

CYP1A2 slow metabolizer more strongly affected by drinking coffee.

None

rs1135840 (C;G)

Magnitude: 1.5
References:3

Carrier of at least one CYP2D6 variants (non-CYP2D6*1)

39.6%

rs2046210 (C;T)

Magnitude: 1.4
References:11

1.4x increased breast cancer risk

45.5%

rs1801157 (A;G)

Magnitude: 1.4
References:6

1.4x higher risk for breast cancer

44.6%

rs1434536 (A;G)

Magnitude: 1.3
References:1

1.29x increased breast cancer risk

None

rs351855 (C;T)

Magnitude: 1.2
References:5

1.2x increased risk for prostate cancer

44.6%

rs13387042 (A;G)

Magnitude: 1.1
References:16

1.12x increased risk for breast cancer

57.4%

rs997669 (A;A)

Magnitude: 1.1
References:1

1.18x higher risk for breast cancer

None

rs889312 (C;C)

Magnitude: 1.1
References:16

Very slightly higher risk for breast cancer

2.0%

References:1

3.0%

References:1

poorer survival rate if breast cancer patient

3.1%

rs4986852 (A;G)

References:2

possible predisposition to breast cancer

4.0%

References:1

8.9%

References:2

9.2%

References:1

9.9%

References:2

10.9%

References:1

0.9x lower risk for breast cancer

14.0%

References:1

15.8%

References:6

16.8%

References:3

0.64x reduced risk for breast cancer, and higher likelihood of favorable postmenopausal hormone therapy

19.8%

References:1

22.8%

References:2

22.8%

References:3

24.8%

References:2

~2x higher risk for adverse drug reactions from cyclophosphamide treatments

25.7%

References:1

26.7%

References:6

27.7%

References:4

28.7%

References:2

28.7%

References:2

30.0%

References:1

30.7%

References:5

common

30.7%

References:1

31.7%

References:10

likely to require more methadone during heroin withdrawal

33.0%

References:2

34.7%

References:56

35.6%

References:1

35.6%

References:2

35.6%

References:1

36.0%

References:8

36.6%

References:1

37.6%

References:2

38.6%

References:3

38.6%

References:20

higher/earlier cancer likelihood??

39.0%

References:1

39.6%

References:1

common

39.6%

rs17822931 (C;C)

References:4

wet earwax

39.6%

References:1

40.6%

References:2

40.6%

References:1

41.6%

References:2

41.6%

References:12

41.6%

References:2

42.0%

References:1

42.6%

References:12

42.6%

References:35

multiple associations, see details

42.6%

rs699947 (A;C)

References:15

1.36x increased risk for thyroid cancer in men

43.6%

References:1

43.6%

References:3

44.4%

References:2

44.6%

References:1

44.6%

References:1

normal

44.6%

References:9

45.5%

References:7

45.5%

References:5

46.5%

References:1

46.5%

References:1

slightly reduced breast cancer odds?

46.5%

References:12

46.5%

References:1

0.5x decreased risk for several cancers

47.5%

References:3

47.9%

References:1

normal

48.5%

References:14

48.5%

References:3

0.64x reduced lymphoma risk

50.0%

References:1

50.5%

References:2

50.5%

References:19

52.0%

References:3

52.5%

References:1

1.08x increased risk for breast cancer

53.5%

References:8

53.5%

References:3

1.3x increased risk of death if diagnosed with breast cancer

57.4%

rs931127 (A;G)

References:1

In women diagnosed with breast cancer, this genotype is less favorable. It is more associated with lymph node metastasis

60.4%

References:2

60.4%

References:2

60.4%

References:1

60.4%

References:1

61.0%

References:1

61.4%

References:3

62.4%

References:1

63.4%

References:15

1.8x higher breast cancer risk

64.4%

References:2

66.3%

References:2

67.3%

References:2

74.0%

References:1

74.3%

References:1

74.3%

References:3

74.3%

References:1

normal

74.7%

References:9

79.2%

References:1

80.2%

References:1

81.0%

References:2

84.2%

References:3

85.1%

References:0

86.1%

References:2

89.1%

References:2

89.1%

References:1

91.1%

References:2

24% chance (lower than average) of docetaxel-induced leukopenia/neutropenia

97.0%

rs2854344 (G;G)

References:1

1.25x risk of developing ovarian cancer

None

References:0

None

References:7

None

References:1

normal

None

References:2

None

References:1

normal

None

References:4

None

References:11

None

References:1

None

References:1

None

References:1

None

References:3

normal

None

rs2981745 (C;C)

References:1

normal

None

References:2

None

References:1

1.55x higher risk for breast cancer

None

rs34815109 (I;I)

References:1

effects of higher bilirubin; irinotecan toxicity; tranilast toxicity http://web.me.com/russbaltman/Site/PharmGKBlog/Entries/2010/10/24_Updated_Irinotecan_Label.html

None

rs3738414 (G;G)

References:1

normal

None

References:8

None

References:2

None

References:1

None

References:3

None

References:1

None

References:24

None

None

References:1

None

References:1

normal

None

References:2

None

References:10

None

References:15

0.6x decreased risk for breast cancer

None

References:4

higher cancer risk

None

References:13

generally more cancer prone

None

References:1

None

References:1

None

References:1

normal

None

References:3

None

References:1

2x higher ER- breast cancer risk

None

References:1

41.6%

ambig
References:11

None

ambig
References:2

None

ambig
References:1

None

ambig
References:1

1.25x higher risk for breast cancer

None

ambig
References:1

None

ambig
References:1

None

ambig
References:4

None

ambig
References:2

0.51x decreased breast cancer risk

None

ambig
References:1

None

Magnitude: 0.1
References:4

a common variant

11.9%

rs2056116 (G;G)

Magnitude: 0
References:2

normal risk

23.8%

rs4415084 (C;C)

Magnitude: 0
References:6

25.7%

rs1126497 (C;C)

Magnitude: 0
References:1

normal

29.7%

rs16942 (A;A)

Magnitude: 0
References:1

29.7%

rs1056836 (C;G)

Magnitude: 0
References:14

normal

30.7%

rs1219648 (A;A)

Magnitude: 0
References:12

1.64x risk for breast cancer

31.6%

rs1799966 (A;A)

Magnitude: 0
References:1

32.0%

rs2420946 (C;C)

Magnitude: 0
References:2

common

35.6%

rs2981582 (C;C)

Magnitude: 0
References:17

normal

47.5%

rs144848 (T;T)

Magnitude: 0
References:3

normal

50.5%

rs6503691 (C;C)

Magnitude: 0
References:2

common

54.5%

rs3803662 (C;C)

Magnitude: 0
References:23

normal

56.4%

rs12255372 (G;G)

Magnitude: 0
References:12

66.3%

Magnitude: 0
References:4

normal risk

68.0%

rs2268578 (C;C)

Magnitude: 0
References:2

normal

69.3%

Magnitude: 0
References:45

70.0%

rs766173 (T;T)

Magnitude: 0
References:1

76.2%

rs10754339 (A;A)

Magnitude: 0
References:1

normal

76.2%

rs7158782 (A;A)

Magnitude: 0
References:1

normal

77.2%

rs500760 (A;A)

Magnitude: 0
References:2

78.2%

rs3218536 (G;G)

Magnitude: 0
References:4

normal risk

81.2%

rs25489 (G;G)

Magnitude: 0
References:4

normal risk

92.1%

Magnitude: 0
References:8

normal

94.1%

rs1800058 (C;C)

Magnitude: 0
References:1

98.0%

rs4986850 (G;G)

Magnitude: 0
References:1

98.0%

rs4987117 (C;C)

Magnitude: 0
References:1

99.0%

rs1799954 (C;C)

Magnitude: 0
References:1

99.0%

Magnitude: 0
References:8

normal/common

None

i4000377 (I;I)

Magnitude: 0
References:0

None

i4000378 (D;D)

Magnitude: 0
References:0

None

i4000379 (I;I)

Magnitude: 0
References:0

None

rs1042638 (C;C)

Magnitude: 0
References:1

None

Magnitude: 0
References:1

None

rs10895068 (G;G)

Magnitude: 0
References:5

normal

None

rs1136200 (C;C)

Magnitude: 0
References:1

None

rs11571746 (T;T)

Magnitude: 0
References:1

None

rs11571747 (A;A)

Magnitude: 0
References:1

None

rs12248560 (C;C)

Magnitude: 0
References:6

normal

None

rs17879961 (T;T)

Magnitude: 0
References:2

None

rs1799950 (A;A)

Magnitude: 0
References:1

normal breast cancer risk

None

rs1800056 (T;T)

Magnitude: 0
References:1

normal

None

rs1800709 (C;C)

Magnitude: 0
References:2

normal

None

rs1801426 (A;A)

Magnitude: 0
References:1

None

rs2227945 (A;A)

Magnitude: 0
References:1

None

rs2740574 (A;A)

Magnitude: 0
References:14

normal

None

rs28897672 (T;T)

Magnitude: 0
References:2

normal

None

rs28897696 (C;C)

Magnitude: 0
References:1

normal

None

rs28897756 (G;G)

Magnitude: 0
References:1

normal

None

rs3218695 (C;C)

Magnitude: 0
References:1

None

Magnitude: 0
References:10

complex; generally normal risk

None

rs41293455 (C;C)

Magnitude: 0
References:2

normal

None

rs41293463 (T;T)

Magnitude: 0
References:2

normal

None

rs41557318 (C;C)

Magnitude: 0
References:1

None

rs4986761 (T;T)

Magnitude: 0
References:1

normal

None

rs55770810 (C;C)

Magnitude: 0
References:1

normal

86.9%

rs11225297 (A;A)

Magnitude: 0
ambig
References:1

None

rs1045485 (G;G)

Magnitude: 0
ambig
References:5

None

rs11571833 (A;A)

Magnitude: 0
ambig
References:1

None

rs1800054 (C;C)

Magnitude: 0
ambig
References:2

None

rs1800057 (C;C)

Magnitude: 0
ambig
References:1

None

rs1801673 (A;A)

Magnitude: 0
ambig
References:1

None

rs2230782 (G;G)

Magnitude: 0
ambig
References:1

None

rs28997576 (G;G)

Magnitude: 0
ambig
References:3

None

rs3218707 (G;G)

Magnitude: 0
ambig
References:1

None

rs4987047 (A;A)

Magnitude: 0
ambig
References:1

216 snps

Cancer

(hide) Cancer

45.0%

Magnitude: 2.1
References:34

1.2x risk of prostate cancer 1.2x risk of prostate cancer

gs140

Magnitude: 1.7

Most non-Scandinavian Caucasians and approximately half of African-Americans are slow metabolizers. This variation is important because of its primary role in the deactivation of many chemicals in the body's environment, including those produced by caffeine and cigarettes as well as aromatic amine and hydrazine drugs used medicinally. In general, slow metabolizers have higher rates of certain types of cancer and are more susceptible to side effects from chemicals metabolized by NAT2. According to this source 6 snps determine NAT2 metabolism. The way their genotypes interact is very complex, which makes this one of the largest genosets in SNPedia. The SNPs are: *rs1208 *rs1041983 *rs1799929 *rs1799930 *rs1799931 *rs1801280

7.0%

References:7

15.8%

References:20

36.6%

References:4

46.5%

References:1

0.5x decreased risk for several cancers

48.5%

References:14

48.5%

References:4

51.5%

References:15

2x higher risk for skin cancer

57.4%

rs2228001 (A;C)

References:6

normal

64.4%

rs401681 (C;C)

References:14

~1.2x increased risk for several types of cancer

73.0%

rs2228000 (C;C)

References:3

normal

None

rs1799782 (C;C)

References:9

lower risk for skin cancer

None

rs2736098 (A;A)

References:6

slightly increased risk for several types of cancers

None

rs1042522 (C;G)

References:24

None

None

References:4

higher cancer risk

None

References:13

generally more cancer prone

75.2%

ambig
References:19

35.6%

Magnitude: 0
References:1

normal

35.6%

rs2464196 (C;C)

Magnitude: 0
References:2

normal

66.3%

Magnitude: 0
References:4

normal risk

69.3%

Magnitude: 0
References:45

99.0%

Magnitude: 0
References:14

Not a C282Y hemochromatosis carrier.

None

Magnitude: 0
References:1

None

rs1229984 (G;G)

Magnitude: 0
References:12

normal; more frequent alcohol consumption

None

rs1801394 (A;G)

Magnitude: 0
References:7

normal

None

rs1573496 (C;C)

Magnitude: 0
ambig
References:5

normal

1 genoset 26 snps

Cannabis dependence

2 snps

Cataracts

1 snp

Cervical cancer

(hide) Cervical cancer

5.9%

References:9

6.2%

References:1

20.8%

References:2

29.7%

References:2

41.0%

References:3

44.4%

References:2

47.5%

References:9

1.4x increased risk of psoriasis and psoriatic arthritis

77.2%

References:2

81.2%

References:1

9 snps

Cholesterol

(hide) Cholesterol

56.4%

Magnitude: 2.1
References:16

1.2x risk of coronary artery disease

80.2%

rs4939883 (C;C)

Magnitude: 1.5
References:6

associated with higher HDL cholesterol

5.0%

References:4

11.9%

References:2

12.9%

References:1

13.9%

References:2

15.8%

References:4

16.8%

References:3

17.0%

References:6

21.8%

References:3

21.8%

References:6

21.8%

References:1

26.7%

References:7

33.7%

References:4

36.6%

References:2

37.6%

References:2

40.6%

References:5

46.5%

References:6

49.5%

References:2

52.5%

References:2

53.5%

References:3

56.4%

References:13

normal

63.4%

References:7

65.3%

References:3

66.3%

References:3

85.1%

References:2

None

ambig
References:1

42.6%

Magnitude: 0
References:2

54.0%

rs9891572 (C;C)

Magnitude: 0
References:2

57.4%

rs7679 (T;T)

Magnitude: 0
References:3

65.3%

rs2304130 (A;A)

Magnitude: 0
References:5

78.2%

rs2075650 (A;A)

Magnitude: 0
References:15

normal

82.2%

rs17228212 (T;T)

Magnitude: 0
References:1

normal

93.1%

rs12272004 (C;C)

Magnitude: 0
References:6

95.0%

rs174570 (C;C)

Magnitude: 0
References:5

95.0%

rs1800961 (C;C)

Magnitude: 0
References:4

99.0%

rs5031002 (G;G)

Magnitude: 0
References:2

None

rs7895372 (C;C)

Magnitude: 0
ambig
References:2

38 snps

Chondrodysplasia

4 snps

Chorionic plate inflammation

2 snps

Chronic kidney disease

(hide) Chronic kidney disease

8.9%

References:1

9.9%

References:1

11.9%

References:1

16.0%

References:2

23.2%

References:1

1.2x increased risk for chronic kidney disease

27.7%

References:2

31.7%

References:1

32.7%

References:1

33.7%

References:19

35.6%

References:1

46.9%

References:1

75.2%

References:1

78.2%

References:1

78.2%

References:7

85.1%

References:1

91.1%

References:1

None

References:1

None

References:2

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

58.0%

Magnitude: 0
References:3

91.0%

rs10794720 (C;C)

Magnitude: 0
References:1

30 snps

Chronic obstructive pulmonary disease

(hide) Chronic obstructive pulmonary disease

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

None

rs543749 (G;G)

Magnitude: 2.1
References:0

if a smoker, somewhat more likely to develop COPD if a smoker, somewhat more likely to develop COPD

16.8%

rs1800469 (T;T)

References:7

normal risk

25.7%

rs17576 (A;A)

References:9

normal risk for lung cancer; higher risk for MI

30.7%

rs16969968 (A;G)

References:24

slightly higher risk for nicotine dependence, lower risk for cocaine dependence

39.6%

References:1

47.5%

References:1

51.5%

References:5

54.5%

References:2

58.4%

References:1

normal

83.2%

References:0

None

References:11

None

References:1

None

References:1

if a smoker, somewhat more likely to develop COPD

None

rs8192288 (G;G)

References:1

normal

None

rs242941 (G;T)

References:2

normal

66.3%

Magnitude: 0
References:4

normal risk

69.3%

rs8192287 (G;G)

Magnitude: 0
References:1

normal

94.1%

rs1009668 (G;G)

Magnitude: 0
References:1

None

rs28929474 (G;G)

Magnitude: 0
References:4

None

rs17580 (A;A)

Magnitude: 0
ambig
References:1

21 snps

Cleft palate

(hide) Cleft palate

51.5%

References:1

53.5%

References:1

58.6%

Magnitude: 0
References:6

normal

69.3%

Magnitude: 0
References:45

4 snps

Cluster headaches

1 snp

Colon cancer

(hide) Colon cancer

45.0%

Magnitude: 2.1
References:34

1.2x risk of prostate cancer 1.2x risk of prostate cancer

38.0%

References:0

39.6%

References:0

39.6%

References:1

None

References:0

None

References:4

higher cancer risk

None

ambig
References:1

45.5%

Magnitude: 0
References:3

normal

90.1%

rs2308327 (A;A)

Magnitude: 0
References:2

normal

9 snps

Conduct disorder

(hide) Conduct disorder

11.9%

References:3

21.8%

References:1

29.7%

References:1

34.0%

References:1

36.6%

References:1

51.0%

References:1

52.0%

References:1

53.5%

References:1

54.5%

References:1

81.2%

References:1

83.2%

References:1

91.1%

Magnitude: 1
References:1

Conduct disorder (CD) is one of the most prevalent childhood psychiatric conditions, and is associated with a number of serious concomitant and future problems. CD symptomatology is known to have a considerable genetic component, with heritability estimates in the range of 50%. Four SNPs reached genome-wide significance with CD symptom count, based on P < 5x10^-8 Two of these SNPs (rs16891867 and rs1861046) were in the gene C1QTNF7 (C1q and tumor necrosis factor-related protein 7). These SNPs were in high LD (r^2=0.97). The other top two SNPs meeting genome-wide significance were intergenic and located on chromosomes 11 and 13. Alleles A/G were found to be associated with CD symptom count or CD case status. [http://www.downstate.edu/hbnl/documents/2010-Dick-Genome-wideassociationstudyof...

91.1%

References:1

40.6%

Magnitude: 0
References:1

88.1%

rs7950811 (C;C)

Magnitude: 0
References:1

97.0%

rs2720508 (T;T)

Magnitude: 0
References:1

99.0%

rs7581919 (T;T)

Magnitude: 0
References:1

None

rs8179116 (G;G)

Magnitude: 0
References:1

18 snps

Coronary artery disease

(hide) Coronary artery disease

19.8%

rs1333049 (C;C)

Magnitude: 4
ambig
References:19

1.9x increased risk for CAD

None

rs2383206 (G;G)

Magnitude: 3
References:5

1.7x increased risk for heart disease spittoon People with this genotype and a long history of high blood sugar are at 7x risk of CAD

20.8%

rs1333048 (C;C)

Magnitude: 2.1
References:3

1.5x increased coronary artery disease risk; 2x increased periodontitis risk 2x increased risk of periodontitis and coronary heart disease as discussed at spittoon

27.7%

Magnitude: 2.1
References:7

increased risk for heart disease

56.4%

Magnitude: 2.1
References:16

1.2x risk of coronary artery disease

None

Magnitude: 2.1
References:20

1.6x risk for MI

69.3%

rs17672135 (T;T)

Magnitude: 2
References:2

1.3x risk

97.0%

rs7250581 (G;G)

Magnitude: 2
References:2

1.4x risk 1.4x higher risk for coronary artery disease

40.6%

rs17465637 (C;C)

Magnitude: 1.34
References:6

1.34x higher risk for myocardial infarction

7.9%

References:10

10.9%

References:4

12.9%

References:2

1.1x risk

17.0%

References:6

17.8%

References:3

19.8%

References:4

19.8%

References:7

20.8%

References:1

1.6x risk

21.8%

rs10757272 (T;T)

References:1

1.54x increased risk for Coronary artery disease

25.0%

References:3

25.7%

References:2

29.7%

References:2

1.9x risk

31.7%

References:3

37.6%

References:1

41.6%

References:1

42.9%

References:7

1.2x risk

43.6%

References:4

48.5%

References:2

78.2%

References:7

80.6%

References:1

85.0%

References:3

85.1%

References:1

None

References:7

~1.3x increased risk for heart disease

None

References:3

None

References:6

None

References:1

None

References:9

32.3%

ambig
References:1

63.0%

ambig
References:1

63.4%

ambig
References:1

75.2%

ambig
References:19

None

ambig
References:1

69.3%

Magnitude: 0
References:45

78.2%

Magnitude: 0
References:16

normal

98.0%

rs6725887 (T;T)

Magnitude: 0
References:4

99.0%

rs17602729 (G;G)

Magnitude: 0
References:3

common

None

rs10455872 (A;A)

Magnitude: 0
References:4

None

rs1800588 (C;C)

Magnitude: 0
References:7

None

rs3008621 (G;G)

Magnitude: 0
References:2

None

rs3798220 (T;T)

Magnitude: 0
References:5

normal

None

Magnitude: 0
References:14

higher risk for several conditions

None

rs1800796 (G;G)

Magnitude: 0
ambig
References:9

appears to be common on the 23andMe platform

51 snps

Crigler-Najjar syndrome

2 snps

Canavan disease

3 snps

Celiac disease

(hide) Celiac disease

1.0%

rs2187668 (A;A)

Magnitude: 3
References:6

Autoimmune disorder risk (lupus, celiac disease) due to 2 HLA-DRB1*0301 alleles

2.0%

References:1

5.0%

References:1

5.9%

References:2

18.8%

References:6

21.8%

References:1

30.7%

References:1

30.7%

References:1

30.7%

References:1

31.3%

References:1

32.7%

References:3

33.7%

References:1

34.7%

References:1

34.7%

References:1

34.7%

References:2

35.0%

References:2

36.6%

References:1

37.6%

References:1

41.6%

References:4

41.6%

References:1

41.6%

References:3

45.5%

References:1

46.5%

References:1

46.5%

References:3

48.5%

References:4

48.5%

References:7

51.5%

References:9

54.5%

References:6

58.4%

References:4

65.3%

References:1

66.3%

References:1

67.3%

References:1

69.3%

Magnitude: 1
References:3

1.1x increased risk for schizophrenia

72.3%

References:1

78.2%

References:1

78.2%

References:7

81.0%

References:2

82.2%

References:7

82.2%

References:2

84.2%

References:1

87.1%

References:1

88.1%

References:6

93.1%

References:1

99.0%

References:1

44.6%

Magnitude: 0
References:1

53.5%

rs7775228 (T;T)

Magnitude: 0
References:2

78.2%

Magnitude: 0
References:16

normal

83.0%

rs2762051 (C;C)

Magnitude: 0
References:1

89.1%

rs6822844 (G;G)

Magnitude: 0
References:14

98.0%

Magnitude: 0
References:25

normal

None

rs13151961 (A;A)

Magnitude: 0
References:6

None

rs17810546 (A;A)

Magnitude: 0
References:5

52 snps

Charcot-Marie-Tooth

7 snps

Colorectal cancer

(hide) Colorectal cancer

45.0%

Magnitude: 2.1
References:34

1.2x risk of prostate cancer 1.2x risk of prostate cancer

36.6%

rs1801274 (T;T)

References:13

complex; generally greater risk for cancer progression

41.4%

References:10

44.6%

References:7

44.6%

References:6

1.11x increased risk for colorectal cancer

44.6%

rs4939827 (C;T)

References:15

0.86x decreased risk for colorectal cancer

46.0%

rs4779584 (C;T)

References:8

1.23x risk for colorectal cancer

46.5%

References:6

47.5%

References:6

48.0%

References:5

51.5%

References:6

53.5%

References:6

86.1%

References:5

1x normal risk for colorectal cancer

None

rs1799732 (I;I)

References:19

normal

None

rs34815109 (I;I)

References:1

effects of higher bilirubin; irinotecan toxicity; tranilast toxicity http://web.me.com/russbaltman/Site/PharmGKBlog/Entries/2010/10/24_Updated_Irinotecan_Label.html

None

References:7

None

References:4

1.46x increased risk for colorectal cancer

None

References:1

None

References:24

None

None

References:4

higher cancer risk

None

References:1

None

References:1

None

References:13

0.73x decreased risk for colorectal cancer

None

ambig
References:0

None

ambig
References:2

37.8%

Magnitude: 0
References:13

normal

41.0%

rs1800734 (G;G)

Magnitude: 0
References:6

48.5%

rs2306536 (C;C)

Magnitude: 0
References:1

average

51.5%

Magnitude: 0
References:55

normal form

52.5%

Magnitude: 0
References:34

A2/A2 [[bupropion]] effective

65.3%

rs3802842 (A;A)

Magnitude: 0
References:9

normal

90.1%

rs2308327 (A;A)

Magnitude: 0
References:2

normal

95.0%

rs16892766 (A;A)

Magnitude: 0
References:7

98.0%

rs4648261 (G;G)

Magnitude: 0
References:2

None

Magnitude: 0
References:1

None

rs16906252 (G;G)

Magnitude: 0
References:3

None

rs1801278 (G;G)

Magnitude: 0
References:3

normal

None

rs34612342 (A;A)

Magnitude: 0
References:3

normal

None

rs36053993 (G;G)

Magnitude: 0
References:2

normal

None

rs1801155 (T;T)

Magnitude: 0
ambig
References:1

common for Caucasians on the 23andme platform

40 snps

Crohn's disease

(hide) Crohn's disease

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

23.8%

rs2241880 (C;C)

Magnitude: 2
References:14

2x-3x increased risk for Crohn's disease in Caucasians

None

rs12567232 (A;G)

Magnitude: 2
References:2

Increased risk for Crohn's Disease

25.3%

rs13361189 (C;T)

Magnitude: 1.3
References:6

1.3x increased risk for Crohn's disease

33.7%

rs4958847 (A;G)

Magnitude: 1.3
References:5

1.3x increased risk for Crohn's disease

8.9%

References:2

8.9%

References:1

10.9%

References:4

10.9%

References:2

1.5x risk of Crohn's disease

14.9%

References:3

17.8%

References:13

1.3x risk for Crohn's; 1.3x for T1D

18.8%

References:6

20.0%

References:2

20.8%

References:5

23.8%

References:2

1.8x risk

23.8%

References:2

24.0%

References:2

24.8%

References:1

24.8%

References:2

24.8%

References:1

25.7%

References:2

26.7%

References:8

28.7%

References:3

32.7%

References:2

33.7%

References:1

33.7%

References:7

35.4%

References:3

35.6%

References:8

1.1x risk

36.6%

References:3

37.6%

References:1

37.6%

References:4

1.2x risk

38.6%

References:2

39.6%

References:4

41.0%

References:3

42.6%

References:3

42.6%

References:2

42.6%

References:1

43.6%

References:1

1.5x risk

43.6%

rs7517847 (G;T)

References:13

possibly reduced risk for Crohn's disease

44.0%

References:2

44.6%

References:2

45.5%

References:2

45.5%

References:10

1.5x risk for certain autoimmune diseases; 2x risk for Graves disease

45.5%

References:5

46.0%

References:5

46.0%

References:8

1.5x risk for Crohn's disease; 2x risk for Graves' disease

46.5%

rs7807268 (C;G)

References:1

1.3x risk

47.4%

References:1

47.5%

References:6

47.5%

References:1

1.5x risk

49.0%

rs6908425 (C;C)

References:5

1.9x risk

49.5%

References:3

49.5%

References:1

1.5x risk of Crohn's disease

49.5%

rs1004819 (C;T)

References:12

1.5x risk

49.5%

rs10883365 (A;G)

References:8

1.2x increased risk for Crohn's disease

49.5%

References:3

49.5%

References:1

50.0%

References:3

1.4x risk

50.5%

References:1

50.5%

References:1

51.5%

References:1

51.5%

References:9

56.4%

References:2

57.4%

References:1

normal

57.4%

References:6

58.4%

References:1

59.4%

References:3

60.4%

References:3

62.4%

References:3

62.4%

References:2

63.4%

References:2

77.2%

References:1

81.2%

References:2

81.2%

References:4

82.2%

References:4

83.2%

References:3

86.9%

References:2

87.1%

References:2

97.0%

References:5

99.0%

References:3

None

References:11

None

References:3

0.72x decreased risk for Crohn's disease

None

rs1992662 (C;C)

References:1

increased risk for Crohn's disease

None

References:1

None

References:2

None

References:2

None

References:5

None

References:2

None

References:2

None

References:2

0.77x risk for Crohn's disease

None

References:1

None

References:2

None

References:1

None

References:2

24.8%

ambig
References:1

37.0%

ambig
References:8

1.4x increased risk of psoriasis, psoriatic arthritis

62.4%

ambig
References:2

69.3%

ambig
References:3

2x risk

75.2%

ambig
References:19

81.2%

ambig
References:2

82.2%

ambig
References:2

normal

None

ambig
References:2

None

ambig
References:4

normal risk

None

ambig
References:1

None

ambig
References:5

Increased risk for Crohn's Disease

13.9%

rs5051 (C;C)

Magnitude: 0
References:1

increased risk for hypertension

16.8%

rs9469220 (G;G)

Magnitude: 0
References:2

normal

31.7%

rs11362 (G;G)

Magnitude: 0
References:4

normal risk

40.0%

Magnitude: 0
References:34

common

71.3%

rs1343151 (C;C)

Magnitude: 0
References:6

normal risk

80.2%

rs1050152 (C;C)

Magnitude: 0
References:6

normal

82.2%

rs11465770 (C;C)

Magnitude: 0
References:1

normal Crohn's Disease risk

84.2%

rs3792876 (C;C)

Magnitude: 0
References:2

85.1%

rs11175593 (C;C)

Magnitude: 0
References:1

85.1%

rs2076756 (A;A)

Magnitude: 0
References:6

normal

88.1%

rs10733113 (G;G)

Magnitude: 0
References:3

95.0%

rs10130695 (C;C)

Magnitude: 0
References:1

95.0%

rs8111071 (A;A)

Magnitude: 0
References:1

normal

97.0%

rs17234657 (T;T)

Magnitude: 0
References:4

normal

98.0%

Magnitude: 0
References:25

normal

99.0%

Magnitude: 0
References:27

common

99.0%

Magnitude: 0
References:7

normal

None

rs11465804 (T;T)

Magnitude: 0
References:6

normal risk

None

Magnitude: 0
References:10

normal although rare for caucasians, normal for the asian population studied

None

rs2066844 (C;C)

Magnitude: 0
References:7

None

rs2066847 (D;D)

Magnitude: 0
References:6

None

rs1800471 (G;G)

Magnitude: 0
ambig
References:5

common This appears to be the common allele among an ambiguous flip

None

rs2066845 (G;G)

Magnitude: 0
ambig
References:8

appears to be common on the 23andMe platform

128 snps

Cystic Fibrosis

(hide) Cystic Fibrosis

7.9%

rs1143634 (T;T)

References:9

complex; see details

47.5%

References:1

None

References:1

None

References:3

None

References:1

None

References:1

None

References:1

None

Magnitude: 0
References:0

None

rs28929474 (G;G)

Magnitude: 0
References:4

None

rs17580 (A;A)

Magnitude: 0
ambig
References:1

10 snps

Deafness

(hide) Deafness

57.4%

rs1027557 (A;A)

Magnitude: 0
References:1

81.2%

rs180275 (C;C)

Magnitude: 0
References:1

None

rs28929485 (C;C)

Magnitude: 0
References:1

None

rs28931593 (G;G)

Magnitude: 0
References:1

None

rs28931594 (G;G)

Magnitude: 0
References:1

None

rs28931595 (G;G)

Magnitude: 0
References:1

None

rs28937893 (G;G)

Magnitude: 0
References:1

None

rs28937894 (C;C)

Magnitude: 0
References:1

None

rs28937895 (G;G)

Magnitude: 0
References:1

None

rs28939690 (A;A)

Magnitude: 0
References:0

None

rs28940307 (C;C)

Magnitude: 0
References:1

None

rs28942096 (C;C)

Magnitude: 0
References:1

None

rs28942097 (C;C)

Magnitude: 0
References:1

None

rs28999111 (C;C)

Magnitude: 0
References:1

None

rs28999112 (C;C)

Magnitude: 0
References:1

None

rs35887622 (A;A)

Magnitude: 0
References:2

None

rs726640 (C;C)

Magnitude: 0
References:1

None

rs648298 (A;G)

Magnitude: 0
References:1

None

rs28931592 (A;A)

Magnitude: 0
ambig
References:1

None

rs28937589 (G;G)

Magnitude: 0
ambig
References:0

None

rs28937591 (C;C)

Magnitude: 0
ambig
References:1

21 snps

Deep vein thrombosis

(hide) Deep vein thrombosis

6.9%

References:1

43.6%

References:1

53.5%

References:2

None

References:2

52.5%

Magnitude: 0
References:2

79.2%

rs2227589 (G;G)

Magnitude: 0
References:1

6 snps

Dementia

2 snps

Diabetes

(hide) Diabetes

None

rs2383206 (G;G)

Magnitude: 3
References:5

1.7x increased risk for heart disease spittoon People with this genotype and a long history of high blood sugar are at 7x risk of CAD

None

Magnitude: 2.1
References:20

1.6x risk for MI

12.1%

References:1

12.9%

References:1

23.8%

References:1

23.8%

References:1

24.0%

References:1

48.5%

References:12

normal

53.5%

References:3

66.3%

References:2

99.0%

References:8

normal

None

rs10757274 (G;G)

References:7

~1.3x increased risk for heart disease

None

ambig
References:17

26.7%

Magnitude: 0.5
References:2

no credible risk

74.3%

rs1057910 (A;A)

Magnitude: 0.1
References:17

normal; no effect on warfarin metabolism

58.0%

Magnitude: 0
References:3

99.0%

Magnitude: 0
References:14

Not a C282Y hemochromatosis carrier.

None

Magnitude: 0
References:10

complex; generally normal risk

None

Magnitude: 0
References:14

higher risk for several conditions

19 snps

Drug abuse

3 snps

Dyslexia

(hide) Dyslexia

None

rs2143340 (C;C)

Magnitude: 2.3
References:3

> 2x risk of dyslexia and poor reading performance

15.8%

References:1

23.8%

References:0

27.7%

References:1

34.7%

References:1

higher risk for dyslexia

55.4%

References:1

60.4%

References:2

67.3%

References:2

82.2%

References:1

None

References:1

normal risk

None

rs807701 (T;T)

References:1

common

None

References:2

86.1%

Magnitude: 0
References:1

86.1%

rs4576240 (G;G)

Magnitude: 0
References:0

90.1%

rs7765678 (T;T)

Magnitude: 0
References:2

None

rs4504469 (C;C)

Magnitude: 0
References:3

common

None

rs793862 (G;G)

Magnitude: 0
References:1

common

17 snps

Dystonia

(hide) Dystonia

None

rs13283584 (C;C)

References:2

32.7%

rs167771 (A;A)

Magnitude: 0
References:3

None

rs1182 (C;C)

Magnitude: 0
References:2

None

rs2296793 (G;G)

Magnitude: 0
References:2

None

rs41298442 (A;A)

Magnitude: 0
References:2

5 snps

Depression

(hide) Depression

27.7%

Magnitude: 2.4
References:27

None

rs25531 (G;G)

Magnitude: 2.1
References:25

happier, less sensitive to pain less sensitive to pain

39.6%

rs1545843 (A;A)

Magnitude: 1.4
References:1

1.4x increased risk for depression (for those under 55)

3.0%

References:1

13.9%

References:11

1.3x increased risk for depression

13.9%

References:7

14.9%

References:2

1.9x higher risk of suicidal thoughts when taking [[citalopram]]

23.8%

References:2

25.7%

References:2

26.7%

References:1

27.7%

References:1

27.7%

References:1

32.7%

References:3

33.0%

References:2

33.7%

References:1

33.7%

References:2

34.7%

References:56

37.6%

References:12

37.6%

References:1

40.0%

References:1

40.6%

References:1

41.6%

References:1

42.6%

References:35

multiple associations, see details

45.5%

References:2

45.5%

References:1

46.5%

References:1

1.3x increased risk for depression

47.0%

References:1

47.5%

References:2

50.5%

References:1

54.5%

References:1

55.4%

References:1

57.4%

References:2

7x less likely to respond to certain antidepressants

59.4%

References:1

64.4%

References:1

65.3%

References:1

65.3%

References:4

more resistant to treatment for depression

65.3%

rs11983225 (T;T)

References:1

7x less likely to respond to certain antidepressants

65.3%

rs4148739 (A;A)

References:1

7x less likely to respond to certain antidepressants

65.3%

References:1

67.3%

References:1

71.3%

References:1

73.0%

References:2

73.3%

References:2

77.2%

References:1

81.0%

References:1

81.2%

References:1

86.1%

References:1

93.1%

References:1

93.1%

References:1

93.9%

References:5

higher risk for RA

96.0%

References:1

None

References:2

if depressed, 2.6x more likely to not respond to antidepressants

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:4

None

References:3

None

References:1

normal risk

None

References:1

None

References:8

common

None

rs3813929 (C;C)

References:11

possible weight gain if taking olanzapine

None

rs4148740 (T;T)

References:1

7x less likely to respond to certain antidepressants

None

References:2

None

References:1

None

References:1

None

References:1

None

References:9

~18% less likely to respond to citalopram

None

References:1

None

References:1

None

References:3

None

References:1

None

References:1

None

References:1

None

References:2

None

References:1

18.8%

ambig
References:1

None

ambig
References:17

None

ambig
References:1

None

Magnitude: 0
References:3

normal

47.5%

rs1954787 (C;T)

Magnitude: 0
References:3

normal risk

57.0%

rs7787082 (G;G)

Magnitude: 0
References:1

7x less likely to respond to certain antidepressants

65.3%

rs12720067 (G;G)

Magnitude: 0
References:1

7x less likely to respond to certain antidepressants

65.3%

rs2032583 (T;T)

Magnitude: 0
References:2

7x less likely to respond to certain antidepressants

65.3%

rs2235015 (G;G)

Magnitude: 0
References:1

7x more likely to respond to certain antidepressants

65.3%

rs2235040 (G;G)

Magnitude: 0
References:1

7x less likely to respond to certain antidepressants

69.3%

Magnitude: 0
References:45

69.3%

rs3761418 (A;A)

Magnitude: 0
References:1

1.3x increased risk for depression

70.3%

rs2267013 (A;A)

Magnitude: 0
References:1

1.3x increased risk for depression

71.3%

rs2235067 (G;G)

Magnitude: 0
References:0

7x less likely to respond to certain antidepressants

71.3%

rs6198 (A;A)

Magnitude: 0
References:4

87.1%

rs4238010 (A;A)

Magnitude: 0
References:2

94.1%

rs2518224 (A;A)

Magnitude: 0
References:2

normal

99.0%

rs5558 (T;T)

Magnitude: 0
References:1

normal

None

rs12936511 (C;C)

Magnitude: 0
References:1

normal

None

rs17110563 (C;C)

Magnitude: 0
References:3

None

rs1799913 (C;C)

Magnitude: 0
References:3

None

rs3892097 (G;G)

Magnitude: 0
References:9

extensive metabolizer

None

rs41282918 (A;A)

Magnitude: 0
References:1

None

rs11178997 (T;T)

Magnitude: 0
ambig
References:6

common for Caucasians on the 23andme platform

None

rs2326810 (G;G)

Magnitude: 0
ambig
References:1

103 snps

Diabetes Mellitus

(hide) Diabetes Mellitus

21.8%

rs9272346 (A;A)

Magnitude: 2.7
References:4

18.5x risk of Type-1 Diabetes Although found in approximately 1/3rd of all people, this variation appears to significantly increase risk of Type-1 diabetes. This increases your relative risk approximately 18x, which changes your lifetime risk from a very small 0.04% to a still very small 0.75% chance. Your odds are not 75%, they are 0.75%, which is less than 1%. You should consult the Type-1 diabetes Medical Condition to see other snps that influence your risk.

None

Magnitude: 2.5
References:16

2.5x increased risk for type-2 diabetes

52.5%

rs4402960 (G;T)

Magnitude: 2
References:19

1.2x increased risk for type-2 diabetes

10.9%

rs12304921 (G;G)

References:2

1.9x risk

17.8%

References:3

17.8%

References:13

1.3x risk for Crohn's; 1.3x for T1D

24.8%

References:3

25.7%

References:8

1.3x risk

26.3%

rs17388568 (A;G)

References:8

1.3x risk

28.7%

References:5

30.7%

References:3

30.7%

References:4

normal

31.7%

References:8

32.0%

References:7

32.7%

References:4

1.3x risk

33.0%

rs5498 (G;G)

References:7

0.6x decreased risk for diabetic nephropathy in females with type-1 diabetes; increased malaria risk

33.7%

References:2

33.7%

References:27

metabolic consequences

38.6%

References:3

40.0%

References:5

43.0%

References:2

44.6%

References:3

44.6%

References:13

somewhat increased risk for multiple autoimmune diseases

45.5%

References:3

45.5%

References:12

1.2x risk

45.5%

References:6

47.0%

References:6

48.0%

References:2

1.3x risk

48.5%

References:4

48.5%

References:4

49.5%

References:2

1.5x risk

49.5%

References:3

52.0%

References:5

53.5%

References:2

56.4%

References:2

61.4%

References:6

61.4%

References:26

increased risk for type-2 diabetes

64.6%

References:4

65.7%

References:3

>1.5x risk for T2D

66.3%

References:5

67.0%

References:3

68.3%

References:4

81.2%

References:2

1.8x risk of type-2 diabetes

82.0%

References:3

85.0%

References:3

None

References:2

None

References:3

None

References:4

None

References:5

None

References:2

None

References:2

None

References:2

None

References:11

CYP2C9*2 carrier; average 20% reduction in warfarin metabolism

None

References:4

None

References:6

74.3%

Magnitude: 0.1
References:17

normal; no effect on warfarin metabolism

0.0%

rs10811661 (C;C)

Magnitude: 0
References:25

normal

32.7%

rs1111875 (A;A)

Magnitude: 0
References:18

1x normal risk of T2D

40.6%

Magnitude: 0
References:16

increased risk for auto-immune diseases

51.5%

Magnitude: 0
References:55

normal form

56.4%

rs8050136 (C;C)

Magnitude: 0
References:26

normal

57.4%

rs7756992 (A;A)

Magnitude: 0
References:9

normal

59.4%

rs9465871 (T;T)

Magnitude: 0
References:4

normal

78.2%

rs17696736 (A;A)

Magnitude: 0
References:9

normal

92.1%

Magnitude: 0
References:8

normal

98.0%

rs2237892 (C;C)

Magnitude: 0
References:11

99.0%

Magnitude: 0
References:7

normal

None

rs2237897 (C;C)

Magnitude: 0
References:8

common

56.4%

Magnitude: 0
ambig
References:57

common

61.4%

rs7754840 (G;G)

Magnitude: 0
ambig
References:11

normal

None

rs1801253 (C;C)

Magnitude: 0
ambig
References:8

responds well to bucindolol; may also depend on rs1801252

71 snps

Earwax

1 snp

Eczema

(hide) Eczema

None

References:1

None

References:1

61.0%

Magnitude: 0
References:2

normal but highest IgE levels

None

rs2427837 (G;G)

Magnitude: 0
References:1

normal but highest IgE levels

4 snps

Emphysema

3 snps

Endometrial cancer

(hide) Endometrial cancer

36.6%

References:2

40.6%

References:3

41.6%

References:8

higher risk for endometrial cancer

42.6%

rs4680 (A;G)

References:35

multiple associations, see details

42.6%

References:4

87.1%

References:6

best inverse correlation between tea-drinking, soy-consuming premenopausal women and risk of endometrial cancer

None

References:4

None

References:24

None

None

References:13

generally more cancer prone

None

rs9340799 (A;G)

References:12

10 snps

Endometriosis

(hide) Endometriosis

12.9%

References:1

None

References:12

75.2%

ambig
References:19

91.0%

Magnitude: 0
References:1

None

Magnitude: 0
References:10

normal although rare for caucasians, normal for the asian population studied

5 snps

Eosinophilic esophagitis

1 snp

Epilepsy

(hide) Epilepsy

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

26.7%

References:6

34.7%

References:56

34.7%

References:1

34.7%

References:2

34.7%

References:1

47.5%

References:6

53.5%

References:7

None

References:1

None

References:4

None

References:2

None

ambig
References:3

None

ambig
References:2

74.3%

Magnitude: 0.1
References:17

normal; no effect on warfarin metabolism

53.5%

rs2273697 (G;G)

Magnitude: 0
References:4

normal/common

87.1%

rs2844682 (C;C)

Magnitude: 0
References:2

99.0%

rs2304016 (A;A)

Magnitude: 0
References:2

17 snps

Familial hypertrophic cardiomyopathy

7 snps

Familial Mediterranean fever

(hide) Familial Mediterranean fever

None

rs11466023 (C;C)

Magnitude: 0
References:1

None

rs28940578 (G;G)

Magnitude: 0
References:1

None

rs28940579 (T;T)

Magnitude: 0
References:1

None

rs28940580 (G;G)

Magnitude: 0
References:0

None

rs3743930 (G;G)

Magnitude: 0
ambig
References:1

5 snps

Familial dysautonomia

2 snps

Fibromyalgia

(hide) Fibromyalgia

8.9%

References:1

15.8%

References:1

30.7%

References:14

normal

33.7%

References:1

42.6%

References:35

multiple associations, see details

None

References:1

None

References:12

complex; see details for increased risks

74.3%

rs4994 (T;T)

Magnitude: 0
References:7

normal

8 snps

Gallbladder cancer

(hide) Gallbladder cancer

None

rs4444903 (A;G)

Magnitude: 2
References:6

3.5x risk of hep-cancer in cirrhosis patients; higher glioma risk

None

rs440446 (C;G)

References:3

increased risk in men for biliary conditions

None

rs1052133 (C;C)

Magnitude: 0
ambig
References:10

normal

3 snps

Gallstone disease

(hide) Gallstone disease

5.0%

References:2

5.0%

References:4

None

References:3

increased risk in men for biliary conditions

74.3%

rs4994 (T;T)

Magnitude: 0
References:7

normal

None

rs11887534 (G;G)

Magnitude: 0
ambig
References:7

normal risk for gallstones

5 snps

Gastric cancer

(hide) Gastric cancer

22.8%

rs2294008 (T;T)

Magnitude: 2.1
References:12

increased risk of gastric and bladder cancer

None

rs2227692 (C;T)

Magnitude: 1.6
References:1

1.6x higher risk for diffuse gastric cancer

22.8%

References:4

37.6%

Magnitude: 1
References:0

among patients with gastric cancer, risk for more aggressive form?

39.6%

rs2275913 (G;G)

References:3

normal

96.0%

References:1

None

References:1

None

References:2

None

References:24

None

None

ambig
References:0

54.5%

Magnitude: 0
References:2

normal

69.3%

Magnitude: 0
References:45

83.2%

rs2070600 (G;G)

Magnitude: 0
References:9

normal

None

Magnitude: 0
References:1

14 snps

Gaucher's disease

(hide) Gaucher's disease

None

References:0

None

References:0

None

References:2

None

Magnitude: 0
References:0

None

i4000419 (C;C)

Magnitude: 0
References:0

normal

None

rs364897 (A;A)

Magnitude: 0
References:2

6 snps

GERD

2 snps

Glaucoma

(hide) Glaucoma

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

10.9%

References:6

30.7%

References:1

31.0%

Magnitude: 1
References:9

possibly higher glaucoma risk?

31.7%

References:1

33.7%

References:1

42.6%

References:0

None

Magnitude: 1
References:8

possibly higher glaucoma risk? glaucoma risk likely to actually be based on nearby rs3825942

63.4%

ambig
References:1

39.6%

Magnitude: 0
References:6

normal

94.1%

rs4656461 (A;A)

Magnitude: 0
References:1

normal

None

rs28936694 (G;G)

Magnitude: 0
References:1

12 snps

Glioma

(hide) Glioma

10.9%

References:4

10.9%

References:6

13.9%

References:1

29.7%

References:1

normal

40.4%

References:18

71.0%

References:1

None

ambig
References:1

32.7%

Magnitude: 0
References:5

39.6%

rs2853676 (G;G)

Magnitude: 0
References:1

60.4%

rs4295627 (T;T)

Magnitude: 0
References:4

68.3%

rs6010620 (G;G)

Magnitude: 0
References:7

85.0%

rs1805388 (C;C)

Magnitude: 0
References:5

12 snps

Glycogen storage disease type 1A

1 snp

Graves' disease

(hide) Graves' disease

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

35.6%

References:5

45.5%

References:10

1.5x risk for certain autoimmune diseases; 2x risk for Graves disease

46.0%

rs2201841 (C;T)

References:8

1.5x risk for Crohn's disease; 2x risk for Graves' disease

46.5%

rs3748079 (G;G)

References:2

1.9x increased risk for SLE (lupus)

46.5%

References:12

49.5%

References:11

None

References:2

None

References:6

normal for RA; 1.4x increased GD risk

None

rs7528684 (G;G)

References:2

1.2x risk

60.4%

rs1800630 (C;C)

Magnitude: 0
References:4

normal

78.2%

rs733618 (A;A)

Magnitude: 0
References:1

normal

88.1%

rs7530511 (C;C)

Magnitude: 0
References:2

normal

None

rs62205366 (T;T)

Magnitude: 0
References:1

14 snps

Gestational diabetes

(hide) Gestational diabetes

None

Magnitude: 2.5
References:16

2.5x increased risk for type-2 diabetes

52.5%

rs4402960 (G;T)

Magnitude: 2
References:19

1.2x increased risk for type-2 diabetes

31.7%

References:8

41.6%

References:7

41.6%

References:5

61.0%

References:5

61.4%

References:26

increased risk for type-2 diabetes

None

rs10830963 (C;G)

References:14

increased type-2 diabetes risk; higher gestational diabetes risk

83.2%

Magnitude: 0.1
ambig
References:19

0.0%

rs10811661 (C;C)

Magnitude: 0
References:25

normal

32.7%

rs1111875 (A;A)

Magnitude: 0
References:18

1x normal risk of T2D

33.7%

rs7923837 (A;A)

Magnitude: 0
References:5

1x normal risk for T2D

51.5%

Magnitude: 0
References:55

normal form

57.4%

rs7756992 (A;A)

Magnitude: 0
References:9

normal

56.4%

Magnitude: 0
ambig
References:57

common

61.4%

rs7754840 (G;G)

Magnitude: 0
ambig
References:11

normal

16 snps

Gilbert syndrome

(hide) Gilbert syndrome

12.1%

References:2

34.7%

References:5

None

References:1

effects of higher bilirubin; irinotecan toxicity; tranilast toxicity http://web.me.com/russbaltman/Site/PharmGKBlog/Entries/2010/10/24_Updated_Irinotecan_Label.html

96.0%

rs4148323 (G;G)

Magnitude: 0
References:6

normal

None

rs28934877 (A;A)

Magnitude: 0
References:2

5 snps

Gout

(hide) Gout

44.6%

References:1

45.5%

References:1

52.5%

References:2

61.4%

References:4

normal

61.4%

References:6

71.3%

References:4

3.4x risk of gout

19.8%

rs1165205 (T;T)

ambig
References:4

normal

58.0%

Magnitude: 0
References:3

85.1%

rs2231142 (C;C)

Magnitude: 0
References:16

normal

9 snps

Hashimoto thyroiditis

2 snps

HDL cholesterol

(hide) HDL cholesterol

39.6%

rs1864163 (A;G)

Magnitude: 2
References:2

associated with higher HDL cholesterol

49.5%

rs3764261 (G;T)

Magnitude: 2
References:13

associated with higher HDL cholesterol

80.2%

rs4939883 (C;C)

Magnitude: 1.5
References:6

associated with higher HDL cholesterol

3.0%

References:3

10.0%

References:2

11.9%

References:2

14.9%

References:3

20.8%

References:5

21.8%

References:6

22.2%

References:1

26.7%

References:7

30.7%

References:3

31.7%

References:0

31.7%

References:3

34.7%

References:3

34.7%

References:2

34.7%

References:3

37.6%

References:2

38.0%

References:2

38.6%

References:4

42.6%

References:8

43.6%

References:7

44.6%

References:1

44.6%

References:2

51.0%

References:9

56.4%

References:3

63.4%

References:6

79.2%

References:1

82.0%

References:5

85.1%

References:2

86.1%

References:4

None

References:1

None

References:3

80.2%

ambig
References:3

None

ambig
References:3

highest phosphatidylethanolamine values

54.0%

rs9891572 (C;C)

Magnitude: 0
References:2

57.4%

rs7679 (T;T)

Magnitude: 0
References:3

65.3%

rs655601 (A;A)

Magnitude: 0
References:2

66.3%

rs2083637 (T;T)

Magnitude: 0
References:5

68.3%

rs261332 (G;G)

Magnitude: 0
References:1

82.2%

rs10503669 (C;C)

Magnitude: 0
References:2

82.2%

rs17482753 (G;G)

Magnitude: 0
References:2

normal

84.2%

rs3905000 (G;G)

Magnitude: 0
References:3

95.0%

rs1800961 (C;C)

Magnitude: 0
References:4

None

rs1800588 (C;C)

Magnitude: 0
References:7

66.3%

rs964184 (C;C)

Magnitude: 0
ambig
References:7

None

rs328 (C;C)

Magnitude: 0
ambig
References:6

47 snps

Hemophilia

58 snps

Hepatitis C

(hide) Hepatitis C

56.6%

rs12979860 (C;C)

References:19

~80% of such hepatitis C patients respond to treatment

60.4%

References:4

None

References:3

None

References:2

None

References:6

None

References:2

None

References:3

None

ambig
References:1

65.3%

Magnitude: 0
References:14

9 snps

Herpes

(hide) Herpes

27.7%

rs241448 (T;T)

References:1

common

42.6%

rs2254958 (C;T)

References:1

1.24x increased risk for Alzheimer's

None

References:1

None

References:1

4 snps

High blood pressure

(hide) High blood pressure

31.7%

rs6997709 (G;T)

Magnitude: 2
References:1

1.2x higher risk for hypertension

13.9%

rs699 (T;T)

References:15

normal risk

26.7%

References:1

28.7%

References:2

30.7%

References:14

normal

35.6%

rs1937506 (A;G)

References:1

1.3x risk

38.6%

rs198358 (A;G)

References:1

lower blood pressure

39.6%

References:2

41.6%

References:1

1.3x risk for hypertension

42.6%

References:2

43.6%

References:9

43.6%

References:1

44.6%

References:3

44.6%

References:1

45.5%

References:1

higher risk for hypertension

46.5%

References:1

47.5%

References:2

1.3x risk

47.5%

References:4

52.5%

References:1

normal

57.4%

rs13333226 (A;A)

Magnitude: 1
References:1

common but slightly higher risk for hypertension

58.4%

References:1

61.4%

References:2

66.3%

References:1

69.0%

References:1

normal

72.3%

References:1

75.0%

References:3

78.2%

References:3

83.2%

References:2

90.8%

References:1

93.1%

References:1

normal

98.0%

References:1

None

References:2

higher hypertension risk

None

References:1

None

References:12

increased prostate cancer risk

None

References:0

None

References:1

normal

None

rs527974 (C;C)

References:1

better response to certain calcium channel blockers

None

References:1

None

References:1

None

References:3

None

References:1

None

References:12

complex; see details for increased risks

None

References:1

None

References:15

increased risk of preeclampsia

None

rs3774426 (C;T)

References:1

normal

None

References:5

None

References:2

1.19x risk for hypertension

None

rs6749447 (G;T)

References:3

slightly higher blood pressure if Caucasian

75.2%

ambig
References:19

None

ambig
References:2

None

ambig
References:1

average

None

ambig
References:0

5.9%

Magnitude: 0
References:1

normal

13.9%

rs5051 (C;C)

Magnitude: 0
References:1

increased risk for hypertension

45.5%

rs7961152 (C;C)

Magnitude: 0
References:1

normal

45.5%

rs688 (C;T)

Magnitude: 0
References:3

normal risk for Alzheimer's; higher total and LDL cholesterol in females

52.5%

rs8192678 (G;G)

Magnitude: 0
References:7

normal

57.4%

rs8176746 (C;C)

Magnitude: 0
References:3

58.0%

Magnitude: 0
References:3

58.4%

rs4399848 (G;G)

Magnitude: 0
References:1

normal

63.4%

rs3754777 (G;G)

Magnitude: 0
References:2

normal

68.3%

rs4961 (G;G)

Magnitude: 0
References:10

normal

68.7%

rs312481 (C;C)

Magnitude: 0
References:1

better response to certain calcium channel blockers

69.3%

Magnitude: 0
References:45

82.2%

rs3794260 (G;G)

Magnitude: 0
References:1

average

93.1%

rs5068 (T;T)

Magnitude: 0
References:1

93.1%

rs7297610 (C;C)

Magnitude: 0
References:2

95.0%

rs315135 (A;A)

Magnitude: 0
References:2

None

rs1801252 (A;A)

Magnitude: 0
References:6

None

None

rs5186 (A;A)

Magnitude: 0
References:16

normal risk

None

Magnitude: 0
References:14

higher risk for several conditions

66.3%

rs11110912 (C;C)

Magnitude: 0
ambig
References:1

1.3x risk

75.2%

rs2820037 (A;A)

Magnitude: 0
ambig
References:2

normal

None

rs1800471 (G;G)

Magnitude: 0
ambig
References:5

common This appears to be the common allele among an ambiguous flip

None

rs1801253 (C;C)

Magnitude: 0
ambig
References:8

responds well to bucindolol; may also depend on rs1801252

75 snps

Hirschsprung disease

7 snps

HIV

(hide) HIV

27.7%

rs9264942 (C;C)

Magnitude: 2.2
References:7

90% reduction in HIV viral load The rs9264942(C;C) genotype is reported to be associated with a 90% reduction in viral load in HIV-infected individuals. See also rs9264942 and HIV.

36.6%

rs1024611 (C;T)

Magnitude: 2
References:3

increased risk of exercise induced ischemia

45.5%

rs1801157 (A;G)

Magnitude: 1.4
References:6

1.4x higher risk for breast cancer

14.0%

rs2572886 (A;G)

References:1

1.4x increased risk of HIV infection

27.7%

rs241448 (T;T)

References:1

common

34.7%

References:56

36.6%

References:13

complex; generally greater risk for cancer progression

37.6%

References:1

42.6%

References:1

1.24x increased risk for Alzheimer's

76.5%

References:1

78.2%

References:1

78.2%

References:1

78.2%

References:2

78.2%

References:1

78.8%

References:2

92.1%

References:13

more likely to gain weight if taking olanzapine

None

References:3

None

References:4

None

References:0

None

References:1

44.6%

ambig
References:2

68.0%

Magnitude: 0
References:10

97.0%

rs17107315 (T;T)

Magnitude: 0
References:3

None

i3003626 (I;I)

Magnitude: 0
References:0

not resistant to HIV

None

rs3093726 (T;T)

Magnitude: 0
References:2

None

Magnitude: 0
References:19

common

None

rs5968255 (T;T)

Magnitude: 0
References:1

27 snps

Hearing loss

(hide) Hearing loss

41.6%

References:1

None

ambig
References:4

63.4%

Magnitude: 0
References:4

66.3%

rs9332377 (C;C)

Magnitude: 0
References:3

95.0%

rs1142345 (A;A)

Magnitude: 0
References:3

5 snps

Heart disease

(hide) Heart disease

19.8%

rs1333049 (C;C)

Magnitude: 4
ambig
References:19

1.9x increased risk for CAD

None

rs2383206 (G;G)

Magnitude: 3
References:5

1.7x increased risk for heart disease spittoon People with this genotype and a long history of high blood sugar are at 7x risk of CAD

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

27.7%

Magnitude: 2.1
References:7

increased risk for heart disease

None

Magnitude: 2.1
References:20

1.6x risk for MI

36.6%

rs1024611 (C;T)

Magnitude: 2
References:3

increased risk of exercise induced ischemia

69.3%

rs17672135 (T;T)

Magnitude: 2
References:2

1.3x risk

97.0%

rs7250581 (G;G)

Magnitude: 2
References:2

1.4x risk 1.4x higher risk for coronary artery disease

40.6%

rs17465637 (C;C)

Magnitude: 1.34
References:6

1.34x higher risk for myocardial infarction

9.0%

References:1

12.9%

References:2

1.1x risk

15.8%

rs5918 (C;T)

References:8

MI risk, aspirin resistance

20.8%

rs383830 (A;T)

References:1

1.6x risk

22.8%

rs1801020 (C;C)

References:5

normal

25.7%

rs17576 (A;A)

References:9

normal risk for lung cancer; higher risk for MI

29.7%

rs8055236 (G;T)

References:2

1.9x risk

37.6%

References:5

42.6%

References:2

42.9%

References:7

1.2x risk

43.6%

rs1010 (A;G)

References:3

1.75x risk of MI

44.6%

rs662 (A;A)

References:10

0.65x lower risk of ovarian cancer; normal PON catalytic efficiency

48.5%

References:0

48.5%

References:1

49.5%

References:0

50.0%

References:0

50.5%

References:19

51.5%

References:0

53.5%

References:0

56.4%

References:16

1.29x increased risk for heart disease

59.0%

References:1

63.4%

References:7

77.2%

References:2

increased risk of coronary heart disease; better response to statins

79.2%

rs174537 (G;G)

References:2

common; higher LDL-C and total cholesterol

82.2%

References:1

84.0%

References:2

85.1%

References:1

88.0%

References:0

88.1%

References:1

91.0%

References:0

None

References:7

~1.3x increased risk for heart disease

None

References:0

None

References:3

None

References:12

increased prostate cancer risk

None

References:0

None

References:8

None

References:4

>1.3x increased risk for heart disease

None

rs7439293 (G;G)

References:2

normal

None

References:0

None

References:4

1.48x risk

None

rs1799983 (G;T)

References:15

increased risk of preeclampsia

None

References:0

None

References:0

75.2%

ambig
References:19

None

ambig
References:8

hypertension not a risk factor for sudden cardiac death

None

ambig
References:8

None

Magnitude: 0.1
References:8

normal

83.2%

Magnitude: 0.1
ambig
References:19

47.5%

rs788016 (A;G)

Magnitude: 0
References:1

59.4%

rs5082 (T;T)

Magnitude: 0
References:1

normal risk

68.3%

rs4961 (G;G)

Magnitude: 0
References:10

normal

69.3%

rs3900940 (T;T)

Magnitude: 0
References:3

normal

72.3%

rs5174 (G;G)

Magnitude: 0
References:4

normal risk

76.2%

Magnitude: 0
References:4

1.12x risk on diuretic; if hypertensive, better outcome when treated with calcium channel blocker than with diuretic

80.0%

rs4986791 (C;C)

Magnitude: 0
References:5

normal

80.0%

rs8089 (T;T)

Magnitude: 0
References:1

normal risk

82.0%

Magnitude: 0
References:9

normal

82.2%

rs17228212 (T;T)

Magnitude: 0
References:1

normal

87.0%

rs4420638 (A;A)

Magnitude: 0
References:26

Normal/Average risk for Alzheimer's

99.0%

Magnitude: 0
References:14

Not a C282Y hemochromatosis carrier.

None

rs11039155 (G;G)

Magnitude: 0
References:1

None

rs34210653 (C;C)

Magnitude: 0
References:1

normal risk

None

Magnitude: 0
References:19

common

None

rs10498345 (T;T)

Magnitude: 0
ambig
References:2

normal

None

rs3135506 (G;G)

Magnitude: 0
ambig
References:7

appears to be common on the 23andMe platform

74 snps

Height

(hide) Height

9.0%

rs1042725 (C;C)

Magnitude: 2
References:8

~0.8cm taller

None

rs143383 (C;T)

Magnitude: 1.2
References:9

1.1x increased risk for osteoarthritis

1.0%

References:1

3.0%

References:1

3.0%

References:3

7.9%

References:1

8.2%

References:1

9.9%

References:1

10.0%

References:2

0.46cm taller on average

11.9%

References:1

13.9%

References:1

14.9%

References:1

15.8%

References:4

16.8%

References:1

17.8%

References:1

19.8%

References:1

20.0%

References:2

21.8%

References:1

21.8%

References:1

21.8%

References:3

22.0%

References:1

22.8%

References:1

24.8%

References:1

25.7%

References:1

25.7%

References:1

25.7%

References:2

26.7%

References:1

26.7%

References:2

27.7%

References:2

27.7%

References:6

28.7%

References:1

28.7%

References:1

30.7%

References:1

31.7%

References:3

32.0%

References:6

32.0%

References:1

32.7%

References:1

33.0%

References:5

34.7%

References:2

35.0%

References:1

35.6%

References:2

35.6%

References:1

36.6%

References:1

36.6%

References:1

36.6%

References:1

36.6%

References:1

36.6%

References:2

37.0%

References:1

37.6%

References:1

37.6%

References:1

37.6%

References:4

38.6%

References:3

38.6%

References:1

38.6%

References:1

39.0%

References:1

39.6%

References:0

39.6%

References:2

None

40.0%

References:2

40.6%

References:2

41.6%

References:1

41.6%

References:1

41.6%

References:1

41.6%

References:3

42.6%

References:1

42.6%

References:3

42.6%

References:1

43.0%

References:1

43.6%

References:1

43.6%

References:1

43.6%

References:4

0.44cm taller

44.6%

References:1

44.6%

References:4

45.5%

References:1

45.5%

References:1

45.5%

References:1

45.5%

References:1

45.5%

References:1

46.0%

References:1

46.5%

References:3

46.5%

References:1

46.5%

References:1

47.5%

References:1

47.5%

References:1

48.5%

References:1

48.5%

References:1

48.5%

References:1

48.5%

References:1

48.5%

References:2

0.34cm taller on average

49.0%

References:1

49.0%

References:1

49.5%

References:1

50.0%

References:1

50.0%

References:1

50.5%

References:5

51.5%

References:5

51.5%

References:1

51.5%

References:1

51.5%

References:1

52.5%

References:1

52.5%

References:1

52.5%

References:1

52.5%

References:1

52.5%

References:1

54.5%

References:1

55.4%

References:1

57.4%

References:3

57.4%

References:4

58.4%

References:3

58.4%

References:1

58.4%

References:1

59.4%

References:5

61.4%

References:4

61.4%

References:2

61.4%

References:1

62.4%

References:1

62.4%

References:1

62.4%

References:1

64.0%

References:1

64.4%

References:1

64.4%

References:1

65.0%

References:1

65.3%

References:1

65.3%

References:1

66.3%

References:6

67.3%

References:1

68.3%

References:1

68.3%

References:1

71.3%

References:1

71.3%

References:1

74.3%

References:2

74.3%

References:1

75.8%

References:6

76.2%

References:2

77.2%

References:2

77.2%

References:2

78.2%

References:1

79.0%

References:1

80.2%

References:1

81.0%

References:0

81.2%

References:2

81.2%

References:0

81.2%

References:1

81.2%

References:1

83.2%

References:1

84.2%

References:1

86.1%

References:1

86.1%

References:1

88.0%

References:1

88.1%

References:1

90.1%

References:5

92.1%

References:1

None

References:2

None

References:2

None

References:3

None

References:2

None

References:1

None

References:1

None

References:1

None

References:1

None

References:2

None

References:2

None

References:1

None

References:1

19.8%

ambig
References:1

38.6%

ambig
References:2

49.5%

ambig
References:1

84.2%

ambig
References:2

93.1%

ambig
References:1

91.1%

Magnitude: 0
References:1

93.1%

rs1520223 (A;A)

Magnitude: 0
References:1

None

rs17104630 (A;A)

Magnitude: 0
References:1

None

rs2179922 (G;G)

Magnitude: 0
References:1

common

172 snps

Hemochromatosis

(hide) Hemochromatosis

gs219

Magnitude: 4

Likely affected by hereditary hemochromatosis due to at least two copies of rs1799945(G) and/or rs1800562(A). This is potentially serious, but can be mild. This is an easily diagnosed and treatable disorder.

None

rs1799945 (G;G)

Magnitude: 4
ambig
References:3

Two copies of H36D, likely affected by mild form of hemochromatosis You would be expected to experience Hereditary hemochromatosis based on your rs1799945(G;G) H63D status. This is a treatable condition.

34.7%

References:3

44.6%

References:4

higher transferrin levels if rs1800562(A;A)

99.0%

Magnitude: 0
References:14

Not a C282Y hemochromatosis carrier.

None

i3002468 (A;A)

Magnitude: 0
References:0

1 genoset 5 snps

Hodgkin lymphoma

4 snps

Homocystinuria

(hide) Homocystinuria

15.8%

rs1801131 (C;C)

References:20

69.3%

Magnitude: 0
References:45

None

rs5742905 (T;T)

Magnitude: 0
References:4

3 snps

Huntington disease

(hide) Huntington disease

35.6%

References:1

58.4%

References:1

62.0%

References:1

70.3%

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

Magnitude: 0
References:1

9 snps

Hypercholesterolemia

(hide) Hypercholesterolemia

34.7%

rs1045642 (T;T)

References:56

85.1%

rs2231142 (C;C)

Magnitude: 0
References:16

normal

94.1%

rs505151 (A;A)

Magnitude: 0
References:1

96.0%

rs4149056 (T;T)

Magnitude: 0
References:23

normal

None

rs28942079 (G;G)

Magnitude: 0
References:2

None

rs45511401 (G;G)

Magnitude: 0
References:3

None

Magnitude: 0
References:14

higher risk for several conditions

55.4%

rs7566605 (G;G)

Magnitude: 0
ambig
References:15

common

8 snps

Hypertriglyceridemia

(hide) Hypertriglyceridemia

33.7%

rs1260326 (C;T)

References:19

33.7%

rs780094 (A;G)

References:27

metabolic consequences

37.6%

References:7

43.6%

References:7

75.2%

References:3

88.1%

References:7

92.1%

References:13

more likely to gain weight if taking olanzapine

None

References:3

None

References:2

None

Magnitude: 0.1
References:8

normal

66.3%

rs964184 (C;C)

Magnitude: 0
ambig
References:7

None

rs3135506 (G;G)

Magnitude: 0
ambig
References:7

appears to be common on the 23andMe platform

None

rs328 (C;C)

Magnitude: 0
ambig
References:6

13 snps

In vitro fertilization

3 snps

Inflammatory bowel disease

(hide) Inflammatory bowel disease

43.6%

rs7517847 (G;T)

References:13

possibly reduced risk for Crohn's disease

44.0%

References:2

50.5%

References:1

51.5%

References:5

58.4%

References:2

68.3%

References:3

99.0%

References:3

None

References:3

0.72x decreased risk for Crohn's disease

75.2%

rs689466 (A;A)

Magnitude: 0
References:8

normal

85.1%

rs2076756 (A;A)

Magnitude: 0
References:6

normal

99.0%

Magnitude: 0
References:27

common

11 snps

Intracranial Aneurysm

1 snp

Ischemia

2 snps

Intrahepatic cholestasis of pregnancy

2 snps

Kawasaki disease

4 snps

Kidney stones

(hide) Kidney stones

26.3%

References:1

27.7%

References:2

76.2%

References:1

None

References:1

None

References:3

53.5%

Magnitude: 0
References:1

58.0%

Magnitude: 0
References:3

60.4%

rs1801725 (G;G)

Magnitude: 0
References:3

8 snps

Lactose intolerance

(hide) Lactose intolerance

gs100

Magnitude: 2.5

77% of Europeans with this genoset are lactose intolerant It is detected by 2 genotypes *rs4988235(C;C) *rs182549(C;C)

70.3%

rs4988235 (C;C)

Magnitude: 1.1
References:8

possibly lactose intolerant see also gs100 if you are a caucasian who also has rs182549(C;C) there is 77% chance of lactose intolerance * See also OMIM 601806.0001

None

rs182549 (C;C)

References:6

possibly lactose intolerant

None

rs4988234 (G;G)

Magnitude: 0
References:0

1 genoset 3 snps

LDL cholesterol

(hide) LDL cholesterol

56.4%

Magnitude: 2.1
References:16

1.2x risk of coronary artery disease

49.5%

rs3764261 (G;T)

Magnitude: 2
References:13

associated with higher HDL cholesterol

0.0%

References:6

7.9%

References:10

11.9%

References:2

15.8%

References:4

17.2%

References:7

20.8%

References:5

22.8%

References:3

33.7%

References:4

33.7%

References:27

metabolic consequences

36.6%

References:2

39.4%

References:3

40.6%

References:2

42.6%

References:8

45.5%

References:2

46.5%

References:2

49.5%

References:2

53.5%

References:4

56.4%

References:16

1.29x increased risk for heart disease

56.4%

rs693 (C;C)

References:13

normal

72.3%

References:1

77.2%

References:3

82.2%

References:4

None

References:5

None

References:3

39.6%

ambig
References:2

None

ambig
References:2

42.6%

Magnitude: 0
References:2

87.0%

rs4420638 (A;A)

Magnitude: 0
References:26

Normal/Average risk for Alzheimer's

99.0%

rs5031002 (G;G)

Magnitude: 0
References:2

None

rs11591147 (G;G)

Magnitude: 0
References:4

None

rs28362286 (C;C)

Magnitude: 0
References:1

33 snps

Left

3 snps

Leprosy

(hide) Leprosy

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

13.1%

References:1

19.8%

References:1

39.6%

References:4

51.5%

References:1

51.5%

References:1

60.4%

References:3

None

References:1

8 snps

Leukemia

(hide) Leukemia

36.6%

References:3

49.5%

References:2

50.5%

References:12

67.3%

References:3

67.3%

References:3

69.0%

References:2

70.3%

References:3

79.2%

References:6

None

References:3

None

References:1

None

References:1

None

References:1

29.7%

Magnitude: 0
References:8

normal

69.3%

Magnitude: 0
References:45

None

rs1045485 (G;G)

Magnitude: 0
ambig
References:5

15 snps

Liver cancer

(hide) Liver cancer

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

45.0%

Magnitude: 2.1
References:34

1.2x risk of prostate cancer 1.2x risk of prostate cancer

None

rs4444903 (A;G)

Magnitude: 2
References:6

3.5x risk of hep-cancer in cirrhosis patients; higher glioma risk

99.0%

Magnitude: 0
References:14

Not a C282Y hemochromatosis carrier.

4 snps

Lumbar disc disease

2 snps

Lung cancer

(hide) Lung cancer

45.0%

Magnitude: 2.1
References:34

1.2x risk of prostate cancer 1.2x risk of prostate cancer

31.0%

Magnitude: 2
References:31

1.3x increased risk of lung cancer

45.5%

rs748404 (T;T)

Magnitude: 1.25
References:2

slightly increased risk (1.25) for lung cancer

13.9%

rs663048 (G;T)

References:1

None

19.8%

References:1

20.8%

References:1

25.7%

References:9

normal risk for lung cancer; higher risk for MI

26.0%

References:1

29.0%

References:4

29.7%

References:1

30.7%

References:24

slightly higher risk for nicotine dependence, lower risk for cocaine dependence

30.7%

References:1

31.7%

References:1

32.7%

References:1

32.7%

References:18

None

38.6%

rs664143 (C;T)

References:2

1.6x increased risk of lung cancer

40.8%

References:1

41.6%

References:12

41.6%

References:2

increased lung cancer risk for never-smoking females

45.5%

References:1

45.5%

References:1

48.5%

References:4

49.5%

References:3

51.5%

References:15

2x higher risk for skin cancer

54.5%

References:2

57.4%

References:6

normal

64.4%

rs401681 (C;C)

References:14

~1.2x increased risk for several types of cancer

None

References:1

None

References:1

None

References:2

None

References:1

None

References:6

None

References:1

None

References:1

None

References:24

None

None

References:1

None

References:3

1.46x higher risk for lung cancer

None

References:4

higher cancer risk

None

References:13

generally more cancer prone

26.7%

rs12050604 (C;C)

Magnitude: 0
References:1

29.7%

rs1056836 (C;G)

Magnitude: 0
References:14

normal

35.6%

rs1169300 (G;G)

Magnitude: 0
References:1

normal

35.6%

rs2464196 (C;C)

Magnitude: 0
References:2

normal

46.5%

rs11614913 (C;T)

Magnitude: 0
References:19

normal

66.3%

Magnitude: 0
References:4

normal risk

67.0%

rs3842 (A;A)

Magnitude: 0
References:1

69.3%

Magnitude: 0
References:45

75.2%

rs2352028 (C;C)

Magnitude: 0
References:2

78.2%

rs3750861 (C;C)

Magnitude: 0
References:1

81.2%

rs2066853 (G;G)

Magnitude: 0
References:4

82.2%

rs1530057 (C;C)

Magnitude: 0
References:1

90.1%

rs2308327 (A;A)

Magnitude: 0
References:2

normal

99.0%

rs8178085 (A;A)

Magnitude: 0
References:1

None

rs17879961 (T;T)

Magnitude: 0
References:2

None

rs2228014 (C;C)

Magnitude: 0
References:1

None

rs3117582 (A;A)

Magnitude: 0
References:8

None

rs1052133 (C;C)

Magnitude: 0
ambig
References:10

normal

57 snps

Lyme disease

1 snp

Lymphoma

(hide) Lymphoma

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

35.6%

References:3

36.6%

References:13

complex; generally greater risk for cancer progression

48.5%

rs3020314 (C;T)

References:3

0.64x reduced lymphoma risk

53.5%

References:6

None

References:5

None

Magnitude: 0
References:10

complex; generally normal risk

7 snps

Li-Fraumeni syndrome

6 snps

Longevity

(hide) Longevity

8.9%

References:2

9.9%

References:1

10.9%

References:1

14.1%

References:1

18.8%

References:2

19.8%

References:1

25.7%

References:1

38.1%

References:1

39.2%

References:1

46.5%

References:3

less mental decline with age

50.0%

References:1

50.5%

References:5

lower risk of dementia and Alzheimer's disease

53.5%

References:1

56.4%

References:1

63.4%

References:1

63.4%

References:1

67.7%

References:1

68.3%

References:1

68.3%

References:1

74.2%

References:1

74.3%

References:1

74.3%

References:1

75.2%

References:1

77.8%

References:1

78.1%

References:1

78.2%

References:1

79.2%

References:1

82.2%

References:1

98.0%

References:3

None

References:3

normal

None

rs2802292 (T;T)

References:3

less likely to live to 100

None

rs34516635 (G;G)

References:1

normal

None

rs1042522 (C;G)

References:24

None

None

rs1061170 (C;T)

References:14

2.5x risk for AMD; higher mortality among nonagenarians

75.2%

ambig
References:19

None

ambig
References:1

None

ambig
References:4

17.8%

Magnitude: 0
References:0

normal

70.1%

rs11073328 (C;C)

Magnitude: 0
References:1

normal

78.2%

rs2075650 (A;A)

Magnitude: 0
References:15

normal

85.7%

rs16922827 (T;T)

Magnitude: 0
References:1

87.1%

rs2811712 (A;A)

Magnitude: 0
References:1

normal risk

93.1%

rs4815617 (C;C)

Magnitude: 0
References:2

43 snps

Lupus

(hide) Lupus

1.0%

rs2187668 (A;A)

Magnitude: 3
References:6

Autoimmune disorder risk (lupus, celiac disease) due to 2 HLA-DRB1*0301 alleles

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

6.9%

References:8

6.9%

References:7

11.9%

References:11

13.4%

References:2

13.9%

References:3

14.1%

References:3

25.7%

References:1

30.7%

References:2

rarer; slight decrease in SLE risk

32.7%

References:1

34.7%

References:1

36.1%

References:1

36.4%

References:7

2x risk for sarcoidosis

36.6%

rs1801274 (T;T)

References:13

complex; generally greater risk for cancer progression

36.6%

References:3

37.6%

References:3

38.6%

References:2

0.9x decreased rheumatoid arthritis risk

39.6%

References:1

40.6%

References:22

40.6%

References:4

41.0%

References:6

1.4x increased risk of SLE

41.6%

References:1

42.6%

References:4

42.6%

References:3

43.6%

References:3

44.6%

References:1

44.6%

References:8

45.5%

References:1

46.5%

References:2

1.9x increased risk for SLE (lupus)

46.5%

References:1

47.0%

References:1

47.5%

References:3

47.5%

References:3

49.5%

References:1

50.5%

References:1

53.5%

References:4

55.4%

References:1

55.4%

References:1

58.4%

References:4

58.4%

References:2

60.0%

References:4

1.6x increased risk for SLE

60.4%

References:8

60.6%

References:2

61.4%

References:9

61.4%

References:7

62.4%

References:1

68.3%

References:2

69.3%

Magnitude: 1
References:3

1.1x increased risk for schizophrenia

71.3%

References:2

73.3%

References:3

77.2%

References:2

81.2%

References:3

93.1%

References:1

None

References:1

None

References:1

>1.4x risk of lupus

None

References:2

None

References:2

None

References:2

None

References:2

1.2x risk

None

References:1

None

References:1

None

References:24

None

None

References:8

None

References:7

1.78x increased risk for SLE

None

References:13

generally more cancer prone

None

References:1

32.7%

ambig
References:3

normal

35.0%

rs1734791 (A;A)

ambig
References:1

normal

40.4%

rs7582694 (G;G)

ambig
References:2

normal

None

rs10181656 (C;C)

ambig
References:7

normal

None

ambig
References:8

32.7%

Magnitude: 0
References:1

normal

36.6%

rs1734792 (C;C)

Magnitude: 0
References:1

1.4x increased risk for lupus

40.0%

Magnitude: 0
References:34

common

40.6%

Magnitude: 0
References:16

increased risk for auto-immune diseases

40.6%

rs3095870 (G;G)

Magnitude: 0
References:2

1.7x increased risk for SLE (lupus)

60.4%

rs1800630 (C;C)

Magnitude: 0
References:4

normal

61.4%

rs3821236 (G;G)

Magnitude: 0
References:4

71.3%

rs10488631 (T;T)

Magnitude: 0
References:10

normal

77.2%

rs419788 (G;G)

Magnitude: 0
References:1

average

92.1%

rs13385731 (T;T)

Magnitude: 0
References:3

94.1%

rs11243676 (G;G)

Magnitude: 0
References:1

96.0%

rs12141391 (C;C)

Magnitude: 0
References:1

96.0%

rs3135388 (C;C)

Magnitude: 0
References:7

normal

98.0%

rs17083844 (G;G)

Magnitude: 0
References:1

98.0%

Magnitude: 0
References:25

normal

None

rs11568821 (G;G)

Magnitude: 0
References:1

None

rs1800947 (G;G)

Magnitude: 0
ambig
References:16

normal

89 snps

Malaria

(hide) Malaria

5.0%

References:2

6.1%

References:1

6.9%

References:6

7.1%

References:7

8.1%

References:1

31.7%

References:1

33.0%

References:7

0.6x decreased risk for diabetic nephropathy in females with type-1 diabetes; increased malaria risk

34.7%

References:5

36.6%

References:13

complex; generally greater risk for cancer progression

None

rs1334512 (T;T)

References:0

normal

None

References:11

None

References:4

None

References:4

None

References:2

None

References:2

None

References:3

32.7%

ambig
References:0

70.3%

ambig
References:1

None

ambig
References:4

75.0%

Magnitude: 0
References:3

92.1%

Magnitude: 0
References:8

normal

None

Magnitude: 0
References:7

normal

22 snps

Malignant melanoma

(hide) Malignant melanoma

77.2%

Magnitude: 2
References:10

2-4x higher risk of sun sensitivity if part of risk haplotype

None

References:5

normal

77.2%

Magnitude: 0
References:10

normal

3 snps

Maple Syrup Urine Disease

4 snps

Memory

(hide) Memory

53.5%

rs17070145 (C;C)

Magnitude: 2.1
References:7

reduced memory abilities

66.0%

rs2619522 (T;T)

Magnitude: 2
References:4

impaired cognitive ability impaired cognitive ability

51.5%

References:1

58.4%

References:4

better long-term memory?

None

References:3

55.4%

Magnitude: 0
References:9

normal

None

rs1018381 (C;C)

Magnitude: 0
References:8

None

Magnitude: 0
References:11

None

Magnitude: 0
References:10

complex; generally normal risk

9 snps

Menarche, age at

(hide) Menarche, age at

8.9%

rs1859345 (C;C)

References:1

slightly earlier age at menarche

9.9%

rs13357391 (C;C)

References:1

slightly earlier age at menarche

22.8%

References:2

40.6%

References:4

normal

42.6%

References:1

69.3%

References:3

age at menarche ~2 months later on average

6 snps

Meniere's disease

1 snp

Meningioma

2 snps

Mesothelioma

(hide) Mesothelioma

38.6%

References:3

50.5%

References:19

None

Magnitude: 0
References:3

3 snps

Muscular dystrophy

18 snps

Myasthenia gravis

3 snps

Myocardial infarction

(hide) Myocardial infarction

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

22.8%

rs762551 (C;C)

Magnitude: 2.5
References:7

CYP1A2 slow metabolizer more strongly affected by drinking coffee.

56.4%

Magnitude: 2.1
References:16

1.2x risk of coronary artery disease

None

Magnitude: 2.1
References:20

1.6x risk for MI

gs194

Magnitude: 2

This genoset looks for the genotypes which most strongly contribute to the risk of myocardial infarction according to http://www3.interscience.wiley.com/cgi-bin/fulltext/123217456/HTMLSTART These are *rs10116277 *rs599839 *rs1746048 *rs17465637 *rs9818870 *rs12526453 *rs3184504 *rs9982601 *rs6725887

30.7%

rs2108622 (C;C)

Magnitude: 2
References:19

lower warfarin dosing

40.6%

rs17465637 (C;C)

Magnitude: 1.34
References:6

1.34x higher risk for myocardial infarction

36.6%

rs2291834 (C;C)

Magnitude: 1.07
References:1

very slightly higher risk for myocardial infarction

2.0%

References:1

6.9%

References:6

7.1%

References:7

7.9%

References:10

13.9%

References:15

normal risk

15.8%

rs5918 (C;T)

References:8

MI risk, aspirin resistance

17.8%

References:3

19.8%

References:7

22.8%

References:1

22.8%

References:5

normal

25.7%

References:3

28.7%

References:10

1.52x increased myocardial infarction risk, 1.67x increased aneurysm risk

28.7%

References:5

30.7%

References:14

normal

31.0%

References:1

33.0%

References:7

0.6x decreased risk for diabetic nephropathy in females with type-1 diabetes; increased malaria risk

33.7%

rs780094 (A;G)

References:27

metabolic consequences

34.7%

References:56

34.7%

References:2

37.6%

References:5

37.6%

References:5

39.6%

References:2

41.0%

References:1

42.6%

References:3

43.0%

References:3

43.6%

References:4

43.6%

References:3

1.75x risk of MI

43.6%

References:1

46.5%

References:1

48.5%

References:4

52.5%

References:3

1.24x increased stroke risk for males

54.5%

References:5

64.4%

References:4

normal

75.2%

References:1

79.2%

References:1

82.2%

References:1

85.1%

References:1

92.1%

References:13

more likely to gain weight if taking olanzapine

None

rs10757274 (G;G)

References:7

~1.3x increased risk for heart disease

None

References:2

None

References:2

None

References:3

None

References:0

None

References:6

None

References:1

None

References:2

normal

None

References:2

None

References:0

None

References:0

None

References:4

None

References:12

complex; see details for increased risks

None

References:1

None

References:5

None

References:9

2.0%

ambig
References:4

None

ambig
References:2

None

ambig
References:17

None

Magnitude: 0.1
References:8

normal

65.3%

rs9934438 (G;G)

Magnitude: 0
References:7

67.3%

rs4253623 (A;A)

Magnitude: 0
References:1

normal

72.3%

rs5174 (G;G)

Magnitude: 0
References:4

normal risk

76.2%

rs4769874 (G;G)

Magnitude: 0
References:0

78.2%

Magnitude: 0
References:16

normal

92.1%

Magnitude: 0
References:8

normal

97.0%

rs7961894 (C;C)

Magnitude: 0
References:5

98.0%

rs6725887 (T;T)

Magnitude: 0
References:4

None

rs16139 (A;A)

Magnitude: 0
References:2

None

rs17222814 (G;G)

Magnitude: 0
References:1

common for Caucasians on the 23andme platform

None

rs17222842 (G;G)

Magnitude: 0
References:0

None

rs1800888 (C;C)

Magnitude: 0
References:6

normal

None

rs28399504 (A;A)

Magnitude: 0
References:5

normal

None

rs4244285 (G;G)

Magnitude: 0
References:10

normal

None

Magnitude: 0
References:19

common

None

Magnitude: 0
References:7

normal

None

rs7213516 (G;G)

Magnitude: 0
References:2

normal

1 genoset 82 snps

Melanoma

(hide) Melanoma

77.2%

Magnitude: 2
References:10

2-4x higher risk of sun sensitivity if part of risk haplotype

6.9%

rs7495174 (G;G)

References:4

blue/gray eyes less likely

24.7%

rs4845618 (G;G)

References:1

normal

46.5%

rs6684439 (C;C)

References:1

normal

48.5%

rs8192284 (A;A)

References:12

normal

50.5%

rs13181 (G;T)

References:12

1.12x increased risk for skin cancer

53.0%

References:1

55.4%

References:6

58.4%

References:4

64.4%

References:14

~1.2x increased risk for several types of cancer

82.2%

References:6

98.0%

References:5

blue/gray eyes more possible

None

References:5

normal

None

References:13

generally more cancer prone

None

rs16891982 (C;C)

ambig
References:8

generally non-European, but if European, 7x more likely to have black hair

69.3%

rs1799944 (A;A)

Magnitude: 0
References:1

77.2%

Magnitude: 0
References:10

normal

80.2%

rs1393350 (G;G)

Magnitude: 0
References:9

98.0%

rs910873 (G;G)

Magnitude: 0
References:5

normal

98.0%

rs1885120 (G;G)

Magnitude: 0
ambig
References:4

20 snps

Migraines

(hide) Migraines

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

43.6%

rs2651899 (A;G)

Magnitude: 1.1
References:0

1.1x higher risk for migraines

45.5%

rs11172113 (C;T)

Magnitude: 1.1
References:0

0.9x lower risk for migraines

17.8%

References:2

21.8%

References:1

22.8%

References:1

30.7%

References:14

normal

31.7%

References:1

32.7%

References:0

37.6%

References:1

44.6%

References:1

45.5%

References:2

48.5%

References:1

73.3%

References:3

2-6x increased risk for cluster headaches

None

References:10

None

References:2

None

References:1

None

References:12

complex; see details for increased risks

None

References:1

None

ambig
References:1

None

ambig
References:1

26.7%

Magnitude: 0
References:1

normal

69.3%

Magnitude: 0
References:45

74.0%

rs2069885 (C;C)

Magnitude: 0
References:2

87.1%

rs1042838 (G;G)

Magnitude: 0
References:5

normal risk

None

rs1043994 (G;G)

Magnitude: 0
References:1

common

None

rs1229984 (G;G)

Magnitude: 0
References:12

normal; more frequent alcohol consumption

None

rs1800888 (C;C)

Magnitude: 0
References:6

normal

None

rs28933398 (T;T)

Magnitude: 0
References:1

None

rs28933399 (T;T)

Magnitude: 0
References:1

None

rs28933400 (T;T)

Magnitude: 0
References:1

None

rs28933401 (G;G)

Magnitude: 0
References:1

None

Magnitude: 0
References:14

higher risk for several conditions

33 snps

Multiple sclerosis

(hide) Multiple sclerosis

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

89.0%

rs3129934 (C;C)

Magnitude: 2.1
References:2

normal 1.6x risk of type-1 diabetes

5.9%

References:2

7.9%

References:1

normal

8.9%

References:1

13.9%

References:1

16.2%

References:2

17.8%

References:1

20.0%

References:3

>1.10x risk

21.0%

References:1

23.8%

References:3

26.7%

References:15

1.3x increased risk for multiple sclerosis

28.7%

References:2

28.7%

References:4

29.7%

References:2

31.7%

References:2

>1.11x risk

33.7%

rs10735781 (C;G)

References:3

1.11x risk

34.0%

rs6498169 (A;G)

References:7

1.14x risk

34.7%

rs6680578 (A;T)

References:3

1.11x risk

34.7%

rs7536563 (A;G)

References:2

1.12x risk

36.4%

rs2076530 (A;A)

References:7

2x risk for sarcoidosis

37.0%

References:2

37.6%

References:3

37.6%

References:6

conflicting reports; possible slight increased risk for multiple sclerosis

37.6%

References:3

39.6%

References:2

39.6%

References:1

40.6%

References:4

40.6%

References:3

40.6%

References:1

40.6%

References:2

40.6%

References:4

43.0%

References:2

43.6%

References:1

43.6%

References:2

43.6%

References:3

44.6%

References:2

44.6%

References:1

44.6%

References:13

somewhat increased risk for multiple autoimmune diseases

45.5%

rs12708716 (A;G)

References:12

1.2x risk

45.5%

rs725613 (A;C)

References:3

1.2x increased type-1 diabetes risk; 1.2x increased multiple sclerosis risk

49.5%

References:2

50.0%

References:1

50.0%

References:2

50.5%

References:2

50.5%

References:2

1.09x increased risk for multiple sclerosis

52.5%

References:2

53.5%

References:4

>1.24x risk

53.5%

References:2

53.5%

References:2

55.4%

References:2

56.4%

References:4

59.4%

References:1

59.4%

References:0

59.6%

References:1

60.4%

References:3

>1.17x risk

64.4%

References:2

66.0%

References:3

66.3%

References:9

1.7x risk for RA; 1.6X for T1D; also MS?

73.3%

References:2

75.2%

References:2

80.2%

References:5

80.2%

References:1

80.6%

References:1

82.2%

References:2

87.0%

References:2

88.1%

References:1

94.0%

References:1

94.1%

References:1

None

References:2

None

References:1

None

References:1

None

References:1

None

References:1

None

References:1

None

References:2

1.2x risk

None

References:1

None

References:1

None

References:1

None

References:4

None

References:1

None

References:1

10.9%

ambig
References:1

1.8x increased risk for multiple sclerosis

45.5%

rs1321172 (G;G)

ambig
References:2

>1.08x risk

None

rs8702 (C;C)

ambig
References:2

average

40.0%

Magnitude: 0
References:34

common

71.3%

rs6604026 (T;T)

Magnitude: 0
References:5

common

76.8%

rs10975200 (A;A)

Magnitude: 0
References:1

77.0%

rs4959039 (A;A)

Magnitude: 0
References:1

normal

85.1%

rs7577363 (G;G)

Magnitude: 0
References:2

common

89.1%

rs3745672 (T;T)

Magnitude: 0
References:1

95.0%

rs7253363 (G;G)

Magnitude: 0
References:2

96.0%

rs3135388 (C;C)

Magnitude: 0
References:7

normal

96.0%

rs3135391 (C;C)

Magnitude: 0
References:1

normal

98.0%

Magnitude: 0
References:25

normal

None

rs4149584 (G;G)

Magnitude: 0
References:4

96 snps

Myopia

38 snps

Neuroblastoma

(hide) Neuroblastoma

28.7%

rs9295536 (A;A)

References:3

2x increased risk for neuroblastoma

32.7%

rs6939340 (G;G)

References:5

2x increased risk for neuroblastoma

34.0%

rs4712653 (C;C)

References:4

normal

36.6%

rs1801274 (T;T)

References:13

complex; generally greater risk for cancer progression

51.5%

rs6435862 (T;T)

Magnitude: 0
References:3

normal

56.0%

rs3768716 (A;A)

Magnitude: 0
References:4

normal

58.4%

rs110419 (G;G)

Magnitude: 0
References:1

7 snps

Nicotine dependence

(hide) Nicotine dependence

31.0%

Magnitude: 2
References:31

1.3x increased risk of lung cancer

2.0%

References:2

21.8%

References:2

26.0%

References:6

30.7%

References:24

slightly higher risk for nicotine dependence, lower risk for cocaine dependence

34.7%

References:2

38.6%

References:1

39.6%

References:1

associated with heavier smoking in Caucasians

46.5%

References:0

46.9%

References:2

48.5%

References:2

62.4%

References:0

75.2%

References:2

76.2%

References:2

None

References:1

None

References:2

29.7%

Magnitude: 0
References:9

normal

64.4%

rs4648317 (C;C)

Magnitude: 0
References:4

normal

None

rs10485057 (A;A)

Magnitude: 0
References:1

normal

19 snps

Niemann-Pick disease

4 snps

Nonalcoholic fatty liver disease

2 snps

Narcolepsy

(hide) Narcolepsy

38.6%

rs2305795 (A;A)

Magnitude: 2
References:1

1.3x risk of narcolepsy compared to (A;G) genotype

61.4%

rs12587781 (T;T)

Magnitude: 0
References:1

63.0%

rs5770917 (T;T)

Magnitude: 0
References:4

normal

72.3%

rs1154155 (T;T)

Magnitude: 0
References:4

normal

96.0%

rs3135388 (C;C)

Magnitude: 0
References:7

normal

5 snps

Non-Hodgkin Lymphoma

(hide) Non-Hodgkin Lymphoma

15.8%

rs5918 (C;T)

References:8

MI risk, aspirin resistance

35.6%

References:3

52.5%

References:1

89.1%

References:1

1.4x increased risk for Non-hodgkin's lymphoma

89.1%

References:1

96.0%

References:1

0.74x decreased risk for Non-hodgkin's lymphoma

None

ambig
References:1

84.2%

Magnitude: 0
References:1

normal

90.1%

rs4648022 (C;C)

Magnitude: 0
References:1

98.0%

rs5743815 (T;T)

Magnitude: 0
References:1

99.0%

rs3132453 (C;C)

Magnitude: 0
References:1

11 snps

Obsessive compulsive disorder

(hide) Obsessive compulsive disorder

62.4%

rs4570625 (G;G)

Magnitude: 1.9
References:7

17.8%

References:2

19.8%

References:2

46.5%

References:2

None

References:2

may be part of a haplotype associated with OCD

None

rs3780413 (G;G)

ambig
References:2

6 snps

Otitis

(hide) Otitis

75.2%

rs1800795 (G;G)

ambig
References:19

None

rs1800750 (G;G)

Magnitude: 0
References:3

normal risk

None

Magnitude: 0
References:10

complex; generally normal risk

3 snps

Otosclerosis

4 snps

Obesity

(hide) Obesity

27.7%

Magnitude: 2.4
References:27

4.0%

References:1

4.0%

References:1

None

5.9%

References:2

7.9%

References:9

complex; see details

7.9%

References:1

8.9%

References:7

increased waist circumference and risk of disk disease

9.9%

References:2

12.1%

References:1

12.1%

References:4

15.8%

References:3

16.8%

References:3

16.8%

References:3

16.8%

References:5

17.0%

References:1

20.0%

References:15

20.8%

References:1

21.2%

References:1

21.2%

References:6

21.8%

References:1

21.8%

References:5

23.8%

References:1

23.8%

References:1

24.0%

References:1

25.3%

References:2

25.7%

References:1

25.7%

References:1

slightly higher fat mass

26.7%

rs324420 (A;C)

References:7

normal

30.7%

References:1

31.7%

References:1

34.7%

References:7

35.6%

References:1

35.6%

References:4

38.6%

References:4

40.6%

References:22

40.6%

References:2

40.6%

References:1

40.6%

References:2

41.6%

References:2

43.6%

References:0

43.6%

References:4

44.6%

References:2

44.6%

References:1

44.6%

References:1

45.0%

References:1

45.5%

References:2

45.5%

References:1

45.5%

References:1

45.5%

References:1

45.5%

References:2

46.5%

References:6

46.5%

References:2

46.5%

References:1

47.5%

References:1

47.5%

References:4

47.5%

References:2

47.5%

References:5

This is the genotype of User:Watson

48.5%

References:0

48.5%

References:5

48.5%

References:1

49.5%

References:0

50.0%

References:0

50.5%

References:2

50.5%

References:1

50.5%

References:2

50.5%

References:1

>2x increased risk for familial obesity

51.5%

References:1

51.5%

References:1

51.5%

References:1

1.8x higher risk for obesity if in haplotype

52.0%

References:1

52.5%

References:2

53.5%

References:2

54.5%

References:1

54.5%

References:2

54.5%

References:1

55.4%

References:1

56.4%

References:2

56.4%

References:1

59.4%

References:5

61.0%

References:5

61.4%

References:1

62.0%

References:2

64.4%

References:1

67.3%

References:1

68.3%

References:2

68.3%

References:1

higher insulinogenic index in obese children

68.3%

References:1

68.3%

References:1

70.3%

References:1

70.3%

References:1

73.3%

References:3

74.3%

References:2

75.0%

References:1

77.2%

References:1

81.2%

References:1

82.0%

References:1

83.2%

References:3

85.1%

References:2

88.1%

References:1

88.1%

References:2

88.8%

References:1

99.0%

References:8

normal

None

References:1

None

References:2

None

References:1

None

References:1

None

References:1

normal risk

None

rs2272383 (G;G)

References:1

higher body mass index

None

References:1

None

References:1

normal

None

References:1

None

References:8

None

References:3

None

References:1

1.8x higher risk for obesity if in haplotype

None

rs266729 (C;G)

References:13

0.73x decreased risk for colorectal cancer

None

References:1

None

References:2

associated with familial obesity

None

References:1

74.3%

ambig
References:2

75.2%

ambig
References:19

77.2%

ambig
References:1

89.1%

ambig
References:2

None

ambig
References:5

None

ambig
References:2

None

ambig
References:3

None

ambig
References:5

None

Magnitude: 0.1
References:8

normal

40.6%

rs1121980 (C;C)

Magnitude: 0
References:10

2.76x risk for obesity

49.0%

rs10871777 (A;A)

Magnitude: 0
References:2

adults likely to be 0.44 BMI units higher

49.5%

rs17782313 (T;T)

Magnitude: 0
References:21

normal

50.5%

rs12970134 (G;G)

Magnitude: 0
References:11

normal

51.5%

rs1421085 (T;T)

Magnitude: 0
References:11

normal

52.5%

Magnitude: 0
References:34

A2/A2 [[bupropion]] effective

56.4%

rs17817449 (T;T)

Magnitude: 0
References:7

normal

56.4%

rs8050136 (C;C)

Magnitude: 0
References:26

normal

59.4%

rs5082 (T;T)

Magnitude: 0
References:1

normal risk

76.2%

rs1528133 (A;A)

Magnitude: 0
References:1

normal risk

88.1%

rs12295638 (T;T)

Magnitude: 0
References:1

91.1%

rs6602024 (G;G)

Magnitude: 0
References:1

normal

92.1%

rs6232 (A;A)

Magnitude: 0
References:6

93.1%

rs2229616 (G;G)

Magnitude: 0
References:2

normal

98.0%

rs10508503 (C;C)

Magnitude: 0
References:4

98.0%

rs1435703 (G;G)

Magnitude: 0
References:1

98.0%

rs2765086 (C;C)

Magnitude: 0
References:1

99.0%

rs3764220 (A;A)

Magnitude: 0
References:2

None

rs16964465 (A;A)

Magnitude: 0
References:2

None

rs16964476 (A;A)

Magnitude: 0
References:2

None

Magnitude: 0
References:14

higher risk for several conditions

None

rs997509 (C;C)

Magnitude: 0
References:2

55.4%

rs7566605 (G;G)

Magnitude: 0
ambig
References:15

common

56.4%

Magnitude: 0
ambig
References:57

common

151 snps

Osteoarthritis

(hide) Osteoarthritis

70.3%

rs10947262 (C;C)

Magnitude: 1.3
References:2

1.3x increased risk for osteoarthritis

None

rs143383 (C;T)

Magnitude: 1.2
References:9

1.1x increased risk for osteoarthritis

34.7%

References:1

40.6%

References:4

normal One report indicates that rs419598(T;T) carriers, if they are also IL1B -511 heterozygotes, have an increased chance of surviving a bout of bacterial meningitis . The (T;T) genotype is the most common in all populations studied.

43.6%

rs6060369 (C;T)

References:4

0.44cm taller

50.5%

rs7639618 (C;T)

References:3

1.45x increased osteoarthritis risk

65.7%

rs10980705 (C;C)

References:3

1x normal risk

77.2%

References:2

78.2%

References:7

None

References:2

1.43x increased osteoarthritis risk

None

References:1

75.2%

ambig
References:19

None

ambig
References:8

53.5%

Magnitude: 0
References:2

None

rs4140564 (T;T)

Magnitude: 0
References:3

None

rs1800796 (G;G)

Magnitude: 0
ambig
References:9

appears to be common on the 23andMe platform

None

rs7775 (C;C)

Magnitude: 0
ambig
References:2

17 snps

Osteoporosis

(hide) Osteoporosis

None

rs143383 (C;T)

Magnitude: 1.2
References:9

1.1x increased risk for osteoarthritis

8.9%

rs1859345 (C;C)

References:1

slightly earlier age at menarche

9.9%

rs13357391 (C;C)

References:1

slightly earlier age at menarche

13.9%

References:10

15.8%

References:3

16.8%

References:1

18.8%

References:1

19.8%

References:1

20.8%

References:7

increased risk for osteoporosis

23.8%

References:1

23.8%

References:1

23.8%

References:1

24.0%

References:1

24.8%

References:1

24.8%

References:1

25.0%

References:1

25.7%

References:1

25.7%

References:5

26.7%

References:6

26.7%

References:10

27.7%

References:1

29.7%

References:15

30.7%

References:1

30.7%

References:1

32.7%

References:2

34.7%

References:2

35.6%

References:2

35.6%

References:1

37.6%

References:1

1.26x risk for lower bone mineral density

38.6%

References:3

38.6%

References:1

39.6%

References:2

40.6%

References:1

40.6%

References:4

41.6%

References:2

41.6%

References:1

42.0%

References:1

increased osteoporosis risk

42.6%

References:1

43.6%

References:0

43.6%

References:1

43.6%

References:1

44.6%

References:5

45.5%

References:5

45.5%

References:1

46.5%

References:2

46.5%

References:1

48.0%

References:1

50.5%

References:1

51.5%

References:2

51.5%

References:1

51.5%

References:1

52.0%

References:2

52.0%

References:2

52.5%

References:1

52.5%

References:1

53.0%

References:1

53.1%

References:1

53.5%

References:1

53.5%

References:8

53.5%

References:6

53.5%

References:1

54.5%

References:1

54.5%

References:3

55.4%

References:3

56.2%

References:1

57.4%

References:2

58.4%

References:1

59.4%

References:1

60.0%

References:1

60.4%

References:1

62.4%

References:1

65.3%

References:1

65.3%

References:1

65.3%

References:1

66.3%

References:1

66.3%

References:1

67.3%

References:4

69.3%

References:1

70.3%

References:3

74.3%

References:4

75.2%

References:1

79.2%

References:1

79.2%

References:1

79.2%

References:3

82.2%

References:1

88.1%

References:3

88.1%

References:4

94.1%

References:1

None

References:4

None

References:4

normal

None

References:1

None

References:3

None

References:2

None

References:1

None

References:1

None

References:1

None

References:2

None

References:3

None

References:1

None

References:2

None

References:1

None

References:1

48.5%

ambig
References:1

71.3%

ambig
References:1

None

ambig
References:3

None

ambig
References:2

None

ambig
References:2

None

ambig
References:1

None

ambig
References:1

None

ambig
References:1

30.7%

Magnitude: 0
References:1

53.5%

rs2297480 (A;A)

Magnitude: 0
References:2

normal

55.0%

rs3130340 (T;T)

Magnitude: 0
References:2

69.3%

Magnitude: 0
References:45

70.3%

rs16964201 (C;C)

Magnitude: 0
References:1

71.3%

rs2306033 (G;G)

Magnitude: 0
References:1

None

rs4140564 (T;T)

Magnitude: 0
References:3

None

rs7771980 (T;T)

Magnitude: 0
References:1

normal

None

rs7775 (C;C)

Magnitude: 0
ambig
References:2

119 snps

Ovarian cancer

(hide) Ovarian cancer

27.7%

rs2072590 (G;T)

Magnitude: 1.2
References:2

1.2x increased risk for ovarian cancer

3.1%

rs4986852 (A;G)

References:2

possible predisposition to breast cancer

10.9%

rs3731239 (C;C)

References:1

0.9x lower risk for breast cancer

35.6%

References:3

36.6%

References:1

normal

38.6%

rs2910164 (C;G)

References:20

higher/earlier cancer likelihood??

40.6%

References:3

44.6%

References:10

0.65x lower risk of ovarian cancer; normal PON catalytic efficiency

53.5%

References:2

74.3%

References:3

77.2%

References:1

97.0%

References:1

1.25x risk of developing ovarian cancer

None

rs17647532 (T;T)

References:1

normal risk

None

References:1

None

References:3

None

References:5

1.65x increased risk only in men for myocardial infarction

None

References:4

higher cancer risk

None

rs523349 (C;G)

References:5

increased ovarian cancer risk

None

References:1

None

ambig
References:1

None

ambig
References:2

30.7%

Magnitude: 0
References:12

1.64x risk for breast cancer

36.6%

rs4320932 (A;A)

Magnitude: 0
References:1

normal

78.2%

rs3218536 (G;G)

Magnitude: 0
References:4

normal risk

87.0%

rs2665390 (T;T)

Magnitude: 0
References:1

87.1%

rs1042838 (G;G)

Magnitude: 0
References:5

normal risk

89.1%

rs10088218 (G;G)

Magnitude: 0
References:2

None

rs1800709 (C;C)

Magnitude: 0
References:2

normal

None

rs2295190 (G;G)

Magnitude: 0
References:1

common

None

rs2740574 (A;A)

Magnitude: 0
References:14

normal

None

rs28897672 (T;T)

Magnitude: 0
References:2

normal

None

rs41293455 (C;C)

Magnitude: 0
References:2

normal

None

rs1045485 (G;G)

Magnitude: 0
ambig
References:5

33 snps

Pachyonychia congenita Type I

(hide) Pachyonychia congenita Type I

None

rs28928894 (T;T)

Magnitude: 0
References:1

normal

None

rs28933087 (T;T)

Magnitude: 0
References:1

normal

None

rs57052654 (T;T)

Magnitude: 0
References:1

normal

None

rs58293603 (T;T)

Magnitude: 0
References:1

normal

None

rs59349773 (A;A)

Magnitude: 0
References:1

normal

None

rs60554162 (G;G)

Magnitude: 0
References:1

normal

None

rs28928895 (T;T)

Magnitude: 0
ambig
References:1

normal

None

rs57424749 (G;G)

Magnitude: 0
ambig
References:1

normal

None

rs59328451 (A;A)

Magnitude: 0
ambig
References:1

normal

9 snps

Panic disorder

(hide) Panic disorder

gs209

Magnitude: 1.8

The haplotype A-A-G for SNPs rs3794808, rs140701 and rs4583306 has a 1.7x increased risk for panic disorder. However it seems quite common among the promethease reports.

4.0%

References:2

5.0%

References:2

12.9%

References:2

13.1%

References:1

20.8%

References:2

24.2%

References:2

31.7%

References:3

increased risk for anxiety disorders

32.0%

References:1

32.3%

References:1

36.6%

References:11

higher risk for RA

37.6%

References:12

51.5%

References:2

52.0%

References:2

55.4%

References:1

68.3%

References:2

78.2%

References:2

86.0%

References:2

99.0%

References:2

None

References:3

None

References:2

None

References:1

None

References:2

58.4%

ambig
References:2

None

ambig
References:2

83.2%

Magnitude: 0
References:2

1 genoset 25 snps

Pelvic organ prolapse

1 snp

Periodontitis

(hide) Periodontitis

20.8%

rs1333048 (C;C)

Magnitude: 2.1
References:3

1.5x increased coronary artery disease risk; 2x increased periodontitis risk 2x increased risk of periodontitis and coronary heart disease as discussed at spittoon

61.4%

rs1047031 (G;G)

References:1

normal

88.1%

References:1

55.4%

ambig
References:1

normal

75.2%

ambig
References:19

None

Magnitude: 0
ambig
References:5

common This appears to be the common allele among an ambiguous flip

6 snps

Peripheral arterial disease

(hide) Peripheral arterial disease

31.0%

Magnitude: 2
References:31

1.3x increased risk of lung cancer

43.0%

rs7025486 (G;G)

References:3

2 snps

Phenylketonuria

4 snps

Photic sneeze reflex

3 snps

Polycystic Kidney disease

(hide) Polycystic Kidney disease

37.6%

References:0

None

References:0

57.4%

Magnitude: 0
References:9

normal

None

rs2435322 (G;G)

Magnitude: 0
References:0

None

rs28937907 (C;C)

Magnitude: 0
References:1

None

rs28939383 (C;C)

Magnitude: 0
References:0

None

rs34197769 (G;G)

Magnitude: 0
References:0

7 snps

Pre-eclampsia

(hide) Pre-eclampsia

13.9%

rs699 (T;T)

References:15

normal risk

54.5%

References:1

73.3%

References:1

None

References:0

None

References:0

None

References:1

normal risk

None

rs1799983 (G;T)

References:15

increased risk of preeclampsia

69.3%

Magnitude: 0
References:45

75.0%

rs4762 (C;C)

Magnitude: 0
References:3

normal risk

99.0%

Magnitude: 0
References:8

normal/common

None

rs5186 (A;A)

Magnitude: 0
References:16

normal risk

11 snps

Premature birth

(hide) Premature birth

51.5%

References:1

83.2%

References:1

None

ambig
References:3

80.0%

Magnitude: 0
References:5

normal

82.0%

Magnitude: 0
References:9

normal

None

rs5743708 (G;G)

Magnitude: 0
References:2

normal

6 snps

Primary biliary cirrhosis

(hide) Primary biliary cirrhosis

15.2%

References:4

16.8%

References:2

22.0%

References:2

34.7%

References:3

43.0%

References:2

43.6%

References:1

46.5%

References:3

62.4%

References:5

73.5%

References:1

79.0%

References:1

71.3%

Magnitude: 0
References:10

normal

11 snps

Psoriasis

(hide) Psoriasis

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

5.0%

rs1265159 (T;T)

Magnitude: 2.5
References:0

psoriasis risk for Chinese? This has no known affect among Caucasian populations, but in a Chinese population this genotype indicates a 22x risk of psoriasis. Source Nature research paper

None

rs1265181 (G;G)

Magnitude: 2
ambig
References:4

possibly increased risk of psoriasis One paper claims a 22x risk of psoriasis among Asians, with no effect on non-asians. However its an ambiguous flip on the minus strand, and occurs often among even the test genomes. Psoriasis doesn't seem to affect any of them so there is little reason to worry. But if you do have psoriasis and this genotype, please contact info@snpedia.com to discuss other neighboring snps on your platform.

9.0%

References:5

10.9%

References:2

15.8%

References:20

15.8%

References:1

21.2%

References:3

24.2%

References:1

31.7%

References:14

32.7%

References:1

33.7%

References:2

36.6%

References:5

36.6%

References:8

40.6%

References:0

46.0%

References:8

1.5x risk for Crohn's disease; 2x risk for Graves' disease

47.5%

References:3

47.5%

References:9

1.4x increased risk of psoriasis and psoriatic arthritis

48.5%

References:5

48.5%

References:3

50.5%

References:12

53.5%

References:1

54.5%

References:2

55.4%

References:2

74.3%

References:1

79.2%

References:2

80.2%

References:2

86.1%

References:1

92.1%

References:13

more likely to gain weight if taking olanzapine

None

References:0

None

References:0

None

References:0

None

References:10

None

References:11

None

References:4

None

References:1

None

References:3

37.0%

ambig
References:8

1.4x increased risk of psoriasis, psoriatic arthritis

68.0%

rs2395029 (T;T)

Magnitude: 0
References:10

69.3%

Magnitude: 0
References:45

88.1%

rs7530511 (C;C)

Magnitude: 0
References:2

normal

95.0%

rs2066808 (T;T)

Magnitude: 0
References:3

99.0%

Magnitude: 0
References:27

common

None

rs28364006 (A;A)

Magnitude: 0
References:1

None

Magnitude: 0
References:10

complex; generally normal risk

None

Magnitude: 0
References:19

common

46 snps

Psoriatic arthritis

2 snps

Pancreatic cancer

(hide) Pancreatic cancer

22.8%

rs521102 (T;T)

References:1

pancreatic cancer patients respond poorer to combined therapy

25.7%

rs2227928 (T;T)

References:1

normal

27.7%

References:3

38.6%

References:2

1.6x increased risk of lung cancer

42.6%

rs505922 (C;T)

References:7

1.2x risk of pancreatic cancer

45.5%

References:5

54.5%

References:3

64.4%

References:14

~1.2x increased risk for several types of cancer

76.2%

rs1801516 (G;G)

References:1

normal

None

References:0

None

References:2

72.3%

Magnitude: 0
References:3

12 snps

Parkinson's disease

(hide) Parkinson's disease

None

rs356219 (G;G)

Magnitude: 1.6
References:7

1.6x increased risk for Parkinson's disease

90.1%

rs3758549 (C;C)

Magnitude: 1.1
References:5

increased risk of parkinson's disease While this does indicate increased risk of in one Parkinson's disease study. It is so common that it makes more sense to think of the other 2 genotypes as rare risk reducers.

3.0%

References:2

9.0%

References:1

9.9%

References:2

12.9%

References:1

12.9%

References:1

12.9%

References:1

12.9%

References:2

27.7%

References:6

29.7%

References:2

36.6%

References:1

39.0%

References:1

39.0%

References:1

40.6%

References:1

42.6%

References:1

44.6%

References:2

45.5%

References:2

46.5%

References:2

50.5%

References:3

1.19x increased risk for T2D

50.5%

References:1

54.5%

References:1

57.4%

References:1

57.4%

References:4

58.4%

References:2

61.4%

References:1

66.3%

References:10

~2x increased risk for Parkinson's disease, and, essential tremor

67.0%

References:1

72.3%

References:1

76.2%

References:2

78.0%

References:2

82.2%

References:3

82.2%

References:3

84.2%

References:2

87.1%

References:1

87.1%

References:1

88.1%

References:1

94.1%

References:1

None

References:1

None

References:1

None

References:1

37.8%

ambig
References:2

50.5%

ambig
References:1

73.3%

ambig
References:1

84.2%

ambig
References:1

None

ambig
References:1

None

ambig
References:4

28.7%

Magnitude: 0
References:1

59.4%

rs6963573 (G;G)

Magnitude: 0
References:1

97.0%

rs283413 (G;G)

Magnitude: 0
References:2

normal

None

rs34637584 (G;G)

Magnitude: 0
References:2

normal

None

rs34778348 (G;G)

Magnitude: 0
References:3

normal

None

rs3892097 (G;G)

Magnitude: 0
References:9

extensive metabolizer

None

rs33949390 (G;G)

Magnitude: 0
ambig
References:3

normal

54 snps

Polycystic ovary syndrome

(hide) Polycystic ovary syndrome

7.9%

References:1

39.6%

References:1

45.5%

References:1

50.5%

References:7

51.5%

References:2

57.4%

References:2

61.0%

References:5

64.0%

References:1

74.3%

References:1

74.3%

References:1

None

References:1

None

References:1

normal risk

67.3%

rs2267668 (A;A)

Magnitude: 0
References:4

13 snps

Post-traumatic stress disorder

(hide) Post-traumatic stress disorder

None

rs25531 (G;G)

Magnitude: 2.1
References:25

happier, less sensitive to pain less sensitive to pain

5.0%

rs806368 (C;C)

Magnitude: 2
References:2

13.9%

rs1360780 (T;T)

References:11

1.3x increased risk for depression

13.9%

References:7

15.0%

References:3

42.6%

References:35

multiple associations, see details

65.3%

rs1049353 (G;G)

References:4

more resistant to treatment for depression

None

References:3

None

References:13

1.4x higher schizophrenia risk

None

rs4606 (C;C)

ambig
References:4

complex; possible association with anxiety related behaviours

10 snps

Primary sclerosing cholangitis

4 snps

Progressive supranuclear palsy

2 snps

Prostate cancer

(hide) Prostate cancer

45.0%

Magnitude: 2.1
References:34

1.2x risk of prostate cancer 1.2x risk of prostate cancer

25.7%

rs4054823 (T;T)

Magnitude: 2
References:1

1.26x higher risk of aggressive form of prostate cancer The (T;T) genotype does not indicate a higher risk of prostate cancer. It indicates that those with prostate cancer have a 26% higher chance of having the aggressive form which requires more aggressive treatment.

38.6%

rs10086908 (C;T)

Magnitude: 2
References:3

1.7x increased risk for prostate cancer

None

rs351855 (C;T)

Magnitude: 1.2
References:5

1.2x increased risk for prostate cancer

6.9%

References:8

12.0%

References:2

15.8%

References:2

16.8%

References:1

18.8%

References:21

20.8%

References:2

27.7%

References:1

somewhat higher risk for prostate cancer

27.7%

References:1

27.7%

References:4

30.0%

References:2

somewhat higher risk for prostate cancer

30.7%

References:1

31.7%

References:1

32.3%

References:1

33.7%

References:1

34.7%

References:5

35.6%

References:3

36.6%

References:2

normal

37.6%

References:2

38.6%

References:2

38.6%

References:1

40.4%

References:2

40.6%

References:1

41.6%

References:1

41.6%

References:2

41.6%

References:5

42.6%

References:5

42.6%

References:8

44.6%

References:1

45.5%

References:5

47.0%

References:4

1.5x increased prostate cancer risk

48.5%

References:2

48.5%

References:1

49.5%

References:2

50.5%

References:1

50.5%

References:19

51.0%

References:1

51.5%

References:2

52.5%

References:4

53.5%

References:1

54.0%

References:10

1.8x increased prostate cancer risk

54.5%

References:1

55.4%

References:1

6x increased risk for prostate cancer, 3x increased BPH risk

55.4%

References:2

56.0%

References:5

60.0%

References:7

63.4%

References:2

66.3%

References:2

66.3%

References:1

67.3%

References:1

68.3%

References:1

70.3%

References:1

73.3%

References:0

77.2%

References:0

78.2%

References:1

78.2%

References:3

84.2%

References:3

86.9%

References:1

88.1%

References:2

None

References:12

increased prostate cancer risk

None

References:3

None

References:1

None

References:9

None

References:3

None

References:1

None

References:1

None

References:1

None

References:2

75.2%

ambig
References:19

None

ambig
References:1

None

ambig
References:2

18.8%

Magnitude: 0
References:7

normal risk

25.7%

rs7652331 (C;C)

Magnitude: 0
References:1

normal risk

29.7%

rs1545985 (A;A)

Magnitude: 0
References:1

normal risk

29.7%

rs1056836 (C;G)

Magnitude: 0
References:14

normal

36.6%

rs2987983 (T;T)

Magnitude: 0
References:5

normal risk This is the typical form, exhibiting normal risk for prostate cancer to learn more visit rs2987983

50.5%

rs4430796 (A;G)

Magnitude: 0
References:15

normal risk

51.5%

rs10492519 (A;A)

Magnitude: 0
References:1

normal risk

53.5%

rs16260 (C;C)

Magnitude: 0
References:6

normal

56.4%

rs12255372 (G;G)

Magnitude: 0
References:12

71.3%

rs7017300 (A;A)

Magnitude: 0
References:2

normal risk

73.0%

rs7837688 (G;G)

Magnitude: 0
References:2

1.7x increased risk for prostate cancer

74.0%

rs10505483 (G;G)

Magnitude: 0
References:1

common

74.3%

rs16901979 (C;C)

Magnitude: 0
References:11

normal risk

74.3%

rs251177 (T;T)

Magnitude: 0
References:1

normal risk

76.2%

rs721048 (G;G)

Magnitude: 0
References:7

normal

77.2%

rs4242382 (G;G)

Magnitude: 0
References:2

normal risk

77.2%

rs4242384 (A;A)

Magnitude: 0
References:2

78.2%

rs1447295 (C;C)

Magnitude: 0
References:14

normal

78.2%

rs1571801 (C;C)

Magnitude: 0
References:1

average

78.2%

rs3750861 (C;C)

Magnitude: 0
References:1

81.2%

rs25489 (G;G)

Magnitude: 0
References:4

normal risk

84.2%

rs11102001 (G;G)

Magnitude: 0
References:1

88.1%

rs7965399 (T;T)

Magnitude: 0
References:1

None

rs10090154 (C;C)

Magnitude: 0
References:5

normal

None

rs20415 (G;G)

Magnitude: 0
References:1

None

rs2740574 (A;A)

Magnitude: 0
References:14

normal

100 snps

Resting heart rate

(hide) Resting heart rate

34.7%

References:1

42.6%

References:1

43.6%

References:3

47.5%

References:1

74.3%

References:1

82.0%

References:5

None

References:1

7 snps

Restless legs syndrome

(hide) Restless legs syndrome

14.9%

rs9296249 (C;C)

References:5

<0.62x risk for restless legs

20.8%

rs3923809 (G;G)

References:6

common

20.8%

References:1

31.3%

References:1

36.6%

References:1

common

36.6%

rs9357271 (C;C)

References:3

<0.63x risk for restless legs

42.6%

References:1

44.6%

References:2

haplotype at risk for restless legs

49.5%

rs9394492 (T;T)

References:1

common

27.7%

rs4489954 (G;G)

Magnitude: 0
References:3

common

29.7%

rs1026732 (G;G)

Magnitude: 0
References:2

common

30.7%

rs3784709 (C;C)

Magnitude: 0
References:2

<0.71x risk for restless legs

31.7%

rs11635424 (G;G)

Magnitude: 0
References:2

common

31.7%

rs12593813 (G;G)

Magnitude: 0
References:4

common

32.0%

rs884202 (A;A)

Magnitude: 0
References:1

<0.69x risk for restless legs

45.5%

rs12469063 (A;A)

Magnitude: 0
References:3

>1.7x risk for restless legs

45.5%

rs2300478 (T;T)

Magnitude: 0
References:6

common

58.6%

rs4626664 (G;G)

Magnitude: 0
References:5

normal

67.3%

rs1975197 (C;C)

Magnitude: 0
References:5

normal

29.7%

rs6494696 (G;G)

Magnitude: 0
ambig
References:3

common

20 snps

Rhinosinusitis

1 snp

Rheumatoid Arthritis

(hide) Rheumatoid Arthritis

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

22.8%

rs762551 (C;C)

Magnitude: 2.5
References:7

CYP1A2 slow metabolizer more strongly affected by drinking coffee.

58.4%

rs2298383 (C;C)

Magnitude: 2
References:3

increased anxiety in response to caffeine associated with increased anxiety in response to caffeine

1.0%

rs3849942 (A;A)

Magnitude: 1.4
References:3

1.4x increased risk for ALS

1.0%

rs2814707 (A;A)

Magnitude: 1.2
References:3

>1.2x increased risk for ALS

2.0%

References:2

5.9%

References:1

6.9%

References:8

7.9%

References:3

7.9%

References:1

11.9%

References:7

13.9%

References:2

15.8%

References:3

reduced risk of rheumatoid arthritis

15.8%

References:20

16.8%

References:2

17.8%

References:2

19.8%

References:3

19.8%

References:2

20.8%

References:4

22.8%

References:2

25.7%

References:1

27.3%

References:2

27.7%

References:1

28.7%

References:2

33.7%

References:2

34.7%

References:56

34.7%

References:3

normal

34.7%

References:4

36.4%

References:7

2x risk for sarcoidosis

36.6%

References:1

36.6%

References:13

complex; generally greater risk for cancer progression

36.6%

rs6313 (C;C)

References:11

higher risk for RA

36.6%

References:3

36.6%

References:1

37.6%

References:12

37.6%

References:2

38.6%

References:2

0.9x decreased rheumatoid arthritis risk

40.4%

References:3

41.0%

References:6

1.4x increased risk of SLE

41.6%

References:3

42.3%

References:2

42.6%

References:1

42.6%

References:1

44.6%

References:13

somewhat increased risk for multiple autoimmune diseases

45.5%

References:4

45.5%

References:5

46.5%

References:2

1.9x increased risk for SLE (lupus)

47.4%

References:2

48.0%

References:1

48.5%

References:1

49.5%

References:2

1.9x risk

49.5%

References:1

49.5%

References:3

1.2x risk

50.5%

References:1

50.5%

References:12

51.5%

References:3

52.5%

References:4

52.5%

References:3

54.5%

References:7

55.4%

References:1

60.4%

References:1

62.0%

References:1

66.3%

References:9

1.7x risk for RA; 1.6X for T1D; also MS?

66.3%

References:1

67.3%

References:1

68.0%

References:3

68.3%

References:2

69.3%

References:1

2x risk

70.3%

References:1

75.2%

References:1

77.8%

References:1

80.2%

References:1

82.2%

References:7

83.0%

References:2

83.2%

References:3

86.1%

References:1

88.1%

References:2

88.1%

References:1

93.9%

References:5

higher risk for RA

None

References:10

None

References:5

normal

None

rs2070744 (C;C)

References:12

increased prostate cancer risk

None

rs2240340 (G;G)

References:2

average

None

References:1

None

References:4

None

References:2

None

References:1

None

References:1

None

References:6

normal for RA; 1.4x increased GD risk

None

rs7528684 (G;G)

References:2

1.2x risk

None

References:3

None

References:3

None

References:4

18.8%

ambig
References:7

24.8%

ambig
References:1

71.3%

ambig
References:1

75.2%

ambig
References:19

80.2%

ambig
References:1

None

ambig
References:1

None

ambig
References:1

normal

None

ambig
References:0

15.0%

Magnitude: 0
References:2

normal

21.2%

rs6682654 (A;A)

Magnitude: 0
References:2

24.8%

rs6457617 (C;C)

Magnitude: 0
References:5

normal

26.7%

rs11761231 (T;T)

Magnitude: 0
References:3

normal

40.0%

Magnitude: 0
References:34

common

40.6%

Magnitude: 0
References:16

increased risk for auto-immune diseases

50.5%

rs3761847 (A;A)

Magnitude: 0
References:11

>1.3x risk

51.5%

rs9550642 (G;G)

Magnitude: 0
References:1

normal

65.3%

rs2837960 (T;T)

Magnitude: 0
References:3

normal

66.3%

rs1953126 (C;C)

Magnitude: 0
References:3

normal

69.3%

Magnitude: 0
References:45

69.3%

rs743777 (A;A)

Magnitude: 0
References:2

1.7x risk

71.3%

rs10488631 (T;T)

Magnitude: 0
References:10

normal

71.3%

rs1343151 (C;C)

Magnitude: 0
References:6

normal risk

76.2%

rs660895 (A;A)

Magnitude: 0
References:2

normal

78.2%

Magnitude: 0
References:16

normal

82.0%

rs6920220 (G;G)

Magnitude: 0
References:14

normal

82.2%

rs2269475 (G;G)

Magnitude: 0
References:1

normal

84.2%

rs2073838 (G;G)

Magnitude: 0
References:2

84.2%

rs3792876 (C;C)

Magnitude: 0
References:2

87.1%

rs10985112 (G;G)

Magnitude: 0
References:1

89.1%

rs6822844 (G;G)

Magnitude: 0
References:14

89.1%

rs6910071 (A;A)

Magnitude: 0
References:2

normal

96.0%

rs1328674 (G;G)

Magnitude: 0
References:1

average

98.0%

Magnitude: 0
References:25

normal

99.0%

Magnitude: 0
References:7

normal

None

rs11568821 (G;G)

Magnitude: 0
References:1

None

rs2230500 (G;G)

Magnitude: 0
References:4

normal risk

None

rs4846051 (A;A)

Magnitude: 0
References:1

130 snps

Sciatica

(hide) Sciatica

78.2%

References:7

75.2%

ambig
References:19

None

ambig
References:2

None

Magnitude: 0
ambig
References:9

appears to be common on the 23andMe platform

4 snps

Secondhand smoke susceptibility

1 snp

Skin cancer

(hide) Skin cancer

77.2%

Magnitude: 2
References:10

2-4x higher risk of sun sensitivity if part of risk haplotype

20.8%

rs7538876 (A;A)

References:6

1.28x increased basal cell carcinoma risk

36.6%

rs801114 (G;T)

References:6

1.28x increased basal cell carcinoma risk

None

References:5

normal

None

References:13

generally more cancer prone

77.2%

Magnitude: 0
References:10

normal

97.0%

rs1805008 (C;C)

Magnitude: 0
References:3

99.0%

rs1805007 (C;C)

Magnitude: 0
References:5

normal risk

8 snps

Smell

1 snp

Smoking

(hide) Smoking

4.0%

rs279858 (G;G)

Magnitude: 2.1
References:1

apparently more prone to alcoholism interacts with the medicine Finasteride

31.0%

Magnitude: 2
References:31

1.3x increased risk of lung cancer

8.0%

References:2

9.9%

References:2

13.0%

References:2

22.8%

References:2

24.8%

References:2

27.7%

References:2

29.7%

References:3

31.0%

References:1

31.2%

References:1

31.7%

References:4

32.7%

References:0

34.7%

References:2

36.0%

References:8

39.6%

References:1

40.6%

References:2

41.6%

References:2

43.6%

References:2

45.5%

References:2

46.5%

References:2

56.4%

References:2

62.4%

References:2

64.4%

References:2

72.0%

References:1

72.3%

References:2

82.2%

References:2

85.1%

References:2

None

References:1

None

References:1

None

References:1

None

References:2

None

References:2

None

References:1

None

References:5

None

References:4

None

References:2

None

References:2

9.9%

ambig
References:1

None

ambig
References:1

52.5%

Magnitude: 0
References:34

A2/A2 [[bupropion]] effective

87.0%

rs1402279 (A;A)

Magnitude: 0
References:2

93.1%

rs3027409 (T;T)

Magnitude: 0
References:2

95.0%

rs7050529 (G;G)

Magnitude: 0
References:2

44 snps

Speech

(hide) Speech

5.9%

rs851715 (G;G)

References:1

None

26.7%

rs2538976 (A;A)

References:1

None

26.7%

rs2710102 (T;T)

References:3

None

26.7%

rs759178 (T;T)

References:1

None

50.5%

rs17236239 (A;A)

References:3

None

None

rs10246256 (C;C)

References:1

None

None

rs1922892 (C;C)

References:1

None

None

rs2538991 (T;T)

References:1

None

None

References:0

None

ambig
References:1

None

10 snps

Stroke

(hide) Stroke

19.8%

rs1333049 (C;C)

Magnitude: 4
ambig
References:19

1.9x increased risk for CAD

None

Magnitude: 2.1
References:20

1.6x risk for MI

None

rs8050894 (C;C)

Magnitude: 2.1
ambig
References:4

warfarin sensitivity (~2.5 mg/day)

30.7%

rs2108622 (C;C)

Magnitude: 2
References:19

lower warfarin dosing

6.9%

References:5

12.9%

References:22

13.9%

References:15

normal risk

16.8%

References:3

17.8%

References:3

17.8%

References:2

23.0%

References:1

27.7%

References:0

28.7%

References:5

30.7%

References:14

normal

33.0%

rs5498 (G;G)

References:7

0.6x decreased risk for diabetic nephropathy in females with type-1 diabetes; increased malaria risk

33.7%

rs780094 (A;G)

References:27

metabolic consequences

34.7%

References:56

35.6%

References:2

37.6%

References:6

mixed evidence of increased risk for stroke 1.3x increased risk for stroke in an initial study, but failed to replicate in a followup.

41.6%

References:4

43.6%

References:1

43.6%

References:1

0.10 decreased risk for brain edema after a stroke

45.0%

References:1

48.5%

References:4

52.5%

References:3

1.24x increased stroke risk for males

77.2%

References:1

97.0%

References:2

None

References:3

None

References:0

None

References:0

None

References:12

increased prostate cancer risk

None

References:7

None

References:2

normal risk

None

References:0

None

References:2

None

References:0

None

References:0

None

References:1

None

References:12

complex; see details for increased risks

None

References:1

None

References:1

None

References:3

2-3x increased risk for ischemic stroke

None

References:5

None

References:1

2x higher stroke risk in Caucasian women

None

References:12

33.0%

ambig
References:0

75.2%

ambig
References:19

None

ambig
References:17

None

ambig
References:1

None

Magnitude: 0
References:2

normal

31.7%

rs966221 (T;T)

Magnitude: 0
References:2

normal

65.3%

rs9934438 (G;G)

Magnitude: 0
References:7

68.3%

rs4961 (G;G)

Magnitude: 0
References:10

normal

69.3%

Magnitude: 0
References:45

75.2%

rs2200733 (C;C)

Magnitude: 0
References:10

normal

76.2%

rs4769874 (G;G)

Magnitude: 0
References:0

76.2%

Magnitude: 0
References:4

1.12x risk on diuretic; if hypertensive, better outcome when treated with calcium channel blocker than with diuretic

81.2%

rs10486776 (G;G)

Magnitude: 0
References:2

88.1%

rs989554 (A;A)

Magnitude: 0
References:0

92.1%

Magnitude: 0
References:8

normal

99.0%

rs28371685 (C;C)

Magnitude: 0
References:2

normal

99.0%

Magnitude: 0
References:8

normal/common

None

rs17222814 (G;G)

Magnitude: 0
References:1

common for Caucasians on the 23andme platform

None

rs17222842 (G;G)

Magnitude: 0
References:0

None

rs2069830 (C;C)

Magnitude: 0
References:2

None

rs2230500 (G;G)

Magnitude: 0
References:4

normal risk

None

rs28399504 (A;A)

Magnitude: 0
References:5

normal

None

rs284875 (G;G)

Magnitude: 0
References:0

None

rs4244285 (G;G)

Magnitude: 0
References:10

normal

None

Magnitude: 0
References:7

normal

None

Magnitude: 0
References:14

higher risk for several conditions

None

rs7900194 (G;G)

Magnitude: 0
References:1

normal

None

rs28371686 (C;C)

Magnitude: 0
ambig
References:2

normal common for Caucasians on the 23andme platform

73 snps

Sudden Infant Death Syndrome

(hide) Sudden Infant Death Syndrome

None

rs1570360 (G;G)

References:10

normal

75.2%

ambig
References:19

None

Magnitude: 0
References:10

complex; generally normal risk

3 snps

Suicide

(hide) Suicide

3.0%

rs7189819 (T;T)

References:1

14.9%

rs4825476 (G;G)

References:2

1.9x higher risk of suicidal thoughts when taking [[citalopram]]

29.7%

rs7305115 (G;G)

References:4

risk of suicide behavior

None

References:2

None

References:2

94.1%

Magnitude: 0
References:2

normal

6 snps

Sun sensitivity

(hide) Sun sensitivity

77.2%

Magnitude: 2
References:10

2-4x higher risk of sun sensitivity if part of risk haplotype

None

References:5

normal

77.2%

Magnitude: 0
References:10

normal

3 snps

Systemic sclerosis

(hide) Systemic sclerosis

63.4%

rs2056626 (T;T)

References:1

None

rs6918698 (C;G)

References:3

~normal risk

17.8%

rs2834167 (G;G)

Magnitude: 0
References:2

normal

24.8%

rs6457617 (C;C)

Magnitude: 0
References:5

normal

35.6%

rs1130866 (C;C)

Magnitude: 0
References:2

normal

61.4%

rs3821236 (G;G)

Magnitude: 0
References:4

71.3%

rs10488631 (T;T)

Magnitude: 0
References:10

normal

98.0%

Magnitude: 0
References:25

normal

8 snps

Sarcoidosis

(hide) Sarcoidosis

1.0%

Magnitude: 2.5
References:30

complex; generally higher risk for certain diseases

36.4%

rs2076530 (A;A)

References:7

2x risk for sarcoidosis

37.6%

rs1049550 (C;T)

References:5

0.62x reduced risk for sarcoidosis

38.6%

References:3

44.6%

References:1

63.4%

References:2

None

References:2

7 snps

Schizophrenia

(hide) Schizophrenia

45.6%

rs4129148 (C;G)

Magnitude: 2
References:1

3x risk

66.0%

rs2619522 (T;T)

Magnitude: 2
References:4

impaired cognitive ability impaired cognitive ability

11.9%

rs464049 (T;T)

Magnitude: 1.5
References:1

increased risk of schizophrenia in limited study

33.7%

rs2007153 (G;G)

Magnitude: 1.5
References:1

increased risk of schizophrenia in limited study

71.3%

rs7341475 (G;G)

Magnitude: 1.5
References:3

1.58x increased schizophrenia risk for women

None

rs4331145 (A;A)

Magnitude: 1.5
References:1

increased risk of schizophrenia in limited study

84.2%

rs3131296 (G;G)

Magnitude: 1.4
References:2

1.4x increased risk for schizophrenia

41.0%

rs9960767 (A;C)

Magnitude: 1.2
References:3

1.2x increased risk for schizophrenia

55.4%

rs1344706 (T;T)

Magnitude: 1.2
References:13

1.2x increased risk for schizophrenia

3.0%

References:1

5.9%

References:1

6.9%

References:1

7.9%

References:3

7.9%

References:1

8.2%

Magnitude: 1
References:1

decreased risk of schizophrenia in limited study

10.1%

References:1

11.9%

References:2

12.9%

References:22

13.0%

References:5

17.8%

References:1

17.8%

References:2

19.8%

References:2

19.8%

References:3

20.8%

References:2

20.8%

References:2

20.8%

References:1

22.0%

Magnitude: 1
References:2

decreased risk of schizophrenia in limited study

22.8%

References:3

23.8%

References:1

23.8%

References:3

24.8%

References:3

26.7%

References:1

27.7%

References:2

28.0%

References:1

30.7%

References:1

34.7%

References:56

34.7%

References:1

35.0%

References:1

36.0%

References:12

36.0%

References:8

37.6%

References:3

39.0%

References:0

40.6%

References:1

41.6%

References:0

41.8%

References:1

42.6%

References:1

42.6%

References:35

multiple associations, see details

43.6%

References:1

43.6%

References:2

45.5%

References:1

46.5%

References:2

46.5%

References:1

46.5%

References:3

47.5%

References:7

47.5%

References:1

47.5%

References:2

47.5%

References:1

48.5%

References:3

48.5%

References:1

48.5%

References:1

48.5%

References:1

48.5%

References:1

48.5%

References:1

49.5%

References:1

49.5%

References:1

50.5%

References:3

1.19x increased risk for T2D

50.5%

References:1

50.5%

References:1

50.5%

References:2

51.5%

References:1

51.5%

References:1

somewhat increased risk for schizophrenia

51.5%

References:7

53.5%

References:1

53.5%

References:1

55.4%

References:2

55.4%

References:1

56.4%

References:1

57.4%

References:2

57.4%

References:2

57.4%

References:2

57.4%

References:1

58.4%

References:2

60.0%

References:1

60.4%

References:4

62.4%

References:5

62.4%

References:1

62.4%

References:2

63.0%

References:2

63.4%

References:1

63.4%

References:1

66.3%

References:4

67.3%

References:2

67.3%

References:1

68.3%

References:1

69.3%

References:2

69.3%

Magnitude: 1
References:3

1.1x increased risk for schizophrenia

71.3%

References:1

73.3%

References:1

normal

73.3%

References:0

74.0%

References:1

77.0%

References:3

78.2%

References:4

78.2%

References:1

79.2%

References:1

80.2%

References:3

84.2%

References:1

84.7%

References:2

86.1%

References:2

86.1%

References:1

87.1%

References:1

88.0%

References:3

92.1%

References:1

93.9%

References:5

higher risk for RA

98.0%

References:2

99.0%

References:1

99.0%

References:2

None

References:1

2.19x increased risk for schizophrenia in females

None

References:3

None

References:1

None

References:1

None

References:1

None

References:1

normal

None

References:1

None

References:19

normal

None

References:1

None

References:2

None

References:2

None

References:2

None

References:1

None

References:2

None

References:1

common

None

References:1

None

References:2

None

References:11

possible weight gain if taking olanzapine

None

References:1

None

References:1

None

References:1

None

References:3

None

References:1

None

References:2

None

References:1

None

References:3

None

References:2

None

References:3

None

References:3

None

References:4

None

References:1

None

References:1

None

References:1

None

References:1

3x risk

None

References:1

None

References:2

None

References:1

2.4x risk

None

References:9

None

References:3

None

References:13

1.4x higher schizophrenia risk

None

rs6603272 (G;T)

References:2

2.7x risk

None

rs6994992 (C;T)

Magnitude: 1
References:4

Carrier for rs6994992(T;T) which one report has associated with both creativity and schizophrenia

None

References:2

43.6%

ambig
References:3

66.0%

ambig
References:4

66.3%

ambig
References:2

71.7%

ambig
References:2

77.1%

ambig
References:1

slightly increased risk for schizophrenia

None

ambig
References:1

None

ambig
References:6

normal risk

None

ambig
References:3

None

ambig
References:4

None

ambig
References:2

None

ambig
References:4

complex; possible association with anxiety related behaviours

None

rs518147 (C;C)

ambig
References:3

less weight gain if taking olanzapine

None

ambig
References:2

25.7%

Magnitude: 0
References:3

normal

29.7%

rs6280 (T;T)

Magnitude: 0
References:9

normal

32.7%

rs167771 (A;A)

Magnitude: 0
References:3

36.6%

rs4320932 (A;A)

Magnitude: 0
References:1

normal

52.5%

Magnitude: 0
References:34

A2/A2 [[bupropion]] effective

55.4%

rs1076560 (C;C)

Magnitude: 0
References:9

normal

69.3%

rs12364283 (A;A)

Magnitude: 0
References:4

69.3%

Magnitude: 0
References:45

74.3%

rs11123857 (A;A)

Magnitude: 0
References:1

80.2%

rs11064768 (A;A)

Magnitude: 0
References:2

86.0%

rs450046 (T;T)

Magnitude: 0
References:2

87.1%

rs16977195 (A;A)

Magnitude: 0
References:2

89.1%

rs1799978 (A;A)

Magnitude: 0
References:4

96.0%

rs6675281 (C;C)

Magnitude: 0
References:3

common

99.0%

rs6267 (G;G)

Magnitude: 0
References:4

common

None

rs1018381 (C;C)

Magnitude: 0
References:8

None

Magnitude: 0
References:11

None

rs2870983 (C;C)

Magnitude: 0
References:0

None

rs3782206 (C;C)

Magnitude: 0
References:3

None

Magnitude: 0
References:14

higher risk for several conditions

None

rs916457 (C;C)

Magnitude: 0
References:1

None

rs11146020 (G;G)

Magnitude: 0
ambig
References:2

194 snps

Sickle Cell Anemia

(hide) Sickle Cell Anemia

27.7%

References:0

None

References:0

None

References:3

1.7x risk for priapism in SCA patients

None

References:0

33.0%

ambig
References:0

39.6%

Magnitude: 0.5
References:1

common, increased risk for sickle cell leg ulcers

88.1%

rs989554 (A;A)

Magnitude: 0
References:0

None

i3003137 (T;T)

Magnitude: 0
References:0

None

rs2249358 (A;A)

Magnitude: 0
References:3

normal risk for priapism in SCA patients

None

rs284875 (G;G)

Magnitude: 0
References:0

10 snps

Sjögren's syndrome

3 snps

Social anxiety disorder

(hide) Social anxiety disorder

None

rs25531 (G;G)

Magnitude: 2.1
References:25

happier, less sensitive to pain less sensitive to pain

31.7%

rs140701 (A;A)

References:3

increased risk for anxiety disorders

None

rs4606 (C;C)

ambig
References:4

complex; possible association with anxiety related behaviours

3 snps

Split hand

1 snp

Tay-Sachs disease

2 snps

Testicular cancer

(hide) Testicular cancer

58.4%

rs4474514 (A;A)

Magnitude: 1.8
References:2

>3x increased testicular cancer risk for men found in 65% of caucasians but linked 3x higher risk of testicular cancer than the (G;G) form.

28.7%

rs4324715 (T;T)

Magnitude: 1.2
References:0

normal

20.8%

References:3

29.7%

References:3

52.5%

References:0

3x increased testicular cancer risk for men

59.0%

rs3782179 (T;T)

Magnitude: 1
References:2

common, but increased risk of testicular cancer

62.4%

rs2059693 (C;T)

References:1

1.3x increased risk for testicular cancer

60.4%

rs1050565 (A;A)

Magnitude: 0
References:3

normal

62.6%

rs995030 (G;G)

Magnitude: 0
References:3

9 snps

Thyroid cancer

(hide) Thyroid cancer

42.6%

rs699947 (A;C)

References:15

1.36x increased risk for thyroid cancer in men

54.5%

rs944289 (C;T)

References:6

1.3x increased thyroid cancer risk

66.3%

rs2145418 (T;T)

References:1

normal

68.3%

rs965513 (G;G)

References:6

normal

None

rs1867277 (G;G)

References:1

normal

5 snps

Tourette syndrome

1 snp

Tuberculosis

(hide) Tuberculosis

36.6%

rs1024611 (C;T)

Magnitude: 2
References:3

increased risk of exercise induced ischemia

None

rs3764880 (A;A)

Magnitude: 1.6
References:2

1.2 - 1.8x increased tuberculosis risk

7.9%

References:3

42.6%

References:2

75.0%

Magnitude: 0
References:3

None

rs5743708 (G;G)

Magnitude: 0
References:2

normal

6 snps

Type-1 diabetes

(hide) Type-1 diabetes

21.8%

rs9272346 (A;A)

Magnitude: 2.7
References:4

None

Magnitude: 2.5
References:16

2.5x increased risk for type-2 diabetes

89.0%

rs3129934 (C;C)

Magnitude: 2.1
References:2

normal 1.6x risk of type-1 diabetes

7.9%

rs4496877 (T;T)

Magnitude: 1.2
References:1

For type-1 diabetics, 1.6x increased nephropathy risk

1.0%

rs3804100 (C;C)

References:1

somwhat increased risk for type-1 diabetes and allergic asthma

5.0%

References:1

5.9%

References:1

10.9%

References:1

10.9%

References:1

12.9%

References:1

17.0%

References:1

17.0%

References:5

17.8%

References:2

17.8%

References:13

1.3x risk for Crohn's; 1.3x for T1D

18.0%

References:1

18.8%

References:6

20.8%

References:1

23.8%

References:1

24.8%

References:1

24.8%

References:3

25.7%

References:1

25.7%

References:8

1.3x risk

25.7%

References:0

26.3%

References:8

1.3x risk

26.7%

rs6897932 (C;T)

References:15

1.3x increased risk for multiple sclerosis

29.7%

References:1

30.7%

References:3

31.7%

References:2

32.7%

References:4

1.3x risk

33.0%

rs5498 (G;G)

References:7

0.6x decreased risk for diabetic nephropathy in females with type-1 diabetes; increased malaria risk

33.7%

References:1

36.4%

References:7

2x risk for sarcoidosis

36.6%

References:1

38.6%

References:3

40.0%

References:5

41.6%

References:4

42.6%

References:1

44.6%

References:4

1.1x risk

44.6%

References:3

44.6%

References:13

somewhat increased risk for multiple autoimmune diseases

44.6%

References:2

45.5%

References:4

45.5%

References:0

45.5%

References:3

45.5%

References:12

1.2x risk

45.5%

rs725613 (A;C)

References:3

1.2x increased type-1 diabetes risk; 1.2x increased multiple sclerosis risk

46.5%

References:0

46.5%

References:1

46.5%

References:12

47.0%

References:6

48.5%

References:7

48.5%

References:5

48.5%

References:2

48.5%

References:3

48.5%

References:1

49.5%

References:2

1.5x risk

49.5%

References:3

51.5%

References:0

51.5%

References:9

52.0%

References:5

52.5%

References:3

53.0%

References:1

53.5%

References:1

54.0%

References:1

54.5%

References:6

55.4%

References:1

56.4%

References:2

57.4%

References:1

0.8x risk

60.0%

rs2304256 (C;C)

References:4

1.6x increased risk for SLE

60.4%

References:2

61.4%

References:26

increased risk for type-2 diabetes

64.4%

References:2

64.6%

References:4

66.3%

References:9

1.7x risk for RA; 1.6X for T1D; also MS?

66.3%

References:5

68.3%

References:2

1.63x increased nephropathy risk among type-1 diabetics

69.3%

rs6932590 (T;T)

Magnitude: 1
References:3

1.1x increased risk for schizophrenia

70.3%

References:3

71.3%

References:1

72.3%

References:1

77.2%

References:1

79.0%

References:1

80.2%

References:1

80.2%

References:5

80.6%

References:1

82.0%

References:3

84.2%

References:1

85.0%

References:3

88.1%

References:6

89.1%

References:1

None

References:1

None

References:1

None

References:10

None

References:1

None

References:1

None

References:5

None

References:1

None

References:1

None

References:1

None

References:2

None

References:3

None

References:1

None

References:2

None

References:1

None

References:1

None

References:1

None

References:0

25.7%

ambig
References:1

42.0%

ambig
References:1

64.4%

ambig
References:5

64.6%

ambig
References:4

slightly increased risk for several autoimmune diseases

67.3%

ambig
References:1

70.3%

ambig
References:1

72.0%

ambig
References:1

1.6x risk

None

ambig
References:1

None

ambig
References:2

26.7%

Magnitude: 0.5
References:2

no credible risk

83.2%

Magnitude: 0.1
ambig
References:19

16.8%

rs2639703 (T;T)

Magnitude: 0
References:1

normal

40.0%

Magnitude: 0
References:34

common

40.6%

Magnitude: 0
References:16

increased risk for auto-immune diseases

65.3%

rs3194051 (A;A)

Magnitude: 0
References:4

>1.1x risk

68.0%

rs3024505 (C;C)

Magnitude: 0
References:11

78.2%

rs17696736 (A;A)

Magnitude: 0
References:9

normal

78.2%

Magnitude: 0
References:16

normal

81.2%

rs11549465 (C;C)

Magnitude: 0
References:3

83.2%

rs2070600 (G;G)

Magnitude: 0
References:9

normal

89.1%

rs6822844 (G;G)

Magnitude: 0
References:14

98.0%

Magnitude: 0
References:25

normal

99.0%

Magnitude: 0
References:7

normal

None

rs12722495 (A;A)

Magnitude: 0
References:0

None

rs17810546 (A;A)

Magnitude: 0
References:5

None

rs1799864 (G;G)

Magnitude: 0
References:5

None

rs2157678 (C;C)

Magnitude: 0
References:1

None

rs35667974 (A;A)

Magnitude: 0
References:5

None

rs35732034 (G;G)

Magnitude: 0
References:1

None

rs41295061 (C;C)

Magnitude: 0
References:4

None

rs2296336 (C;C)

Magnitude: 0
ambig
References:1

2.9.x risk

None

rs3094628 (C;C)

Magnitude: 0
ambig
References:1

None

rs35337543 (G;G)

Magnitude: 0
ambig
References:1

140 snps

Taste

(hide) Taste

gs227

Magnitude: 3

You are heterozygous at all 3 of the SNPs which are known to influence the ability to taste bitterness. This means you are better than average at detecting bitter tastes while young, but that this ability will decrease to less than average during adulthood. As a child you will probably hate brussel sprouts, and by early adulthood will discover that olives and brussel sprouts now taste good. A 2010 study shows the change bitter sensitivity which occurs over the lifespan (from bitter sensitive to less so) is more common in people with this genoset. Children with this genotype could perceive a bitter taste at lower PROP concentrations than could heterozygous adults. The threshold for adolescents was intermediate. The 3 snps are rs10246939, rs1726866, rs713598 in the gene TAS2R38.

gs184

Magnitude: 1.2

normal tasting ability for bitterness

51.5%

rs1726866 (C;T)

Magnitude: 0.1
References:2

can taste bitter

52.0%

rs10246939 (C;T)

Magnitude: 0.1
References:3

can taste bitter

None

rs713598 (C;G)

Magnitude: 0.1
References:3

can taste bitter

None

rs307377 (C;C)

Magnitude: 0
References:1

2 genosets 4 snps

Torsion dystonia

1 snp

Type-2 diabetes

(hide) Type-2 diabetes

None

Magnitude: 2.5
References:16

2.5x increased risk for type-2 diabetes

52.5%

rs4402960 (G;T)

Magnitude: 2
References:19

1.2x increased risk for type-2 diabetes

0.0%

References:1

4.0%

References:1

6.9%

References:6

7.1%

References:7

8.9%

References:1

10.9%

References:2

1.9x risk

10.9%

References:6

11.9%

References:1

16.8%

References:5

17.0%

References:5

18.8%

References:1

18.8%

References:1

19.8%

References:2

21.8%

References:1

22.8%

References:1

27.7%

References:1

29.7%

References:2

29.7%

References:1

slightly decreased risk for type-2 diabetes

30.7%

rs5370 (G;G)

References:4

normal

30.7%

References:1

31.7%

References:8

31.7%

References:5

32.0%

References:7

32.3%

References:1

33.7%

References:1

33.7%

References:19

33.7%

References:27

metabolic consequences

34.0%

References:1

34.7%

References:1

35.6%

References:1

35.6%

References:1

35.6%

References:2

35.6%

References:2

36.6%

References:2

37.0%

References:2

None

37.6%

References:2

41.6%

References:7

41.6%

References:2

41.6%

References:5

42.0%

References:1

42.6%

References:1

42.6%

References:1

1.3x risk

43.0%

References:2

44.6%

References:9

44.6%

References:1

1.18x risk 1.18x risk of type-2 diabetes

45.5%

References:1

45.5%

References:2

45.5%

References:6

46.5%

References:2

47.5%

References:1

normal increased risk of type-2 diabetes

47.5%

References:2

47.5%

References:5

This is the genotype of User:Watson

48.0%

rs1495377 (C;G)

References:2

1.3x risk

48.5%

References:2

48.5%

References:4

1.32x increased risk of early-onset type-2 diabetes

48.5%

rs3020314 (C;T)

References:3

0.64x reduced lymphoma risk

48.5%

References:4

49.5%

References:5

49.5%

References:1

50.5%

References:3

1.19x increased risk for T2D

50.5%

References:7

52.0%

References:1

52.5%

References:1

53.0%

References:1

53.5%

References:5

53.5%

References:5

1.2x increased risk for type-2 diabetes

53.5%

References:2

54.5%

References:1

55.4%

References:1

55.4%

References:1

56.0%

References:2

56.4%

References:2

56.4%

References:1

57.3%

References:1

57.4%

References:2

57.4%

References:1

58.0%

References:1

58.0%

References:1

58.4%

References:4

58.4%

References:4

58.4%

References:1

normal

58.4%

References:3

58.6%

References:4

60.6%

References:1

1.9x risk

61.0%

References:5

61.2%

References:1

61.4%

References:6

61.4%

References:26

increased risk for type-2 diabetes

61.4%

References:1

61.4%

References:2

62.4%

References:2

1.16x increased risk for type-2 diabetes

63.4%

References:2

65.7%

References:3

>1.5x risk for T2D

68.3%

References:4

71.3%

References:1

72.3%

References:16

76.2%

References:1

76.2%

References:8

77.0%

References:2

80.6%

References:1

81.2%

References:2

1.8x risk of type-2 diabetes

93.1%

References:1

96.0%

References:3

None

References:1

None

References:1

None

References:2

None

References:3

None

References:1

None

References:4

None

References:3

None

References:3

None

References:1

0.91x decreased risk for T2D

None

rs2209972 (T;T)

References:1

normal risk

None

References:8

None

References:1

normal risk

None

rs2272383 (G;G)

References:1

higher body mass index

None

References:1

None

References:2

None

References:1

None

References:1

None

References:1

None

References:2

None

References:1

None

References:2

None

References:1

None

References:1

None

References:2

None

References:2

None

References:1

None

References:1

None

References:1

normal

None

References:1

None

References:4

None

References:24

None

None

rs1042714 (C;G)

References:12

complex; see details for increased risks

None

rs10830963 (C;G)

References:14

increased type-2 diabetes risk; higher gestational diabetes risk

None

References:2

None

References:8

None

References:1

None

References:3

None

References:2

None

References:11

CYP2C9*2 carrier; average 20% reduction in warfarin metabolism

None

References:3

None

References:1

None

References:1

None

References:0

None

References:1

None

References:1

15.8%

ambig
References:1

41.6%

ambig
References:3

48.0%

ambig
References:7

1.9x increased risk for type-2 diabetes

67.3%

ambig
References:2

75.2%

ambig
References:19

77.2%

ambig
References:2

None

ambig
References:2

if diabetic, poorer response to rosiglitazone

None

ambig
References:2

None

ambig
References:1

risk of progressing from IGT to T2D; reduced by exercise

None

ambig
References:3

None

ambig
References:1

None

ambig
References:2

None

ambig
References:4

26.7%

Magnitude: 0.5
References:2

no credible risk

74.3%

rs1057910 (A;A)

Magnitude: 0.1
References:17

normal; no effect on warfarin metabolism

83.2%

Magnitude: 0.1
ambig
References:19

0.0%

rs10811661 (C;C)

Magnitude: 0
References:25

normal

18.8%

rs1859962 (T;T)

Magnitude: 0
References:7

normal risk

23.8%

rs1535435 (A;G)

Magnitude: 0
References:1

32.7%

rs1111875 (A;A)

Magnitude: 0
References:18

1x normal risk of T2D

33.7%

rs7923837 (A;A)

Magnitude: 0
References:5

1x normal risk for T2D

39.4%

rs7659604 (C;C)

Magnitude: 0
References:1

1.1x risk

40.6%

rs1121980 (C;C)

Magnitude: 0
References:10

2.76x risk for obesity

49.5%

rs17782313 (T;T)

Magnitude: 0
References:21

normal

50.5%

rs4430796 (A;G)

Magnitude: 0
References:15

normal risk

51.5%

Magnitude: 0
References:55

normal form

56.4%

rs12255372 (G;G)

Magnitude: 0
References:12

56.4%

rs8050136 (C;C)

Magnitude: 0
References:26

normal

57.4%

rs7756992 (A;A)

Magnitude: 0
References:9

normal

59.4%

rs9465871 (T;T)

Magnitude: 0
References:4

normal

65.3%

rs3750425 (C;C)

Magnitude: 0
References:1

67.3%

rs2267668 (A;A)

Magnitude: 0
References:4

76.2%

rs1528133 (A;A)

Magnitude: 0
References:1

normal risk

76.2%

rs1799884 (G;G)

Magnitude: 0
References:6

normal

83.2%

rs2197423 (C;C)

Magnitude: 0
References:0

83.2%

rs6802898 (C;C)

Magnitude: 0
References:1

93.1%

rs11964281 (C;C)

Magnitude: 0
References:1

97.0%

rs3847109 (G;G)

Magnitude: 0
References:1

98.0%

rs2237892 (C;C)

Magnitude: 0
References:11

None

rs11039155 (G;G)

Magnitude: 0
References:1

None

rs17036101 (G;G)

Magnitude: 0
References:1

None

rs2237897 (C;C)

Magnitude: 0
References:8

common

None

rs34241435 (G;G)

Magnitude: 0
References:1

None

Magnitude: 0
References:14

higher risk for several conditions

None

rs8052394 (A;A)

Magnitude: 0
References:1

None

rs997509 (C;C)

Magnitude: 0
References:2

56.4%

Magnitude: 0
ambig
References:57

common

61.4%

rs7754840 (G;G)

Magnitude: 0
ambig
References:11

normal

198 snps

Ulcer

(hide) Ulcer

None

rs28399504 (A;A)

Magnitude: 0
References:5

normal

None

rs4244285 (G;G)

Magnitude: 0
References:10

normal

None

Magnitude: 0
References:7

normal

3 snps

Ulcerative colitis

(hide) Ulcerative colitis

23.8%

rs2241880 (C;C)

Magnitude: 2
References:14

2x-3x increased risk for Crohn's disease in Caucasians

7.9%

rs1143634 (T;T)

References:9

complex; see details

8.9%

References:2

8.9%

References:2

10.9%

References:4

14.9%

References:3

18.8%

References:2

24.8%

References:5

24.8%

References:4

26.7%

References:10

27.7%

References:1

27.7%

References:2

30.7%

References:1

32.7%

References:1

33.7%

References:7

34.7%

References:56

34.7%

References:2

34.7%

References:1

35.6%

References:8

1.1x risk

39.6%

References:3

40.0%

References:3

40.6%

References:1

42.6%

References:6

44.6%

References:3

45.5%

References:10

1.5x risk for certain autoimmune diseases; 2x risk for Graves disease

46.0%

rs2201841 (C;T)

References:8

1.5x risk for Crohn's disease; 2x risk for Graves' disease

46.5%

References:1

46.5%

References:6

normal

47.5%

References:6

47.5%

References:2

48.0%

References:5

48.5%

References:3

48.5%

References:1

49.5%

References:3

50.0%

References:1

50.5%

References:1

51.5%

References:2

51.5%

References:9

52.0%

References:2

52.5%

References:1

59.4%

References:2

65.3%

References:3

69.1%

References:2

83.2%

References:3

None

References:1

None

References:2

40.0%

Magnitude: 0
References:34

common

63.4%

rs1317209 (C;C)

Magnitude: 0
References:2

68.0%

rs3024505 (C;C)

Magnitude: 0
References:11

75.2%

rs689466 (A;A)

Magnitude: 0
References:8

normal

75.2%

rs9263739 (C;C)

Magnitude: 0
References:1

92.1%

rs2870946 (A;A)

Magnitude: 0
References:3

99.0%

Magnitude: 0
References:27

common

53 snps

Ureterolithiasis

4 snps

Venous thromboembolism

(hide) Venous thromboembolism

30.7%

rs2108622 (C;C)

Magnitude: 2
References:19

lower warfarin dosing

17.8%

References:1

42.6%

References:7

1.2x risk of pancreatic cancer

43.6%

References:1

44.6%

References:10

0.65x lower risk of ovarian cancer; normal PON catalytic efficiency

45.5%

References:5

51.0%

References:9

None

References:6

None

References:12

complex; see details for increased risks

None

References:5

None

References:1

None

References:3

EPCR H1 haplotype; reduced risk of VTE?

52.5%

rs1613662 (A;A)

Magnitude: 0
References:2

65.3%

rs9923231 (C;C)

Magnitude: 0
References:14

normal

65.3%

rs9934438 (G;G)

Magnitude: 0
References:7

72.3%

rs867186 (A;A)

Magnitude: 0
References:5

normal risk for VTE

81.2%

rs5361 (A;A)

Magnitude: 0
References:1

normal risk

99.0%

rs268 (A;A)

Magnitude: 0
References:3

99.0%

Magnitude: 0
References:8

normal/common

None

i3002432 (G;G)

Magnitude: 0
References:0

None

rs1799864 (G;G)

Magnitude: 0
References:5

21 snps

Vitamin D Insufficiency

1 snp

Vitiligo

(hide) Vitiligo

15.8%

References:1

16.8%

References:1

16.8%

References:1

17.8%

References:1

19.8%

References:2

32.7%

References:2

34.7%

References:2

39.6%

References:1

45.5%

References:4

47.5%

References:1

49.5%

References:11

54.5%

References:6

74.3%

References:2

higher risk for generalized vitiligo

77.2%

References:2

98.0%

References:2

None

References:2

2.96x

None

ambig
References:0

58.4%

Magnitude: 0
References:1

68.3%

rs10503019 (G;G)

Magnitude: 0
References:1

76.2%

rs6502867 (T;T)

Magnitude: 0
References:2

80.2%

rs1393350 (G;G)

Magnitude: 0
References:9

98.0%

Magnitude: 0
References:25

normal

22 snps

Von Willebrand disease

(hide) Von Willebrand disease

16.8%

rs216321 (C;T)

References:0

50.5%

rs7639618 (C;T)

References:3

1.45x increased osteoarthritis risk

58.4%

References:0

67.3%

References:0

None

References:2

1.43x increased osteoarthritis risk

None

rs34230288 (G;G)

Magnitude: 0
References:0